[
  {
    "source_file_section": "TITLE",
    "source_heading_number": "",
    "parent_heading_num_seq": [
      ""
    ],
    "parent_sec_id_seq": [
      1
    ],
    "derived_heading_level": 1,
    "pt_from_ontology": [
      ""
    ],
    "medical_terms": [],
    "page": 1,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "2_section_metadata",
    "sec_id": 1,
    "child_secid_seq": [
      [
        1,
        "",
        "TITLE",
        1
      ]
    ]
  },
  {
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "45c815a5-d0e9-4a06-b3a0-85639a2e4018",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 1,
    "line_id": 1,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Nirsevimab, a Monoclonal",
    "font_info": {
      "IsBold": true,
      "font_size": 32,
      "font_style": "",
      "entity": [
        {
          "start_idx": 101,
          "end_idx": 110,
          "standard_entity_name": "Molecule",
          "subcategory": "Molecule",
          "confidence": 75,
          "text": "Nirsevimab"
        }
      ],
      "roi_id": {
        "para": "b65c0409-d255-444b-82fe-ec80544c759f",
        "childbox": "0b9678bf-e859-46f5-89f9-508c7c1a465a",
        "subtext": "18adb4b5-7fd3-42b8-8219-a02b7a4166c6"
      },
      "Bold": true,
      "Caps": false,
      "ColorRGB": 0,
      "DStrike": false,
      "Emboss": false,
      "Highlight": "",
      "Imprint": false,
      "Italics": false,
      "Outline": false,
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": 32,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 1,
    "line_id": 2,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "Antibody With Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm and Term Infants in China",
    "font_info": {
      "IsBold": true,
      "font_size": 32,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "b2724572-03cd-40a7-93b1-58ae145742ce",
        "childbox": "7dff3bcc-a929-4eac-8f3d-aca30d4c2719",
        "subtext": "c15ea88a-c3e7-4634-9c68-74e1b6c48ea9"
      },
      "Bold": true,
      "Caps": false,
      "ColorRGB": 0,
      "DStrike": false,
      "Emboss": false,
      "Highlight": "",
      "Imprint": false,
      "Italics": false,
      "Outline": false,
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": 32,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 1,
    "line_id": 3,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "b4b161d0-1314-4744-89b8-261f2e4d6786",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 1,
    "line_id": 4,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": {
      "Table": "<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th>ColIndex</th>\n      <th>1.0</th>\n      <th>2.0</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>Sponsor Protocol Number:</td>\n      <td>D5290C00006</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>Investigational Product:</td>\n      <td>Nirsevimab (MEDI8897)</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>Sponsor:</td>\n      <td>AstraZeneca AB, 151 85 Södertälje, Sweden</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>Study Physician:</td>\n      <td>Natalya Makulova, MD, PhD Global Clinical Programme Lead, AstraZeneca Phone: 301-398-3329</td>\n    </tr>\n  </tbody>\n</table>",
      "TableProperties": "[{\"1.0\":{\"entities\":[],\"content\":\"Sponsor Protocol Number: \",\"roi_id\":{\"table_roi_id\":\"d3985bf8-4c71-468a-b0c3-12cc1513a522\",\"row_roi_id\":\"ba966aad-be02-43b6-a655-49648ea2fdf9\",\"column_roi_id\":\"03261c5b-d015-4192-a533-3def2c392576\",\"datacell_roi_id\":\"ec822646-0a8a-4a02-9a9e-54c592172def\"},\"table_index\":0.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"D5290C00006\",\"roi_id\":{\"table_roi_id\":\"d3985bf8-4c71-468a-b0c3-12cc1513a522\",\"row_roi_id\":\"ba966aad-be02-43b6-a655-49648ea2fdf9\",\"column_roi_id\":\"9c534e34-42fd-4b33-a8b0-565a7d374e8b\",\"datacell_roi_id\":\"ab00754d-7451-4716-b929-63a592c59eef\"},\"table_index\":0.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"Investigational Product:\",\"roi_id\":{\"table_roi_id\":\"d3985bf8-4c71-468a-b0c3-12cc1513a522\",\"row_roi_id\":\"3a9013b6-bca6-4dad-9de2-bb8c47a9f016\",\"column_roi_id\":\"647f01f1-d924-440b-b670-16fdbaa5e824\",\"datacell_roi_id\":\"98f5d30b-192b-4fc1-9885-078e2be48b13\"},\"table_index\":0.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[{\"start_idx\":0,\"end_idx\":9,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"Nirsevimab\"},{\"start_idx\":12,\"end_idx\":19,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":87.0,\"text\":\"MEDI8897\"}],\"content\":\"Nirsevimab (MEDI8897)\",\"roi_id\":{\"table_roi_id\":\"d3985bf8-4c71-468a-b0c3-12cc1513a522\",\"row_roi_id\":\"3a9013b6-bca6-4dad-9de2-bb8c47a9f016\",\"column_roi_id\":\"fd7c769f-b99d-48ab-be96-a279053c556c\",\"datacell_roi_id\":\"afb8c186-888b-4417-9199-03663ed193b5\"},\"table_index\":0.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"Sponsor: \",\"roi_id\":{\"table_roi_id\":\"d3985bf8-4c71-468a-b0c3-12cc1513a522\",\"row_roi_id\":\"4e0154f0-2319-43ab-a4f3-88b69d638b85\",\"column_roi_id\":\"c3eda066-5b9c-4b73-b82e-401b2f4c10a6\",\"datacell_roi_id\":\"d5f9743e-7613-4e5c-b284-a9c2d6e60a41\"},\"table_index\":0.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[{\"start_idx\":16,\"end_idx\":40,\"standard_entity_name\":\"ANY: Address\",\"subcategory\":\"ANY: Address\",\"confidence\":100.0,\"text\":\"151 85 S\\u00f6dert\\u00e4lje, Sweden\"},{\"start_idx\":0,\"end_idx\":10,\"standard_entity_name\":\"ANY: Organization\",\"subcategory\":\"ANY: Organization\",\"confidence\":100.0,\"text\":\"AstraZeneca\"},{\"start_idx\":0,\"end_idx\":13,\"standard_entity_name\":\"ANY: Organization\",\"subcategory\":\"ANY: Organization\",\"confidence\":75.0,\"text\":\"AstraZeneca AB\"},{\"start_idx\":16,\"end_idx\":40,\"standard_entity_name\":\"Sponsor Address\",\"subcategory\":\"Sponsor Address\",\"confidence\":100.0,\"text\":\"151 85 S\\u00f6dert\\u00e4lje, Sweden\"},{\"start_idx\":0,\"end_idx\":13,\"standard_entity_name\":\"Sponsor Name\",\"subcategory\":\"Sponsor Name\",\"confidence\":100.0,\"text\":\"AstraZeneca AB\"}],\"content\":\"AstraZeneca AB, 151 85 S\\u00f6dert\\u00e4lje, Sweden\",\"roi_id\":{\"table_roi_id\":\"d3985bf8-4c71-468a-b0c3-12cc1513a522\",\"row_roi_id\":\"4e0154f0-2319-43ab-a4f3-88b69d638b85\",\"column_roi_id\":\"12f97a13-2519-460d-829f-066e0e672314\",\"datacell_roi_id\":\"c04d5f7f-294b-4d85-9093-cb5d6f05ad83\"},\"table_index\":0.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"Study Physician:\",\"roi_id\":{\"table_roi_id\":\"d3985bf8-4c71-468a-b0c3-12cc1513a522\",\"row_roi_id\":\"52cea1c6-b59d-43a6-a8f3-9c0014aeac5e\",\"column_roi_id\":\"529b94ae-1594-4105-b846-637163cdaf7f\",\"datacell_roi_id\":\"8ea2ae1f-7c7d-49d1-919a-9042524bdd14\"},\"table_index\":0.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[{\"start_idx\":0,\"end_idx\":15,\"standard_entity_name\":\"QUALIFIED PHYSICIAN: Person Name\",\"subcategory\":\"QUALIFIED PHYSICIAN: Person Name\",\"confidence\":100.0,\"text\":\"Natalya Makulova\"},{\"start_idx\":16,\"end_idx\":19,\"standard_entity_name\":\"QUALIFIED PHYSICIAN: Person Title\",\"subcategory\":\"QUALIFIED PHYSICIAN: Person Title\",\"confidence\":100.0,\"text\":\", MD\"},{\"start_idx\":20,\"end_idx\":24,\"standard_entity_name\":\"QUALIFIED PHYSICIAN: Person Title\",\"subcategory\":\"QUALIFIED PHYSICIAN: Person Title\",\"confidence\":100.0,\"text\":\", PhD\"},{\"start_idx\":16,\"end_idx\":24,\"standard_entity_name\":\"QUALIFIED PHYSICIAN: Person Title\",\"subcategory\":\"QUALIFIED PHYSICIAN: Person Title\",\"confidence\":100.0,\"text\":\", MD, PhD\"},{\"start_idx\":58,\"end_idx\":68,\"standard_entity_name\":\"ANY: Organization\",\"subcategory\":\"ANY: Organization\",\"confidence\":75.0,\"text\":\"AstraZeneca\"},{\"start_idx\":58,\"end_idx\":68,\"standard_entity_name\":\"Sponsor Name\",\"subcategory\":\"Sponsor Name\",\"confidence\":100.0,\"text\":\"AstraZeneca\"},{\"start_idx\":77,\"end_idx\":88,\"standard_entity_name\":\"ANY: Telephone\\/Fax\",\"subcategory\":\"ANY: Telephone\\/Fax\",\"confidence\":100.0,\"text\":\"301-398-3329\"}],\"content\":\"Natalya Makulova, MD, PhD Global Clinical Programme Lead, AstraZeneca Phone: 301-398-3329\",\"roi_id\":{\"table_roi_id\":\"d3985bf8-4c71-468a-b0c3-12cc1513a522\",\"row_roi_id\":\"52cea1c6-b59d-43a6-a8f3-9c0014aeac5e\",\"column_roi_id\":\"d5ecc877-87b5-40b2-98b0-6df3c83dd6fd\",\"datacell_roi_id\":\"e80f4410-0453-4fb5-9da3-b6437099ebaf\"},\"table_index\":0.0,\"qc_change_type\":\"\"}}]",
      "SectionHeaderPrintPage": "0",
      "TableIndex": "1",
      "TableName": "",
      "Header": [
        1,
        3
      ]
    },
    "font_info": {
      "IsBold": true,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "ec822646-0a8a-4a02-9a9e-54c592172def",
        "childbox": "90a22bf9-1fa3-4fec-896a-ec27d3b27d65",
        "subtext": "9803ecd5-b3c7-49a5-8244-5789d5722e00"
      },
      "Bold": true,
      "Caps": false,
      "ColorRGB": 0,
      "DStrike": false,
      "Emboss": false,
      "Highlight": "",
      "Imprint": false,
      "Italics": false,
      "Outline": false,
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "derived_section_type": "table",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 1,
    "line_id": 5,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "Contract Research Organization:",
    "font_info": {
      "IsBold": true,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "e6f23b2b-f640-414d-b1b7-e694485584c3",
        "childbox": "4ca5dbd7-4beb-44f8-959c-48460b32ea12",
        "subtext": "534f6070-8d73-4a99-ab64-770c3bf806a0"
      },
      "Bold": true,
      "Caps": false,
      "ColorRGB": 0,
      "DStrike": false,
      "Emboss": false,
      "Highlight": "",
      "Imprint": false,
      "Italics": false,
      "Outline": false,
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 1,
    "line_id": 6,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "IQVIA RDS (Shanghai) Co., Ltd.",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [
        {
          "start_idx": 0,
          "end_idx": 29,
          "standard_entity_name": "ANY: Organization",
          "subcategory": "ANY: Organization",
          "confidence": 87,
          "text": "IQVIA RDS (Shanghai) Co., Ltd."
        }
      ],
      "roi_id": {
        "para": "e6f23b2b-f640-414d-b1b7-e694485584c3",
        "childbox": "4ca5dbd7-4beb-44f8-959c-48460b32ea12",
        "subtext": "26125037-556d-4b0d-b68e-8917f84e813a"
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "DStrike": false,
      "Emboss": false,
      "Highlight": "",
      "Imprint": false,
      "Italics": false,
      "Outline": false,
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 1,
    "line_id": 7,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "3rd Floor, Building A, Fenglin International Tower",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [
        {
          "start_idx": 0,
          "end_idx": 49,
          "standard_entity_name": "ANY: Address",
          "subcategory": "ANY: Address",
          "confidence": 100,
          "text": "3rd Floor, Building A, Fenglin International Tower"
        }
      ],
      "roi_id": {
        "para": "900b932c-1ab1-478c-ac8d-474fcd9723de",
        "childbox": "61c17aaf-c11d-49d7-9968-cbbfd306f3ec",
        "subtext": "c54c1be8-4f6c-4b3a-bdbc-94a02ee2e748"
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "DStrike": false,
      "Emboss": false,
      "Highlight": "",
      "Imprint": false,
      "Italics": false,
      "Outline": false,
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 1,
    "line_id": 8,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "No. 388 Fenglin Road, Xuhui District, Shanghai 200032",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [
        {
          "start_idx": 0,
          "end_idx": 52,
          "standard_entity_name": "ANY: Address",
          "subcategory": "ANY: Address",
          "confidence": 100,
          "text": "No. 388 Fenglin Road, Xuhui District, Shanghai 200032"
        }
      ],
      "roi_id": {
        "para": "cf914d02-ac5d-4551-b544-578a2af197dd",
        "childbox": "1eaa1f47-871e-4a23-8e1c-bde0ae2b9518",
        "subtext": "73bf2c2c-5187-4ac9-9cd4-a5a10fa96a35"
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "DStrike": false,
      "Emboss": false,
      "Highlight": "",
      "Imprint": false,
      "Italics": false,
      "Outline": false,
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 1,
    "line_id": 9,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": {
      "Table": "<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th>ColIndex</th>\n      <th>1.0</th>\n      <th>2.0</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>Principal Investigator:</td>\n      <td>Prof. Hanmin Liu West China Second University Hospital, Sichuan University No. 20 San Duan South Renmin Road Chengdu, Sichuan Province 610041, China</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>Protocol History, Date :</td>\n      <td>Original Protocol, 07Jun2020</td>\n    </tr>\n  </tbody>\n</table>",
      "TableProperties": "[{\"1.0\":{\"entities\":[],\"content\":\"Principal Investigator: \",\"roi_id\":{\"table_roi_id\":\"75501e94-9b31-4e22-b1c9-56ca84a109dc\",\"row_roi_id\":\"9bad5207-d62e-4556-b4c3-70ff5760e9ae\",\"column_roi_id\":\"872b748e-030c-4a01-a8de-f0438a9f8040\",\"datacell_roi_id\":\"4347d8f3-2e89-4568-8465-7bbb04d79f12\"},\"table_index\":1.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[{\"start_idx\":0,\"end_idx\":4,\"standard_entity_name\":\"PRIMARY INVESTIGATOR: Person Title\",\"subcategory\":\"PRIMARY INVESTIGATOR: Person Title\",\"confidence\":100.0,\"text\":\"Prof.\"},{\"start_idx\":6,\"end_idx\":15,\"standard_entity_name\":\"PRIMARY INVESTIGATOR: Person Name\",\"subcategory\":\"PRIMARY INVESTIGATOR: Person Name\",\"confidence\":100.0,\"text\":\"Hanmin Liu\"},{\"start_idx\":17,\"end_idx\":53,\"standard_entity_name\":\"ANY: Organization\",\"subcategory\":\"ANY: Organization\",\"confidence\":87.0,\"text\":\"West China Second University Hospital\"},{\"start_idx\":17,\"end_idx\":53,\"standard_entity_name\":\"PRIMARY INVESTIGATOR: Affiliation\",\"subcategory\":\"PRIMARY INVESTIGATOR: Affiliation\",\"confidence\":100.0,\"text\":\"West China Second University Hospital\"},{\"start_idx\":56,\"end_idx\":62,\"standard_entity_name\":\"PRIMARY INVESTIGATOR: Address\",\"subcategory\":\"PRIMARY INVESTIGATOR: Address\",\"confidence\":100.0,\"text\":\"Sichuan\"},{\"start_idx\":118,\"end_idx\":124,\"standard_entity_name\":\"PRIMARY INVESTIGATOR: Address\",\"subcategory\":\"PRIMARY INVESTIGATOR: Address\",\"confidence\":100.0,\"text\":\"Sichuan\"}],\"content\":\"Prof. Hanmin Liu West China Second University Hospital, Sichuan University No. 20 San Duan South Renmin Road Chengdu, Sichuan Province 610041, China\",\"roi_id\":{\"table_roi_id\":\"75501e94-9b31-4e22-b1c9-56ca84a109dc\",\"row_roi_id\":\"9bad5207-d62e-4556-b4c3-70ff5760e9ae\",\"column_roi_id\":\"bc53841c-abe2-458e-baf2-3c2e31c9c12d\",\"datacell_roi_id\":\"3659d80f-b931-4bbe-91c7-a1b4416f435c\"},\"table_index\":1.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"Protocol History, Date :\",\"roi_id\":{\"table_roi_id\":\"75501e94-9b31-4e22-b1c9-56ca84a109dc\",\"row_roi_id\":\"6ecaa707-1507-4363-8eed-202ab5ff8a22\",\"column_roi_id\":\"549e5028-661d-492c-822c-da3ece83a37a\",\"datacell_roi_id\":\"0c440200-b076-407c-9888-9de933da7fa4\"},\"table_index\":1.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"Original Protocol, 07Jun2020\",\"roi_id\":{\"table_roi_id\":\"75501e94-9b31-4e22-b1c9-56ca84a109dc\",\"row_roi_id\":\"6ecaa707-1507-4363-8eed-202ab5ff8a22\",\"column_roi_id\":\"71063972-3deb-4201-aefd-829305bdf51a\",\"datacell_roi_id\":\"dac0a4c5-a48d-4240-bca3-91a4b029af6a\"},\"table_index\":1.0,\"qc_change_type\":\"\"}}]",
      "SectionHeaderPrintPage": "0",
      "TableIndex": "2",
      "TableName": "",
      "Header": []
    },
    "font_info": {
      "IsBold": true,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "4347d8f3-2e89-4568-8465-7bbb04d79f12",
        "childbox": "bc9d33a9-7316-48a8-ae05-5dad5fb3c421",
        "subtext": "38412a77-090a-4a86-bef5-636d137d55dc"
      },
      "Bold": true,
      "Caps": false,
      "ColorRGB": 0,
      "DStrike": false,
      "Emboss": false,
      "Highlight": "",
      "Imprint": false,
      "Italics": false,
      "Outline": false,
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "derived_section_type": "table",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 1,
    "line_id": 10,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "c6188284-7dc9-4bc9-9a20-b1866f41f4d2",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 1,
    "line_id": 11,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "e626008a-515c-4198-8c40-a3ad22819d1c",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 1,
    "line_id": 12,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "This document contains trade secrets and commercial information that is privileged or confidential and may not be disclosed without prior authorization from AstraZeneca.",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [
        {
          "start_idx": 157,
          "end_idx": 167,
          "standard_entity_name": "ANY: Organization",
          "subcategory": "ANY: Organization",
          "confidence": 75,
          "text": "AstraZeneca"
        },
        {
          "start_idx": 157,
          "end_idx": 167,
          "standard_entity_name": "Sponsor Name",
          "subcategory": "Sponsor Name",
          "confidence": 100,
          "text": "AstraZeneca"
        }
      ],
      "roi_id": {
        "para": "def4bcb0-f5e6-4c53-8c8c-51cdbd7d516d",
        "childbox": "1390fefb-f0da-4d8f-a863-5d0c2befb4ea",
        "subtext": "81dda9cd-7131-489f-9cf1-483e0f4337e0"
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "DStrike": false,
      "Emboss": false,
      "Highlight": "",
      "Imprint": false,
      "Italics": false,
      "Outline": false,
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 1,
    "line_id": 13,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "PROTOCOL SYNOPSIS",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "Heading1",
      "entity": [],
      "roi_id": {
        "para": "7372542f-2f90-4313-930f-f2334a29a4c5",
        "childbox": "",
        "subtext": ""
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "DStrike": false,
      "Emboss": false,
      "Highlight": "",
      "Imprint": false,
      "Italics": false,
      "Outline": false,
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "derived_section_type": "header",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 1,
    "line_id": 14,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": {
      "Table": "<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th>ColIndex</th>\n      <th>1.0</th>\n      <th>2.0</th>\n      <th>3.0</th>\n      <th>4.0</th>\n      <th>5.0</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>TITLE  A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Nirsevimab, a Monoclonal Antibody With Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm and Term Infants in China</td>\n      <td>TITLE  A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Nirsevimab, a Monoclonal Antibody With Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm and Term Infants in China</td>\n      <td>TITLE  A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Nirsevimab, a Monoclonal Antibody With Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm and Term Infants in China</td>\n      <td>TITLE  A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Nirsevimab, a Monoclonal Antibody With Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm and Term Infants in China</td>\n      <td>TITLE  A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Nirsevimab, a Monoclonal Antibody With Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm and Term Infants in China</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>HYPOTHESES  Primary Hypothesis Compared to placebo, a single intramuscular (IM) nirsevimab dose, 50 mg if weight < 5 kg or 100 mg if weight ≥ 5 kg, will be efficacious in reducing medically attended lower respiratory tract infection (LRTI) caused by real-time reverse transcriptase-polymerase chain reaction (RT-PCR)-confirmed respiratory syncytial virus (RSV) in healthy preterm and term infants born ≥ 29 weeks 0 days gestational age (GA) and entering their first RSV season, and the safety profile will be acceptable. Secondary Hypotheses There will be a reduction in the incidence of hospitalizations attributable to RT-PCR-confirmed RSV. The predicted serum exposures of nirsevimab will be adequate for the duration of the RSV season. Antidrug antibody (ADA) to nirsevimab will not impact the serum concentrations or safety of nirsevimab through 150 days post dosing (ie, during a typical 5-month RSV season).</td>\n      <td>HYPOTHESES  Primary Hypothesis Compared to placebo, a single intramuscular (IM) nirsevimab dose, 50 mg if weight < 5 kg or 100 mg if weight ≥ 5 kg, will be efficacious in reducing medically attended lower respiratory tract infection (LRTI) caused by real-time reverse transcriptase-polymerase chain reaction (RT-PCR)-confirmed respiratory syncytial virus (RSV) in healthy preterm and term infants born ≥ 29 weeks 0 days gestational age (GA) and entering their first RSV season, and the safety profile will be acceptable. Secondary Hypotheses There will be a reduction in the incidence of hospitalizations attributable to RT-PCR-confirmed RSV. The predicted serum exposures of nirsevimab will be adequate for the duration of the RSV season. Antidrug antibody (ADA) to nirsevimab will not impact the serum concentrations or safety of nirsevimab through 150 days post dosing (ie, during a typical 5-month RSV season).</td>\n      <td>HYPOTHESES  Primary Hypothesis Compared to placebo, a single intramuscular (IM) nirsevimab dose, 50 mg if weight < 5 kg or 100 mg if weight ≥ 5 kg, will be efficacious in reducing medically attended lower respiratory tract infection (LRTI) caused by real-time reverse transcriptase-polymerase chain reaction (RT-PCR)-confirmed respiratory syncytial virus (RSV) in healthy preterm and term infants born ≥ 29 weeks 0 days gestational age (GA) and entering their first RSV season, and the safety profile will be acceptable. Secondary Hypotheses There will be a reduction in the incidence of hospitalizations attributable to RT-PCR-confirmed RSV. The predicted serum exposures of nirsevimab will be adequate for the duration of the RSV season. Antidrug antibody (ADA) to nirsevimab will not impact the serum concentrations or safety of nirsevimab through 150 days post dosing (ie, during a typical 5-month RSV season).</td>\n      <td>HYPOTHESES  Primary Hypothesis Compared to placebo, a single intramuscular (IM) nirsevimab dose, 50 mg if weight < 5 kg or 100 mg if weight ≥ 5 kg, will be efficacious in reducing medically attended lower respiratory tract infection (LRTI) caused by real-time reverse transcriptase-polymerase chain reaction (RT-PCR)-confirmed respiratory syncytial virus (RSV) in healthy preterm and term infants born ≥ 29 weeks 0 days gestational age (GA) and entering their first RSV season, and the safety profile will be acceptable. Secondary Hypotheses There will be a reduction in the incidence of hospitalizations attributable to RT-PCR-confirmed RSV. The predicted serum exposures of nirsevimab will be adequate for the duration of the RSV season. Antidrug antibody (ADA) to nirsevimab will not impact the serum concentrations or safety of nirsevimab through 150 days post dosing (ie, during a typical 5-month RSV season).</td>\n      <td>HYPOTHESES  Primary Hypothesis Compared to placebo, a single intramuscular (IM) nirsevimab dose, 50 mg if weight < 5 kg or 100 mg if weight ≥ 5 kg, will be efficacious in reducing medically attended lower respiratory tract infection (LRTI) caused by real-time reverse transcriptase-polymerase chain reaction (RT-PCR)-confirmed respiratory syncytial virus (RSV) in healthy preterm and term infants born ≥ 29 weeks 0 days gestational age (GA) and entering their first RSV season, and the safety profile will be acceptable. Secondary Hypotheses There will be a reduction in the incidence of hospitalizations attributable to RT-PCR-confirmed RSV. The predicted serum exposures of nirsevimab will be adequate for the duration of the RSV season. Antidrug antibody (ADA) to nirsevimab will not impact the serum concentrations or safety of nirsevimab through 150 days post dosing (ie, during a typical 5-month RSV season).</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>OBJECTIVES AND ASSOCIATED ENDPOINTS  Type  Objective  Endpoint</td>\n      <td>OBJECTIVES AND ASSOCIATED ENDPOINTS  Type  Objective  Endpoint</td>\n      <td>OBJECTIVES AND ASSOCIATED ENDPOINTS  Type  Objective  Endpoint</td>\n      <td>OBJECTIVES AND ASSOCIATED ENDPOINTS  Type  Objective  Endpoint</td>\n      <td>OBJECTIVES AND ASSOCIATED ENDPOINTS  Type  Objective  Endpoint</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td></td>\n      <td>Primary</td>\n      <td>Primary</td>\n      <td>Primary</td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td></td>\n      <td>Efficacy</td>\n      <td>To assess the efficacy of nirsevimab in reducing medically attended LRTI due to RT-PCR-confirmed RSV, compared to placebo, when administered as a single fixed IM dose to healthy preterm and term infants born ≥ 29 weeks 0 days GA and entering their first RSV season</td>\n      <td>Incidence of medically attended LRTI (inpatient and outpatient) due to RT-PCRconfirmed RSV through 150 days after dosing (ie, during a typical 5-month RSV season)</td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>5</th>\n      <td></td>\n      <td>Secondary</td>\n      <td>Secondary</td>\n      <td>Secondary</td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>6</th>\n      <td></td>\n      <td>Efficacy</td>\n      <td>To assess the efficacy of nirsevimab in reducing hospitalizations due to RT-PCR-confirmed RSV, compared to placebo</td>\n      <td>Incidence of hospitalizations due to RT-PCR-confirmed RSV through 150 days after dosing (ie, during a typical 5-month RSV season)</td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>7</th>\n      <td></td>\n      <td>Safety</td>\n      <td>To evaluate the safety and tolerability of nirsevimab when administered as a single fixed IM dose, compared to placebo</td>\n      <td>Safety and tolerability of nirsevimab as assessed by the occurrence of treatmentemergent adverse events (TEAEs), treatment-emergent serious adverse events (TESAEs), adverse events of special interest (AESIs), and new onset chronic diseases (NOCDs)</td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>8</th>\n      <td></td>\n      <td>Pharmacokinetics (PK)</td>\n      <td>To evaluate serum concentrations of nirsevimab</td>\n      <td>Summary of nirsevimab serum concentrations and estimated PK parameters (maximum observed concentration, area under the concentration-time curve, apparent clearance, and terminal-phase halflife), if data permit</td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>9</th>\n      <td></td>\n      <td>ADA</td>\n      <td>To evaluate ADA responses to nirsevimab in serum</td>\n      <td>Incidence of ADA to nirsevimab in serum</td>\n      <td></td>\n    </tr>\n  </tbody>\n</table>",
      "TableProperties": "[{\"1.0\":{\"entities\":[{\"start_idx\":108,\"end_idx\":117,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"Nirsevimab\"},{\"start_idx\":108,\"end_idx\":117,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"Nirsevimab\"},{\"start_idx\":108,\"end_idx\":117,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"Nirsevimab\"}],\"content\":\"TITLE  A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Nirsevimab, a Monoclonal Antibody With Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm and Term Infants in China\",\"roi_id\":{\"table_roi_id\":\"a36f291b-21c0-48b2-8855-b0c2ee4bdfaf\",\"row_roi_id\":\"81d652a1-0b68-45c2-82c0-332931644b60\",\"column_roi_id\":\"c85f95a7-cd34-4e79-b09f-5826814356c8\",\"datacell_roi_id\":\"78330f89-f091-4264-bd3a-51460848a415\"},\"table_index\":2.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[{\"start_idx\":108,\"end_idx\":117,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"Nirsevimab\"},{\"start_idx\":108,\"end_idx\":117,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"Nirsevimab\"},{\"start_idx\":108,\"end_idx\":117,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"Nirsevimab\"}],\"content\":\"TITLE  A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Nirsevimab, a Monoclonal Antibody With Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm and Term Infants in China\",\"roi_id\":{\"table_roi_id\":\"a36f291b-21c0-48b2-8855-b0c2ee4bdfaf\",\"row_roi_id\":\"81d652a1-0b68-45c2-82c0-332931644b60\",\"column_roi_id\":\"c85f95a7-cd34-4e79-b09f-5826814356c8\",\"datacell_roi_id\":\"78330f89-f091-4264-bd3a-51460848a415\"},\"table_index\":2.0,\"qc_change_type\":\"\"},\"3.0\":{\"entities\":[{\"start_idx\":108,\"end_idx\":117,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"Nirsevimab\"},{\"start_idx\":108,\"end_idx\":117,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"Nirsevimab\"},{\"start_idx\":108,\"end_idx\":117,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"Nirsevimab\"}],\"content\":\"TITLE  A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Nirsevimab, a Monoclonal Antibody With Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm and Term Infants in China\",\"roi_id\":{\"table_roi_id\":\"a36f291b-21c0-48b2-8855-b0c2ee4bdfaf\",\"row_roi_id\":\"81d652a1-0b68-45c2-82c0-332931644b60\",\"column_roi_id\":\"c85f95a7-cd34-4e79-b09f-5826814356c8\",\"datacell_roi_id\":\"78330f89-f091-4264-bd3a-51460848a415\"},\"table_index\":2.0,\"qc_change_type\":\"\"},\"4.0\":{\"entities\":[{\"start_idx\":108,\"end_idx\":117,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"Nirsevimab\"},{\"start_idx\":108,\"end_idx\":117,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"Nirsevimab\"},{\"start_idx\":108,\"end_idx\":117,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"Nirsevimab\"}],\"content\":\"TITLE  A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Nirsevimab, a Monoclonal Antibody With Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm and Term Infants in China\",\"roi_id\":{\"table_roi_id\":\"a36f291b-21c0-48b2-8855-b0c2ee4bdfaf\",\"row_roi_id\":\"81d652a1-0b68-45c2-82c0-332931644b60\",\"column_roi_id\":\"c85f95a7-cd34-4e79-b09f-5826814356c8\",\"datacell_roi_id\":\"78330f89-f091-4264-bd3a-51460848a415\"},\"table_index\":2.0,\"qc_change_type\":\"\"},\"5.0\":{\"entities\":[{\"start_idx\":108,\"end_idx\":117,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"Nirsevimab\"},{\"start_idx\":108,\"end_idx\":117,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"Nirsevimab\"},{\"start_idx\":108,\"end_idx\":117,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"Nirsevimab\"}],\"content\":\"TITLE  A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Nirsevimab, a Monoclonal Antibody With Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm and Term Infants in China\",\"roi_id\":{\"table_roi_id\":\"a36f291b-21c0-48b2-8855-b0c2ee4bdfaf\",\"row_roi_id\":\"81d652a1-0b68-45c2-82c0-332931644b60\",\"column_roi_id\":\"c85f95a7-cd34-4e79-b09f-5826814356c8\",\"datacell_roi_id\":\"78330f89-f091-4264-bd3a-51460848a415\"},\"table_index\":2.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[{\"start_idx\":80,\"end_idx\":89,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":676,\"end_idx\":685,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":767,\"end_idx\":776,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":832,\"end_idx\":841,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":80,\"end_idx\":89,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":676,\"end_idx\":685,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":767,\"end_idx\":776,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":832,\"end_idx\":841,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":80,\"end_idx\":89,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":100.0,\"text\":\"nirsevimab\"},{\"start_idx\":676,\"end_idx\":685,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":100.0,\"text\":\"nirsevimab\"},{\"start_idx\":767,\"end_idx\":776,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":100.0,\"text\":\"nirsevimab\"},{\"start_idx\":832,\"end_idx\":841,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":100.0,\"text\":\"nirsevimab\"}],\"content\":\"HYPOTHESES  Primary Hypothesis Compared to placebo, a single intramuscular (IM) nirsevimab dose, 50 mg if weight < 5 kg or 100 mg if weight \\u2265 5 kg, will be efficacious in reducing medically attended lower respiratory tract infection (LRTI) caused by real-time reverse transcriptase-polymerase chain reaction (RT-PCR)-confirmed respiratory syncytial virus (RSV) in healthy preterm and term infants born \\u2265 29 weeks 0 days gestational age (GA) and entering their first RSV season, and the safety profile will be acceptable. Secondary Hypotheses There will be a reduction in the incidence of hospitalizations attributable to RT-PCR-confirmed RSV. The predicted serum exposures of nirsevimab will be adequate for the duration of the RSV season. Antidrug antibody (ADA) to nirsevimab will not impact the serum concentrations or safety of nirsevimab through 150 days post dosing (ie, during a typical 5-month RSV season).\",\"roi_id\":{\"table_roi_id\":\"a36f291b-21c0-48b2-8855-b0c2ee4bdfaf\",\"row_roi_id\":\"e5ef1bdc-ff8a-4f54-b295-85f369f4b077\",\"column_roi_id\":\"b1fddcd5-f55e-465f-b5af-6f00f0ab95b6\",\"datacell_roi_id\":\"995bf8a4-16a9-4729-aa4c-3fe71fbc5b41\"},\"table_index\":2.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[{\"start_idx\":80,\"end_idx\":89,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":676,\"end_idx\":685,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":767,\"end_idx\":776,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":832,\"end_idx\":841,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":80,\"end_idx\":89,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":676,\"end_idx\":685,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":767,\"end_idx\":776,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":832,\"end_idx\":841,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":80,\"end_idx\":89,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":100.0,\"text\":\"nirsevimab\"},{\"start_idx\":676,\"end_idx\":685,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":100.0,\"text\":\"nirsevimab\"},{\"start_idx\":767,\"end_idx\":776,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":100.0,\"text\":\"nirsevimab\"},{\"start_idx\":832,\"end_idx\":841,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":100.0,\"text\":\"nirsevimab\"}],\"content\":\"HYPOTHESES  Primary Hypothesis Compared to placebo, a single intramuscular (IM) nirsevimab dose, 50 mg if weight < 5 kg or 100 mg if weight \\u2265 5 kg, will be efficacious in reducing medically attended lower respiratory tract infection (LRTI) caused by real-time reverse transcriptase-polymerase chain reaction (RT-PCR)-confirmed respiratory syncytial virus (RSV) in healthy preterm and term infants born \\u2265 29 weeks 0 days gestational age (GA) and entering their first RSV season, and the safety profile will be acceptable. Secondary Hypotheses There will be a reduction in the incidence of hospitalizations attributable to RT-PCR-confirmed RSV. The predicted serum exposures of nirsevimab will be adequate for the duration of the RSV season. Antidrug antibody (ADA) to nirsevimab will not impact the serum concentrations or safety of nirsevimab through 150 days post dosing (ie, during a typical 5-month RSV season).\",\"roi_id\":{\"table_roi_id\":\"a36f291b-21c0-48b2-8855-b0c2ee4bdfaf\",\"row_roi_id\":\"e5ef1bdc-ff8a-4f54-b295-85f369f4b077\",\"column_roi_id\":\"b1fddcd5-f55e-465f-b5af-6f00f0ab95b6\",\"datacell_roi_id\":\"995bf8a4-16a9-4729-aa4c-3fe71fbc5b41\"},\"table_index\":2.0,\"qc_change_type\":\"\"},\"3.0\":{\"entities\":[{\"start_idx\":80,\"end_idx\":89,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":676,\"end_idx\":685,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":767,\"end_idx\":776,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":832,\"end_idx\":841,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":80,\"end_idx\":89,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":676,\"end_idx\":685,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":767,\"end_idx\":776,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":832,\"end_idx\":841,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":80,\"end_idx\":89,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":100.0,\"text\":\"nirsevimab\"},{\"start_idx\":676,\"end_idx\":685,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":100.0,\"text\":\"nirsevimab\"},{\"start_idx\":767,\"end_idx\":776,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":100.0,\"text\":\"nirsevimab\"},{\"start_idx\":832,\"end_idx\":841,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":100.0,\"text\":\"nirsevimab\"}],\"content\":\"HYPOTHESES  Primary Hypothesis Compared to placebo, a single intramuscular (IM) nirsevimab dose, 50 mg if weight < 5 kg or 100 mg if weight \\u2265 5 kg, will be efficacious in reducing medically attended lower respiratory tract infection (LRTI) caused by real-time reverse transcriptase-polymerase chain reaction (RT-PCR)-confirmed respiratory syncytial virus (RSV) in healthy preterm and term infants born \\u2265 29 weeks 0 days gestational age (GA) and entering their first RSV season, and the safety profile will be acceptable. Secondary Hypotheses There will be a reduction in the incidence of hospitalizations attributable to RT-PCR-confirmed RSV. The predicted serum exposures of nirsevimab will be adequate for the duration of the RSV season. Antidrug antibody (ADA) to nirsevimab will not impact the serum concentrations or safety of nirsevimab through 150 days post dosing (ie, during a typical 5-month RSV season).\",\"roi_id\":{\"table_roi_id\":\"a36f291b-21c0-48b2-8855-b0c2ee4bdfaf\",\"row_roi_id\":\"e5ef1bdc-ff8a-4f54-b295-85f369f4b077\",\"column_roi_id\":\"b1fddcd5-f55e-465f-b5af-6f00f0ab95b6\",\"datacell_roi_id\":\"995bf8a4-16a9-4729-aa4c-3fe71fbc5b41\"},\"table_index\":2.0,\"qc_change_type\":\"\"},\"4.0\":{\"entities\":[{\"start_idx\":80,\"end_idx\":89,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":676,\"end_idx\":685,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":767,\"end_idx\":776,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":832,\"end_idx\":841,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":80,\"end_idx\":89,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":676,\"end_idx\":685,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":767,\"end_idx\":776,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":832,\"end_idx\":841,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":80,\"end_idx\":89,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":100.0,\"text\":\"nirsevimab\"},{\"start_idx\":676,\"end_idx\":685,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":100.0,\"text\":\"nirsevimab\"},{\"start_idx\":767,\"end_idx\":776,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":100.0,\"text\":\"nirsevimab\"},{\"start_idx\":832,\"end_idx\":841,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":100.0,\"text\":\"nirsevimab\"}],\"content\":\"HYPOTHESES  Primary Hypothesis Compared to placebo, a single intramuscular (IM) nirsevimab dose, 50 mg if weight < 5 kg or 100 mg if weight \\u2265 5 kg, will be efficacious in reducing medically attended lower respiratory tract infection (LRTI) caused by real-time reverse transcriptase-polymerase chain reaction (RT-PCR)-confirmed respiratory syncytial virus (RSV) in healthy preterm and term infants born \\u2265 29 weeks 0 days gestational age (GA) and entering their first RSV season, and the safety profile will be acceptable. Secondary Hypotheses There will be a reduction in the incidence of hospitalizations attributable to RT-PCR-confirmed RSV. The predicted serum exposures of nirsevimab will be adequate for the duration of the RSV season. Antidrug antibody (ADA) to nirsevimab will not impact the serum concentrations or safety of nirsevimab through 150 days post dosing (ie, during a typical 5-month RSV season).\",\"roi_id\":{\"table_roi_id\":\"a36f291b-21c0-48b2-8855-b0c2ee4bdfaf\",\"row_roi_id\":\"e5ef1bdc-ff8a-4f54-b295-85f369f4b077\",\"column_roi_id\":\"b1fddcd5-f55e-465f-b5af-6f00f0ab95b6\",\"datacell_roi_id\":\"995bf8a4-16a9-4729-aa4c-3fe71fbc5b41\"},\"table_index\":2.0,\"qc_change_type\":\"\"},\"5.0\":{\"entities\":[{\"start_idx\":80,\"end_idx\":89,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":676,\"end_idx\":685,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":767,\"end_idx\":776,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":832,\"end_idx\":841,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":80,\"end_idx\":89,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":676,\"end_idx\":685,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":767,\"end_idx\":776,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":832,\"end_idx\":841,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":80,\"end_idx\":89,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":100.0,\"text\":\"nirsevimab\"},{\"start_idx\":676,\"end_idx\":685,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":100.0,\"text\":\"nirsevimab\"},{\"start_idx\":767,\"end_idx\":776,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":100.0,\"text\":\"nirsevimab\"},{\"start_idx\":832,\"end_idx\":841,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":100.0,\"text\":\"nirsevimab\"}],\"content\":\"HYPOTHESES  Primary Hypothesis Compared to placebo, a single intramuscular (IM) nirsevimab dose, 50 mg if weight < 5 kg or 100 mg if weight \\u2265 5 kg, will be efficacious in reducing medically attended lower respiratory tract infection (LRTI) caused by real-time reverse transcriptase-polymerase chain reaction (RT-PCR)-confirmed respiratory syncytial virus (RSV) in healthy preterm and term infants born \\u2265 29 weeks 0 days gestational age (GA) and entering their first RSV season, and the safety profile will be acceptable. Secondary Hypotheses There will be a reduction in the incidence of hospitalizations attributable to RT-PCR-confirmed RSV. The predicted serum exposures of nirsevimab will be adequate for the duration of the RSV season. Antidrug antibody (ADA) to nirsevimab will not impact the serum concentrations or safety of nirsevimab through 150 days post dosing (ie, during a typical 5-month RSV season).\",\"roi_id\":{\"table_roi_id\":\"a36f291b-21c0-48b2-8855-b0c2ee4bdfaf\",\"row_roi_id\":\"e5ef1bdc-ff8a-4f54-b295-85f369f4b077\",\"column_roi_id\":\"b1fddcd5-f55e-465f-b5af-6f00f0ab95b6\",\"datacell_roi_id\":\"995bf8a4-16a9-4729-aa4c-3fe71fbc5b41\"},\"table_index\":2.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"OBJECTIVES AND ASSOCIATED ENDPOINTS  Type  Objective  Endpoint\",\"roi_id\":{\"table_roi_id\":\"a36f291b-21c0-48b2-8855-b0c2ee4bdfaf\",\"row_roi_id\":\"c9b448f1-ae85-4d73-bdcd-041467e99b8c\",\"column_roi_id\":\"7e03b1bd-7692-4e0e-8acd-2667dfae6066\",\"datacell_roi_id\":\"40f55840-e3f4-4ea3-9c40-38856084d2a3\"},\"table_index\":2.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"OBJECTIVES AND ASSOCIATED ENDPOINTS  Type  Objective  Endpoint\",\"roi_id\":{\"table_roi_id\":\"a36f291b-21c0-48b2-8855-b0c2ee4bdfaf\",\"row_roi_id\":\"c9b448f1-ae85-4d73-bdcd-041467e99b8c\",\"column_roi_id\":\"7e03b1bd-7692-4e0e-8acd-2667dfae6066\",\"datacell_roi_id\":\"40f55840-e3f4-4ea3-9c40-38856084d2a3\"},\"table_index\":2.0,\"qc_change_type\":\"\"},\"3.0\":{\"entities\":[],\"content\":\"OBJECTIVES AND ASSOCIATED ENDPOINTS  Type  Objective  Endpoint\",\"roi_id\":{\"table_roi_id\":\"a36f291b-21c0-48b2-8855-b0c2ee4bdfaf\",\"row_roi_id\":\"c9b448f1-ae85-4d73-bdcd-041467e99b8c\",\"column_roi_id\":\"7e03b1bd-7692-4e0e-8acd-2667dfae6066\",\"datacell_roi_id\":\"40f55840-e3f4-4ea3-9c40-38856084d2a3\"},\"table_index\":2.0,\"qc_change_type\":\"\"},\"4.0\":{\"entities\":[],\"content\":\"OBJECTIVES AND ASSOCIATED ENDPOINTS  Type  Objective  Endpoint\",\"roi_id\":{\"table_roi_id\":\"a36f291b-21c0-48b2-8855-b0c2ee4bdfaf\",\"row_roi_id\":\"c9b448f1-ae85-4d73-bdcd-041467e99b8c\",\"column_roi_id\":\"7e03b1bd-7692-4e0e-8acd-2667dfae6066\",\"datacell_roi_id\":\"40f55840-e3f4-4ea3-9c40-38856084d2a3\"},\"table_index\":2.0,\"qc_change_type\":\"\"},\"5.0\":{\"entities\":[],\"content\":\"OBJECTIVES AND ASSOCIATED ENDPOINTS  Type  Objective  Endpoint\",\"roi_id\":{\"table_roi_id\":\"a36f291b-21c0-48b2-8855-b0c2ee4bdfaf\",\"row_roi_id\":\"c9b448f1-ae85-4d73-bdcd-041467e99b8c\",\"column_roi_id\":\"7e03b1bd-7692-4e0e-8acd-2667dfae6066\",\"datacell_roi_id\":\"40f55840-e3f4-4ea3-9c40-38856084d2a3\"},\"table_index\":2.0,\"qc_change_type\":\"\"}},{\"1.0\":\"\",\"2.0\":{\"entities\":[],\"content\":\"Primary \",\"roi_id\":{\"table_roi_id\":\"a36f291b-21c0-48b2-8855-b0c2ee4bdfaf\",\"row_roi_id\":\"37cce636-428f-46d9-925c-fdff3e888e80\",\"column_roi_id\":\"0c0cb0d5-adb3-4316-938f-7ecbf42d1fdf\",\"datacell_roi_id\":\"5afe4e5d-11cf-41e5-9328-2410d0d9a003\"},\"table_index\":2.0,\"qc_change_type\":\"\"},\"3.0\":{\"entities\":[],\"content\":\"Primary \",\"roi_id\":{\"table_roi_id\":\"a36f291b-21c0-48b2-8855-b0c2ee4bdfaf\",\"row_roi_id\":\"37cce636-428f-46d9-925c-fdff3e888e80\",\"column_roi_id\":\"0c0cb0d5-adb3-4316-938f-7ecbf42d1fdf\",\"datacell_roi_id\":\"5afe4e5d-11cf-41e5-9328-2410d0d9a003\"},\"table_index\":2.0,\"qc_change_type\":\"\"},\"4.0\":{\"entities\":[],\"content\":\"Primary \",\"roi_id\":{\"table_roi_id\":\"a36f291b-21c0-48b2-8855-b0c2ee4bdfaf\",\"row_roi_id\":\"37cce636-428f-46d9-925c-fdff3e888e80\",\"column_roi_id\":\"0c0cb0d5-adb3-4316-938f-7ecbf42d1fdf\",\"datacell_roi_id\":\"5afe4e5d-11cf-41e5-9328-2410d0d9a003\"},\"table_index\":2.0,\"qc_change_type\":\"\"},\"5.0\":\"\"},{\"1.0\":\"\",\"2.0\":{\"entities\":[],\"content\":\"Efficacy\",\"roi_id\":{\"table_roi_id\":\"a36f291b-21c0-48b2-8855-b0c2ee4bdfaf\",\"row_roi_id\":\"fcda2b82-2970-4c9e-9970-fa605d7161c0\",\"column_roi_id\":\"e247d2ad-035b-4e44-bdc3-114837f94e8d\",\"datacell_roi_id\":\"326b71fd-2f5e-4a02-b088-7352c0684f10\"},\"table_index\":2.0,\"qc_change_type\":\"\"},\"3.0\":{\"entities\":[{\"start_idx\":26,\"end_idx\":35,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"}],\"content\":\"To assess the efficacy of nirsevimab in reducing medically attended LRTI due to RT-PCR-confirmed RSV, compared to placebo, when administered as a single fixed IM dose to healthy preterm and term infants born \\u2265 29 weeks 0 days GA and entering their first RSV season\",\"roi_id\":{\"table_roi_id\":\"a36f291b-21c0-48b2-8855-b0c2ee4bdfaf\",\"row_roi_id\":\"fcda2b82-2970-4c9e-9970-fa605d7161c0\",\"column_roi_id\":\"fb9cde2b-2cd4-40bc-ba98-732c959acfe8\",\"datacell_roi_id\":\"cdbb865c-f5da-4a75-b8c8-7967c35c110c\"},\"table_index\":2.0,\"qc_change_type\":\"\"},\"4.0\":{\"entities\":[],\"content\":\"Incidence of medically attended LRTI (inpatient and outpatient) due to RT-PCRconfirmed RSV through 150 days after dosing (ie, during a typical 5-month RSV season)\",\"roi_id\":{\"table_roi_id\":\"a36f291b-21c0-48b2-8855-b0c2ee4bdfaf\",\"row_roi_id\":\"fcda2b82-2970-4c9e-9970-fa605d7161c0\",\"column_roi_id\":\"f065381b-5beb-433f-bb92-4a00c079ddbf\",\"datacell_roi_id\":\"9b43c1a3-d4b2-4afd-97bd-6a2afd97a94c\"},\"table_index\":2.0,\"qc_change_type\":\"\"},\"5.0\":\"\"},{\"1.0\":\"\",\"2.0\":{\"entities\":[],\"content\":\"Secondary\",\"roi_id\":{\"table_roi_id\":\"a36f291b-21c0-48b2-8855-b0c2ee4bdfaf\",\"row_roi_id\":\"8e6a0abc-ad5f-4fc6-98cf-12d127e8ba44\",\"column_roi_id\":\"0a4403e4-50eb-4d37-8ed7-e32e0a9e8fd7\",\"datacell_roi_id\":\"5bceb069-5367-49f4-9ad3-7b166d03c725\"},\"table_index\":2.0,\"qc_change_type\":\"\"},\"3.0\":{\"entities\":[],\"content\":\"Secondary\",\"roi_id\":{\"table_roi_id\":\"a36f291b-21c0-48b2-8855-b0c2ee4bdfaf\",\"row_roi_id\":\"8e6a0abc-ad5f-4fc6-98cf-12d127e8ba44\",\"column_roi_id\":\"0a4403e4-50eb-4d37-8ed7-e32e0a9e8fd7\",\"datacell_roi_id\":\"5bceb069-5367-49f4-9ad3-7b166d03c725\"},\"table_index\":2.0,\"qc_change_type\":\"\"},\"4.0\":{\"entities\":[],\"content\":\"Secondary\",\"roi_id\":{\"table_roi_id\":\"a36f291b-21c0-48b2-8855-b0c2ee4bdfaf\",\"row_roi_id\":\"8e6a0abc-ad5f-4fc6-98cf-12d127e8ba44\",\"column_roi_id\":\"0a4403e4-50eb-4d37-8ed7-e32e0a9e8fd7\",\"datacell_roi_id\":\"5bceb069-5367-49f4-9ad3-7b166d03c725\"},\"table_index\":2.0,\"qc_change_type\":\"\"},\"5.0\":\"\"},{\"1.0\":\"\",\"2.0\":{\"entities\":[],\"content\":\"Efficacy\",\"roi_id\":{\"table_roi_id\":\"a36f291b-21c0-48b2-8855-b0c2ee4bdfaf\",\"row_roi_id\":\"1b8c177a-5f2b-4123-a15d-9f7ddc1b43dd\",\"column_roi_id\":\"cfd6e5e6-e5b0-49d0-a6fe-e66b56fc46b8\",\"datacell_roi_id\":\"da5fe1f2-e9cf-42d7-adbe-9f424415da5a\"},\"table_index\":2.0,\"qc_change_type\":\"\"},\"3.0\":{\"entities\":[{\"start_idx\":26,\"end_idx\":35,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":26,\"end_idx\":35,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"}],\"content\":\"To assess the efficacy of nirsevimab in reducing hospitalizations due to RT-PCR-confirmed RSV, compared to placebo\",\"roi_id\":{\"table_roi_id\":\"a36f291b-21c0-48b2-8855-b0c2ee4bdfaf\",\"row_roi_id\":\"1b8c177a-5f2b-4123-a15d-9f7ddc1b43dd\",\"column_roi_id\":\"5c46bfa2-d2e6-4bba-a82f-228767f84a17\",\"datacell_roi_id\":\"f8b3a518-aae1-46a8-aaa3-9cac8df4ab80\"},\"table_index\":2.0,\"qc_change_type\":\"\"},\"4.0\":{\"entities\":[],\"content\":\"Incidence of hospitalizations due to RT-PCR-confirmed RSV through 150 days after dosing (ie, during a typical 5-month RSV season)\",\"roi_id\":{\"table_roi_id\":\"a36f291b-21c0-48b2-8855-b0c2ee4bdfaf\",\"row_roi_id\":\"1b8c177a-5f2b-4123-a15d-9f7ddc1b43dd\",\"column_roi_id\":\"05204e47-6136-42b9-8772-e071df885d97\",\"datacell_roi_id\":\"4a3239df-a0dd-401a-91cd-160d16f076d3\"},\"table_index\":2.0,\"qc_change_type\":\"\"},\"5.0\":\"\"},{\"1.0\":\"\",\"2.0\":{\"entities\":[],\"content\":\"Safety\",\"roi_id\":{\"table_roi_id\":\"a36f291b-21c0-48b2-8855-b0c2ee4bdfaf\",\"row_roi_id\":\"851707bf-3abe-42fc-ac47-01c760a6f684\",\"column_roi_id\":\"e4f2c669-2a87-45ae-8b97-f32867ffd42f\",\"datacell_roi_id\":\"8893710d-297d-42e9-a9e6-9808aaf9f5cb\"},\"table_index\":2.0,\"qc_change_type\":\"\"},\"3.0\":{\"entities\":[{\"start_idx\":43,\"end_idx\":52,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"}],\"content\":\"To evaluate the safety and tolerability of nirsevimab when administered as a single fixed IM dose, compared to placebo\",\"roi_id\":{\"table_roi_id\":\"a36f291b-21c0-48b2-8855-b0c2ee4bdfaf\",\"row_roi_id\":\"851707bf-3abe-42fc-ac47-01c760a6f684\",\"column_roi_id\":\"0e895868-23c3-41fc-81fe-271283106fb4\",\"datacell_roi_id\":\"7245db80-96fa-4ff1-956e-e23c87bae16f\"},\"table_index\":2.0,\"qc_change_type\":\"\"},\"4.0\":{\"entities\":[{\"start_idx\":27,\"end_idx\":36,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"}],\"content\":\"Safety and tolerability of nirsevimab as assessed by the occurrence of treatmentemergent adverse events (TEAEs), treatment-emergent serious adverse events (TESAEs), adverse events of special interest (AESIs), and new onset chronic diseases (NOCDs)\",\"roi_id\":{\"table_roi_id\":\"a36f291b-21c0-48b2-8855-b0c2ee4bdfaf\",\"row_roi_id\":\"851707bf-3abe-42fc-ac47-01c760a6f684\",\"column_roi_id\":\"f08b0518-b9c9-423f-b0aa-f2f1f8f85220\",\"datacell_roi_id\":\"86b21d08-997d-4013-94a4-c9df1874c9f1\"},\"table_index\":2.0,\"qc_change_type\":\"\"},\"5.0\":\"\"},{\"1.0\":\"\",\"2.0\":{\"entities\":[],\"content\":\"Pharmacokinetics (PK)\",\"roi_id\":{\"table_roi_id\":\"a36f291b-21c0-48b2-8855-b0c2ee4bdfaf\",\"row_roi_id\":\"96c62218-c902-4e80-bd00-04d65d9a0a02\",\"column_roi_id\":\"527d8cfd-9ec0-4315-9aa0-b78ec28b7fe6\",\"datacell_roi_id\":\"95a9301c-0009-4f9a-bac5-8f5626c84348\"},\"table_index\":2.0,\"qc_change_type\":\"\"},\"3.0\":{\"entities\":[{\"start_idx\":36,\"end_idx\":45,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"}],\"content\":\"To evaluate serum concentrations of nirsevimab\",\"roi_id\":{\"table_roi_id\":\"a36f291b-21c0-48b2-8855-b0c2ee4bdfaf\",\"row_roi_id\":\"96c62218-c902-4e80-bd00-04d65d9a0a02\",\"column_roi_id\":\"fadd0131-7b6e-4f08-b8bc-a32720f665ff\",\"datacell_roi_id\":\"bccd7c7e-7ff5-451b-864b-4b4f2aa0ded9\"},\"table_index\":2.0,\"qc_change_type\":\"\"},\"4.0\":{\"entities\":[{\"start_idx\":11,\"end_idx\":20,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"}],\"content\":\"Summary of nirsevimab serum concentrations and estimated PK parameters (maximum observed concentration, area under the concentration-time curve, apparent clearance, and terminal-phase halflife), if data permit\",\"roi_id\":{\"table_roi_id\":\"a36f291b-21c0-48b2-8855-b0c2ee4bdfaf\",\"row_roi_id\":\"96c62218-c902-4e80-bd00-04d65d9a0a02\",\"column_roi_id\":\"144cbd98-8214-4ff2-8587-5cb01166ffd4\",\"datacell_roi_id\":\"c28555da-126c-48a8-813b-e7abcc3a0410\"},\"table_index\":2.0,\"qc_change_type\":\"\"},\"5.0\":\"\"},{\"1.0\":\"\",\"2.0\":{\"entities\":[],\"content\":\"ADA\",\"roi_id\":{\"table_roi_id\":\"a36f291b-21c0-48b2-8855-b0c2ee4bdfaf\",\"row_roi_id\":\"2f3da840-100f-4180-b7ae-ad7e54e5cdd9\",\"column_roi_id\":\"c9c13d1c-04b2-41c5-896a-40467ffaed39\",\"datacell_roi_id\":\"af0cd80f-9d79-4d28-8eea-53084103e2da\"},\"table_index\":2.0,\"qc_change_type\":\"\"},\"3.0\":{\"entities\":[{\"start_idx\":29,\"end_idx\":38,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":100.0,\"text\":\"nirsevimab\"}],\"content\":\"To evaluate ADA responses to nirsevimab in serum\",\"roi_id\":{\"table_roi_id\":\"a36f291b-21c0-48b2-8855-b0c2ee4bdfaf\",\"row_roi_id\":\"2f3da840-100f-4180-b7ae-ad7e54e5cdd9\",\"column_roi_id\":\"d7a43690-6251-4bbf-9067-136bed709431\",\"datacell_roi_id\":\"e996bdcc-68bf-4626-91b7-862278c333a5\"},\"table_index\":2.0,\"qc_change_type\":\"\"},\"4.0\":{\"entities\":[{\"start_idx\":20,\"end_idx\":29,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":100.0,\"text\":\"nirsevimab\"}],\"content\":\"Incidence of ADA to nirsevimab in serum\",\"roi_id\":{\"table_roi_id\":\"a36f291b-21c0-48b2-8855-b0c2ee4bdfaf\",\"row_roi_id\":\"2f3da840-100f-4180-b7ae-ad7e54e5cdd9\",\"column_roi_id\":\"d6bdf59e-2c1f-4b52-85bb-7e00a2d44209\",\"datacell_roi_id\":\"cb9d434f-ad25-4378-8267-e355ae4ed464\"},\"table_index\":2.0,\"qc_change_type\":\"\"},\"5.0\":\"\"}]",
      "SectionHeaderPrintPage": "1",
      "TableIndex": "3",
      "TableName": "Protocol Synopsis",
      "Header": [
        1,
        2
      ]
    },
    "font_info": {
      "IsBold": true,
      "font_size": 20,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "b316cd53-f891-4012-9b92-007b17b29599",
        "childbox": "2d3fb9d5-03d0-4362-918c-5e45c404e5a6",
        "subtext": "3b0207f8-c7b4-4e42-836f-281730c910bb"
      },
      "Bold": true,
      "Caps": false,
      "ColorRGB": 0,
      "DStrike": false,
      "Emboss": false,
      "Highlight": "",
      "Imprint": false,
      "Italics": false,
      "Outline": false,
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": 20,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "derived_section_type": "table",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 1,
    "line_id": 15,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "778a5b96-3128-4c2f-9c6d-e824afe7384d",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 1,
    "line_id": 16,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "e892e8f9-676f-4624-a0f2-9f2165370a14",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 1,
    "line_id": 17,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "3c2d58f3-4977-407e-b061-66c172b9614d",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 1,
    "line_id": 18,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "9631c655-19fd-40b1-9c6c-eafdbdcb9abb",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 1,
    "line_id": 19,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "10fb72bf-8678-49a2-b5b4-6bd8881f99b1",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 1,
    "line_id": 20,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "f9a72dc6-feff-4aed-ad38-ce39a3e7cee3",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 1,
    "line_id": 21,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "da89de06-fe39-4684-a286-18f23511749f",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 1,
    "line_id": 22,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "5a61080d-5953-449a-a1cc-d37cafd0657f",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 1,
    "line_id": 23,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "5d3df976-3025-4a10-b65c-462f0a81600c",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 1,
    "line_id": 24,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "a58ff6be-ae05-4622-a697-e7f79499b011",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 1,
    "line_id": 25,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "7b783580-8d72-4561-8ddc-3dccadb94ad4",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 1,
    "line_id": 26,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "bcf981a3-0b74-4654-95ec-d0631f5edbab",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 1,
    "line_id": 27,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "c4b32d4b-1f70-4c6c-b687-f596ea0d3da2",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 1,
    "line_id": 28,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "acdfc355-b248-4573-a481-fb7556611f93",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 1,
    "line_id": 29,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "5f3a2359-96aa-49d9-bb00-220c45233cdf",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 1,
    "line_id": 30,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "481ef599-87bb-4cbb-b9c3-4eea935bba82",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 1,
    "line_id": 31,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "eef9590c-a845-433c-ac38-92844a5855e6",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 1,
    "line_id": 32,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": {
      "Table": "<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th>ColIndex</th>\n      <th>1.0</th>\n      <th>2.0</th>\n      <th>3.0</th>\n      <th>4.0</th>\n      <th>5.0</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td></td>\n      <td>Type</td>\n      <td>Objective</td>\n      <td>Endpoint</td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td></td>\n      <td>Exploratory</td>\n      <td>Exploratory</td>\n      <td>Exploratory</td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td></td>\n      <td>Healthcare resource utilization (HRU)</td>\n      <td>To assess HRU for nirsevimab recipients compared to placebo recipients</td>\n      <td>Magnitude of HRU (eg, number of admissions to hospitals and intensive care units and duration of stay; number of subjects who require respiratory support and supplemental oxygen and the duration of use; number and type of outpatient visits, eg, emergency room [ER], outpatient clinic; and number of prescription and over-thecounter [OTC] medications and duration of use)</td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td></td>\n      <td>RSV resistance monitoring</td>\n      <td>To characterize resistance to nirsevimab through genotypic and phenotypic analyses</td>\n      <td>Genotypic analysis and susceptibility of RSV variants to neutralization by nirsevimab</td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td></td>\n      <td>RSV LRTI after Day 151</td>\n      <td>To assess the incidence of medically attended LRTI due to RT-PCRconfirmed RSV after Day 151 for nirsevimab recipients compared to placebo</td>\n      <td>Incidence of medically attended LRTI (inpatient and outpatient) due to RT-PCRconfirmed RSV from Day 152 to Day 361</td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>5</th>\n      <td>STUDY DESIGN Study D5290C00006  is a Phase 3, randomized, double-blind, placebo-controlled study to determine if nirsevimab will prevent medically attended RSV-confirmed LRTI in healthy preterm and term infants born ≥ 29 weeks 0 days GA and entering their first RSV season. Approximately 800 subjects will be randomized. Randomization will be stratified by subject age at the time of randomization (≤ 3 months, > 3 to ≤ 6 months, > 6 months), and by GA (< 35 weeks GA, ≥ 35 weeks GA). Enrollment of infants > 6 months of age will be limited to approximately 100. All subjects will be followed through 1 year after dose administration. Subjects will be monitored throughout the study for LRTI. All subjects seeking medical attention for a respiratory illness (inpatient or outpatient setting) will be evaluated for the occurrence of LRTI. All subjects found to have an LRTI and all subjects who require hospitalization for a respiratory infection, even if there is not a diagnosis of LRTI, should have respiratory samples obtained and respiratory assessment forms completed. Samples should be collected for all of these respiratory events even those not meeting the protocoldefined endpoint of LRTI. Subjects who have a primary hospitalization for a respiratory infection (ie, upper or lower respiratory tract), a respiratory deterioration during a hospitalization, or who seek outpatient medical attention (including ER visits) for a lower respiratory illness, will be assessed clinically for the presence of LRTI and for RSV by central laboratory diagnostic testing of respiratory secretions. In addition to the clinical assessment of LRTI, there is a protocol definition using objective criteria for the determination of a protocol-defined medically attended LRTI. To meet the protocol-defined endpoint of medically attended LRTI, subjects with signs of LRTI must have documented at least one physical examination finding of rhonchi, rales, crackles, or wheeze AND at least one of the following clinical signs: Increased respiratory rate at rest (age < 2 months, ≥ 60 breaths/minute; age 2 to 6 months, ≥ 50 breaths/minute; age > 6 months, ≥ 40 breaths/minute), OR Hypoxemia (in room air: oxygen saturation < 95% at altitudes ≤ 1,800 meters or < 92% at altitudes > 1,800 meters), OR Clinical signs of severe respiratory disease (eg, acute hypoxic or ventilatory failure, new onset apnea, nasal flaring, intercostal, subcostal or supraclavicular retractions, grunting) or dehydration secondary to inadequate oral intake due to respiratory distress (need for intravenous fluid) A diagnosis of RSV LRTI requires having a respiratory sample positive for RSV. Testing for RSV will be performed centrally in China using an RT-PCR assay.</td>\n      <td>STUDY DESIGN Study D5290C00006  is a Phase 3, randomized, double-blind, placebo-controlled study to determine if nirsevimab will prevent medically attended RSV-confirmed LRTI in healthy preterm and term infants born ≥ 29 weeks 0 days GA and entering their first RSV season. Approximately 800 subjects will be randomized. Randomization will be stratified by subject age at the time of randomization (≤ 3 months, > 3 to ≤ 6 months, > 6 months), and by GA (< 35 weeks GA, ≥ 35 weeks GA). Enrollment of infants > 6 months of age will be limited to approximately 100. All subjects will be followed through 1 year after dose administration. Subjects will be monitored throughout the study for LRTI. All subjects seeking medical attention for a respiratory illness (inpatient or outpatient setting) will be evaluated for the occurrence of LRTI. All subjects found to have an LRTI and all subjects who require hospitalization for a respiratory infection, even if there is not a diagnosis of LRTI, should have respiratory samples obtained and respiratory assessment forms completed. Samples should be collected for all of these respiratory events even those not meeting the protocoldefined endpoint of LRTI. Subjects who have a primary hospitalization for a respiratory infection (ie, upper or lower respiratory tract), a respiratory deterioration during a hospitalization, or who seek outpatient medical attention (including ER visits) for a lower respiratory illness, will be assessed clinically for the presence of LRTI and for RSV by central laboratory diagnostic testing of respiratory secretions. In addition to the clinical assessment of LRTI, there is a protocol definition using objective criteria for the determination of a protocol-defined medically attended LRTI. To meet the protocol-defined endpoint of medically attended LRTI, subjects with signs of LRTI must have documented at least one physical examination finding of rhonchi, rales, crackles, or wheeze AND at least one of the following clinical signs: Increased respiratory rate at rest (age < 2 months, ≥ 60 breaths/minute; age 2 to 6 months, ≥ 50 breaths/minute; age > 6 months, ≥ 40 breaths/minute), OR Hypoxemia (in room air: oxygen saturation < 95% at altitudes ≤ 1,800 meters or < 92% at altitudes > 1,800 meters), OR Clinical signs of severe respiratory disease (eg, acute hypoxic or ventilatory failure, new onset apnea, nasal flaring, intercostal, subcostal or supraclavicular retractions, grunting) or dehydration secondary to inadequate oral intake due to respiratory distress (need for intravenous fluid) A diagnosis of RSV LRTI requires having a respiratory sample positive for RSV. Testing for RSV will be performed centrally in China using an RT-PCR assay.</td>\n      <td>STUDY DESIGN Study D5290C00006  is a Phase 3, randomized, double-blind, placebo-controlled study to determine if nirsevimab will prevent medically attended RSV-confirmed LRTI in healthy preterm and term infants born ≥ 29 weeks 0 days GA and entering their first RSV season. Approximately 800 subjects will be randomized. Randomization will be stratified by subject age at the time of randomization (≤ 3 months, > 3 to ≤ 6 months, > 6 months), and by GA (< 35 weeks GA, ≥ 35 weeks GA). Enrollment of infants > 6 months of age will be limited to approximately 100. All subjects will be followed through 1 year after dose administration. Subjects will be monitored throughout the study for LRTI. All subjects seeking medical attention for a respiratory illness (inpatient or outpatient setting) will be evaluated for the occurrence of LRTI. All subjects found to have an LRTI and all subjects who require hospitalization for a respiratory infection, even if there is not a diagnosis of LRTI, should have respiratory samples obtained and respiratory assessment forms completed. Samples should be collected for all of these respiratory events even those not meeting the protocoldefined endpoint of LRTI. Subjects who have a primary hospitalization for a respiratory infection (ie, upper or lower respiratory tract), a respiratory deterioration during a hospitalization, or who seek outpatient medical attention (including ER visits) for a lower respiratory illness, will be assessed clinically for the presence of LRTI and for RSV by central laboratory diagnostic testing of respiratory secretions. In addition to the clinical assessment of LRTI, there is a protocol definition using objective criteria for the determination of a protocol-defined medically attended LRTI. To meet the protocol-defined endpoint of medically attended LRTI, subjects with signs of LRTI must have documented at least one physical examination finding of rhonchi, rales, crackles, or wheeze AND at least one of the following clinical signs: Increased respiratory rate at rest (age < 2 months, ≥ 60 breaths/minute; age 2 to 6 months, ≥ 50 breaths/minute; age > 6 months, ≥ 40 breaths/minute), OR Hypoxemia (in room air: oxygen saturation < 95% at altitudes ≤ 1,800 meters or < 92% at altitudes > 1,800 meters), OR Clinical signs of severe respiratory disease (eg, acute hypoxic or ventilatory failure, new onset apnea, nasal flaring, intercostal, subcostal or supraclavicular retractions, grunting) or dehydration secondary to inadequate oral intake due to respiratory distress (need for intravenous fluid) A diagnosis of RSV LRTI requires having a respiratory sample positive for RSV. Testing for RSV will be performed centrally in China using an RT-PCR assay.</td>\n      <td>STUDY DESIGN Study D5290C00006  is a Phase 3, randomized, double-blind, placebo-controlled study to determine if nirsevimab will prevent medically attended RSV-confirmed LRTI in healthy preterm and term infants born ≥ 29 weeks 0 days GA and entering their first RSV season. Approximately 800 subjects will be randomized. Randomization will be stratified by subject age at the time of randomization (≤ 3 months, > 3 to ≤ 6 months, > 6 months), and by GA (< 35 weeks GA, ≥ 35 weeks GA). Enrollment of infants > 6 months of age will be limited to approximately 100. All subjects will be followed through 1 year after dose administration. Subjects will be monitored throughout the study for LRTI. All subjects seeking medical attention for a respiratory illness (inpatient or outpatient setting) will be evaluated for the occurrence of LRTI. All subjects found to have an LRTI and all subjects who require hospitalization for a respiratory infection, even if there is not a diagnosis of LRTI, should have respiratory samples obtained and respiratory assessment forms completed. Samples should be collected for all of these respiratory events even those not meeting the protocoldefined endpoint of LRTI. Subjects who have a primary hospitalization for a respiratory infection (ie, upper or lower respiratory tract), a respiratory deterioration during a hospitalization, or who seek outpatient medical attention (including ER visits) for a lower respiratory illness, will be assessed clinically for the presence of LRTI and for RSV by central laboratory diagnostic testing of respiratory secretions. In addition to the clinical assessment of LRTI, there is a protocol definition using objective criteria for the determination of a protocol-defined medically attended LRTI. To meet the protocol-defined endpoint of medically attended LRTI, subjects with signs of LRTI must have documented at least one physical examination finding of rhonchi, rales, crackles, or wheeze AND at least one of the following clinical signs: Increased respiratory rate at rest (age < 2 months, ≥ 60 breaths/minute; age 2 to 6 months, ≥ 50 breaths/minute; age > 6 months, ≥ 40 breaths/minute), OR Hypoxemia (in room air: oxygen saturation < 95% at altitudes ≤ 1,800 meters or < 92% at altitudes > 1,800 meters), OR Clinical signs of severe respiratory disease (eg, acute hypoxic or ventilatory failure, new onset apnea, nasal flaring, intercostal, subcostal or supraclavicular retractions, grunting) or dehydration secondary to inadequate oral intake due to respiratory distress (need for intravenous fluid) A diagnosis of RSV LRTI requires having a respiratory sample positive for RSV. Testing for RSV will be performed centrally in China using an RT-PCR assay.</td>\n      <td>STUDY DESIGN Study D5290C00006  is a Phase 3, randomized, double-blind, placebo-controlled study to determine if nirsevimab will prevent medically attended RSV-confirmed LRTI in healthy preterm and term infants born ≥ 29 weeks 0 days GA and entering their first RSV season. Approximately 800 subjects will be randomized. Randomization will be stratified by subject age at the time of randomization (≤ 3 months, > 3 to ≤ 6 months, > 6 months), and by GA (< 35 weeks GA, ≥ 35 weeks GA). Enrollment of infants > 6 months of age will be limited to approximately 100. All subjects will be followed through 1 year after dose administration. Subjects will be monitored throughout the study for LRTI. All subjects seeking medical attention for a respiratory illness (inpatient or outpatient setting) will be evaluated for the occurrence of LRTI. All subjects found to have an LRTI and all subjects who require hospitalization for a respiratory infection, even if there is not a diagnosis of LRTI, should have respiratory samples obtained and respiratory assessment forms completed. Samples should be collected for all of these respiratory events even those not meeting the protocoldefined endpoint of LRTI. Subjects who have a primary hospitalization for a respiratory infection (ie, upper or lower respiratory tract), a respiratory deterioration during a hospitalization, or who seek outpatient medical attention (including ER visits) for a lower respiratory illness, will be assessed clinically for the presence of LRTI and for RSV by central laboratory diagnostic testing of respiratory secretions. In addition to the clinical assessment of LRTI, there is a protocol definition using objective criteria for the determination of a protocol-defined medically attended LRTI. To meet the protocol-defined endpoint of medically attended LRTI, subjects with signs of LRTI must have documented at least one physical examination finding of rhonchi, rales, crackles, or wheeze AND at least one of the following clinical signs: Increased respiratory rate at rest (age < 2 months, ≥ 60 breaths/minute; age 2 to 6 months, ≥ 50 breaths/minute; age > 6 months, ≥ 40 breaths/minute), OR Hypoxemia (in room air: oxygen saturation < 95% at altitudes ≤ 1,800 meters or < 92% at altitudes > 1,800 meters), OR Clinical signs of severe respiratory disease (eg, acute hypoxic or ventilatory failure, new onset apnea, nasal flaring, intercostal, subcostal or supraclavicular retractions, grunting) or dehydration secondary to inadequate oral intake due to respiratory distress (need for intravenous fluid) A diagnosis of RSV LRTI requires having a respiratory sample positive for RSV. Testing for RSV will be performed centrally in China using an RT-PCR assay.</td>\n    </tr>\n  </tbody>\n</table>",
      "TableProperties": "[{\"1.0\":\"\",\"2.0\":{\"entities\":[],\"content\":\"Type\",\"roi_id\":{\"table_roi_id\":\"717bf5c9-580a-4a74-94c6-562a58af1122\",\"row_roi_id\":\"2a774db0-bb9f-45d3-a132-be3657433d66\",\"column_roi_id\":\"2fc6b09d-4a1f-4708-a1a9-6a254538d0a9\",\"datacell_roi_id\":\"317c701e-1c1c-4c2c-a63b-66aa251328fa\"},\"table_index\":3.0,\"qc_change_type\":\"\"},\"3.0\":{\"entities\":[],\"content\":\"Objective\",\"roi_id\":{\"table_roi_id\":\"717bf5c9-580a-4a74-94c6-562a58af1122\",\"row_roi_id\":\"2a774db0-bb9f-45d3-a132-be3657433d66\",\"column_roi_id\":\"70a523eb-0698-4d40-a958-36498ce7ad22\",\"datacell_roi_id\":\"e4636bb0-c046-4473-9a93-c93822bef69e\"},\"table_index\":3.0,\"qc_change_type\":\"\"},\"4.0\":{\"entities\":[],\"content\":\"Endpoint\",\"roi_id\":{\"table_roi_id\":\"717bf5c9-580a-4a74-94c6-562a58af1122\",\"row_roi_id\":\"2a774db0-bb9f-45d3-a132-be3657433d66\",\"column_roi_id\":\"790c01c5-01d5-47f0-933e-635bb0f02a8f\",\"datacell_roi_id\":\"cf70e021-fe3b-44d8-8965-4eea7f777c8c\"},\"table_index\":3.0,\"qc_change_type\":\"\"},\"5.0\":\"\"},{\"1.0\":\"\",\"2.0\":{\"entities\":[],\"content\":\"Exploratory\",\"roi_id\":{\"table_roi_id\":\"717bf5c9-580a-4a74-94c6-562a58af1122\",\"row_roi_id\":\"efa56fa1-5bfb-4864-812c-5ec4fc356a80\",\"column_roi_id\":\"781f87e5-3ab5-4c3f-9e59-69f27b276558\",\"datacell_roi_id\":\"9af61c05-e519-4ff0-b61b-60ebc2a5dcba\"},\"table_index\":3.0,\"qc_change_type\":\"\"},\"3.0\":{\"entities\":[],\"content\":\"Exploratory\",\"roi_id\":{\"table_roi_id\":\"717bf5c9-580a-4a74-94c6-562a58af1122\",\"row_roi_id\":\"efa56fa1-5bfb-4864-812c-5ec4fc356a80\",\"column_roi_id\":\"781f87e5-3ab5-4c3f-9e59-69f27b276558\",\"datacell_roi_id\":\"9af61c05-e519-4ff0-b61b-60ebc2a5dcba\"},\"table_index\":3.0,\"qc_change_type\":\"\"},\"4.0\":{\"entities\":[],\"content\":\"Exploratory\",\"roi_id\":{\"table_roi_id\":\"717bf5c9-580a-4a74-94c6-562a58af1122\",\"row_roi_id\":\"efa56fa1-5bfb-4864-812c-5ec4fc356a80\",\"column_roi_id\":\"781f87e5-3ab5-4c3f-9e59-69f27b276558\",\"datacell_roi_id\":\"9af61c05-e519-4ff0-b61b-60ebc2a5dcba\"},\"table_index\":3.0,\"qc_change_type\":\"\"},\"5.0\":\"\"},{\"1.0\":\"\",\"2.0\":{\"entities\":[],\"content\":\"Healthcare resource utilization (HRU)\",\"roi_id\":{\"table_roi_id\":\"717bf5c9-580a-4a74-94c6-562a58af1122\",\"row_roi_id\":\"d661f3a8-dfdf-44d8-95a3-7c02a6303267\",\"column_roi_id\":\"a89d21bd-78ec-45e0-a789-d2744dbf4ce1\",\"datacell_roi_id\":\"19e1c0a9-0575-4537-820c-1a8a73da3b18\"},\"table_index\":3.0,\"qc_change_type\":\"\"},\"3.0\":{\"entities\":[{\"start_idx\":18,\"end_idx\":27,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"}],\"content\":\"To assess HRU for nirsevimab recipients compared to placebo recipients\",\"roi_id\":{\"table_roi_id\":\"717bf5c9-580a-4a74-94c6-562a58af1122\",\"row_roi_id\":\"d661f3a8-dfdf-44d8-95a3-7c02a6303267\",\"column_roi_id\":\"7c671192-a4e8-40ae-ac33-2cac034c6ddb\",\"datacell_roi_id\":\"6a24dbd9-9837-4f87-993f-4ab882c90271\"},\"table_index\":3.0,\"qc_change_type\":\"\"},\"4.0\":{\"entities\":[],\"content\":\"Magnitude of HRU (eg, number of admissions to hospitals and intensive care units and duration of stay; number of subjects who require respiratory support and supplemental oxygen and the duration of use; number and type of outpatient visits, eg, emergency room [ER], outpatient clinic; and number of prescription and over-thecounter [OTC] medications and duration of use)\",\"roi_id\":{\"table_roi_id\":\"717bf5c9-580a-4a74-94c6-562a58af1122\",\"row_roi_id\":\"d661f3a8-dfdf-44d8-95a3-7c02a6303267\",\"column_roi_id\":\"78e3cd08-72f2-484b-a8a6-eccc0ef56c41\",\"datacell_roi_id\":\"734cdd60-0b03-4f2a-8bd5-541bd8828150\"},\"table_index\":3.0,\"qc_change_type\":\"\"},\"5.0\":\"\"},{\"1.0\":\"\",\"2.0\":{\"entities\":[],\"content\":\"RSV resistance monitoring\",\"roi_id\":{\"table_roi_id\":\"717bf5c9-580a-4a74-94c6-562a58af1122\",\"row_roi_id\":\"a26c2533-0ccd-4629-b95f-215eb09c7569\",\"column_roi_id\":\"df28f263-42f1-4882-bb57-b9888c5f0bda\",\"datacell_roi_id\":\"d6426a10-2060-4975-8498-b34fa676c36c\"},\"table_index\":3.0,\"qc_change_type\":\"\"},\"3.0\":{\"entities\":[{\"start_idx\":30,\"end_idx\":39,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":100.0,\"text\":\"nirsevimab\"}],\"content\":\"To characterize resistance to nirsevimab through genotypic and phenotypic analyses\",\"roi_id\":{\"table_roi_id\":\"717bf5c9-580a-4a74-94c6-562a58af1122\",\"row_roi_id\":\"a26c2533-0ccd-4629-b95f-215eb09c7569\",\"column_roi_id\":\"cb435324-30fb-483c-9e91-27e96aae253c\",\"datacell_roi_id\":\"1e56da78-5cca-4079-84bc-944e3e5bf2e3\"},\"table_index\":3.0,\"qc_change_type\":\"\"},\"4.0\":{\"entities\":[{\"start_idx\":75,\"end_idx\":84,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"}],\"content\":\"Genotypic analysis and susceptibility of RSV variants to neutralization by nirsevimab\",\"roi_id\":{\"table_roi_id\":\"717bf5c9-580a-4a74-94c6-562a58af1122\",\"row_roi_id\":\"a26c2533-0ccd-4629-b95f-215eb09c7569\",\"column_roi_id\":\"8da08ef4-e98f-43ad-a6bb-d012e9629b17\",\"datacell_roi_id\":\"8d2037c2-b370-4010-abd0-feed40633e5a\"},\"table_index\":3.0,\"qc_change_type\":\"\"},\"5.0\":\"\"},{\"1.0\":\"\",\"2.0\":{\"entities\":[{\"start_idx\":15,\"end_idx\":17,\"standard_entity_name\":\"OTHER: Person Name\",\"subcategory\":\"OTHER: Person Name\",\"confidence\":100.0,\"text\":\"Day\"}],\"content\":\"RSV LRTI after Day 151\",\"roi_id\":{\"table_roi_id\":\"717bf5c9-580a-4a74-94c6-562a58af1122\",\"row_roi_id\":\"63ef8ac8-3ac9-4d58-af77-8dbaa8f02a5e\",\"column_roi_id\":\"b513caf8-edbb-45b8-bd6d-828ba9bbd67f\",\"datacell_roi_id\":\"ed171f01-9ff1-49e0-847b-a2f9abcbd620\"},\"table_index\":3.0,\"qc_change_type\":\"\"},\"3.0\":{\"entities\":[{\"start_idx\":96,\"end_idx\":105,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":84,\"end_idx\":86,\"standard_entity_name\":\"OTHER: Person Name\",\"subcategory\":\"OTHER: Person Name\",\"confidence\":100.0,\"text\":\"Day\"}],\"content\":\"To assess the incidence of medically attended LRTI due to RT-PCRconfirmed RSV after Day 151 for nirsevimab recipients compared to placebo\",\"roi_id\":{\"table_roi_id\":\"717bf5c9-580a-4a74-94c6-562a58af1122\",\"row_roi_id\":\"63ef8ac8-3ac9-4d58-af77-8dbaa8f02a5e\",\"column_roi_id\":\"9802a2a3-bd08-4ef6-baad-108adf341aa0\",\"datacell_roi_id\":\"c44a5448-b672-486f-8b2d-598dba643436\"},\"table_index\":3.0,\"qc_change_type\":\"\"},\"4.0\":{\"entities\":[{\"start_idx\":96,\"end_idx\":98,\"standard_entity_name\":\"OTHER: Person Name\",\"subcategory\":\"OTHER: Person Name\",\"confidence\":100.0,\"text\":\"Day\"},{\"start_idx\":107,\"end_idx\":109,\"standard_entity_name\":\"OTHER: Person Name\",\"subcategory\":\"OTHER: Person Name\",\"confidence\":100.0,\"text\":\"Day\"}],\"content\":\"Incidence of medically attended LRTI (inpatient and outpatient) due to RT-PCRconfirmed RSV from Day 152 to Day 361\",\"roi_id\":{\"table_roi_id\":\"717bf5c9-580a-4a74-94c6-562a58af1122\",\"row_roi_id\":\"63ef8ac8-3ac9-4d58-af77-8dbaa8f02a5e\",\"column_roi_id\":\"f672dc4b-4644-469a-82b4-871d7476d26b\",\"datacell_roi_id\":\"1bb86a48-7d14-4019-b086-7181dafe55b5\"},\"table_index\":3.0,\"qc_change_type\":\"\"},\"5.0\":\"\"},{\"1.0\":{\"entities\":[{\"start_idx\":113,\"end_idx\":122,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"}],\"content\":\"STUDY DESIGN Study D5290C00006  is a Phase 3, randomized, double-blind, placebo-controlled study to determine if nirsevimab will prevent medically attended RSV-confirmed LRTI in healthy preterm and term infants born \\u2265 29 weeks 0 days GA and entering their first RSV season. Approximately 800 subjects will be randomized. Randomization will be stratified by subject age at the time of randomization (\\u2264 3 months, > 3 to \\u2264 6 months, > 6 months), and by GA (< 35 weeks GA, \\u2265 35 weeks GA). Enrollment of infants > 6 months of age will be limited to approximately 100. All subjects will be followed through 1 year after dose administration. Subjects will be monitored throughout the study for LRTI. All subjects seeking medical attention for a respiratory illness (inpatient or outpatient setting) will be evaluated for the occurrence of LRTI. All subjects found to have an LRTI and all subjects who require hospitalization for a respiratory infection, even if there is not a diagnosis of LRTI, should have respiratory samples obtained and respiratory assessment forms completed. Samples should be collected for all of these respiratory events even those not meeting the protocoldefined endpoint of LRTI. Subjects who have a primary hospitalization for a respiratory infection (ie, upper or lower respiratory tract), a respiratory deterioration during a hospitalization, or who seek outpatient medical attention (including ER visits) for a lower respiratory illness, will be assessed clinically for the presence of LRTI and for RSV by central laboratory diagnostic testing of respiratory secretions. In addition to the clinical assessment of LRTI, there is a protocol definition using objective criteria for the determination of a protocol-defined medically attended LRTI. To meet the protocol-defined endpoint of medically attended LRTI, subjects with signs of LRTI must have documented at least one physical examination finding of rhonchi, rales, crackles, or wheeze AND at least one of the following clinical signs: Increased respiratory rate at rest (age < 2 months, \\u2265 60 breaths\\/minute; age 2 to 6 months, \\u2265 50 breaths\\/minute; age > 6 months, \\u2265 40 breaths\\/minute), OR Hypoxemia (in room air: oxygen saturation < 95% at altitudes \\u2264 1,800 meters or < 92% at altitudes > 1,800 meters), OR Clinical signs of severe respiratory disease (eg, acute hypoxic or ventilatory failure, new onset apnea, nasal flaring, intercostal, subcostal or supraclavicular retractions, grunting) or dehydration secondary to inadequate oral intake due to respiratory distress (need for intravenous fluid) A diagnosis of RSV LRTI requires having a respiratory sample positive for RSV. Testing for RSV will be performed centrally in China using an RT-PCR assay.\",\"roi_id\":{\"table_roi_id\":\"717bf5c9-580a-4a74-94c6-562a58af1122\",\"row_roi_id\":\"52f61f25-8bba-4f44-af6f-ab30760004ce\",\"column_roi_id\":\"23d0d626-3091-407f-b9ed-0d445f9737fb\",\"datacell_roi_id\":\"ed1f164e-be24-4395-817d-6a4c5f3664e3\"},\"table_index\":3.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[{\"start_idx\":113,\"end_idx\":122,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"}],\"content\":\"STUDY DESIGN Study D5290C00006  is a Phase 3, randomized, double-blind, placebo-controlled study to determine if nirsevimab will prevent medically attended RSV-confirmed LRTI in healthy preterm and term infants born \\u2265 29 weeks 0 days GA and entering their first RSV season. Approximately 800 subjects will be randomized. Randomization will be stratified by subject age at the time of randomization (\\u2264 3 months, > 3 to \\u2264 6 months, > 6 months), and by GA (< 35 weeks GA, \\u2265 35 weeks GA). Enrollment of infants > 6 months of age will be limited to approximately 100. All subjects will be followed through 1 year after dose administration. Subjects will be monitored throughout the study for LRTI. All subjects seeking medical attention for a respiratory illness (inpatient or outpatient setting) will be evaluated for the occurrence of LRTI. All subjects found to have an LRTI and all subjects who require hospitalization for a respiratory infection, even if there is not a diagnosis of LRTI, should have respiratory samples obtained and respiratory assessment forms completed. Samples should be collected for all of these respiratory events even those not meeting the protocoldefined endpoint of LRTI. Subjects who have a primary hospitalization for a respiratory infection (ie, upper or lower respiratory tract), a respiratory deterioration during a hospitalization, or who seek outpatient medical attention (including ER visits) for a lower respiratory illness, will be assessed clinically for the presence of LRTI and for RSV by central laboratory diagnostic testing of respiratory secretions. In addition to the clinical assessment of LRTI, there is a protocol definition using objective criteria for the determination of a protocol-defined medically attended LRTI. To meet the protocol-defined endpoint of medically attended LRTI, subjects with signs of LRTI must have documented at least one physical examination finding of rhonchi, rales, crackles, or wheeze AND at least one of the following clinical signs: Increased respiratory rate at rest (age < 2 months, \\u2265 60 breaths\\/minute; age 2 to 6 months, \\u2265 50 breaths\\/minute; age > 6 months, \\u2265 40 breaths\\/minute), OR Hypoxemia (in room air: oxygen saturation < 95% at altitudes \\u2264 1,800 meters or < 92% at altitudes > 1,800 meters), OR Clinical signs of severe respiratory disease (eg, acute hypoxic or ventilatory failure, new onset apnea, nasal flaring, intercostal, subcostal or supraclavicular retractions, grunting) or dehydration secondary to inadequate oral intake due to respiratory distress (need for intravenous fluid) A diagnosis of RSV LRTI requires having a respiratory sample positive for RSV. Testing for RSV will be performed centrally in China using an RT-PCR assay.\",\"roi_id\":{\"table_roi_id\":\"717bf5c9-580a-4a74-94c6-562a58af1122\",\"row_roi_id\":\"52f61f25-8bba-4f44-af6f-ab30760004ce\",\"column_roi_id\":\"23d0d626-3091-407f-b9ed-0d445f9737fb\",\"datacell_roi_id\":\"ed1f164e-be24-4395-817d-6a4c5f3664e3\"},\"table_index\":3.0,\"qc_change_type\":\"\"},\"3.0\":{\"entities\":[{\"start_idx\":113,\"end_idx\":122,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"}],\"content\":\"STUDY DESIGN Study D5290C00006  is a Phase 3, randomized, double-blind, placebo-controlled study to determine if nirsevimab will prevent medically attended RSV-confirmed LRTI in healthy preterm and term infants born \\u2265 29 weeks 0 days GA and entering their first RSV season. Approximately 800 subjects will be randomized. Randomization will be stratified by subject age at the time of randomization (\\u2264 3 months, > 3 to \\u2264 6 months, > 6 months), and by GA (< 35 weeks GA, \\u2265 35 weeks GA). Enrollment of infants > 6 months of age will be limited to approximately 100. All subjects will be followed through 1 year after dose administration. Subjects will be monitored throughout the study for LRTI. All subjects seeking medical attention for a respiratory illness (inpatient or outpatient setting) will be evaluated for the occurrence of LRTI. All subjects found to have an LRTI and all subjects who require hospitalization for a respiratory infection, even if there is not a diagnosis of LRTI, should have respiratory samples obtained and respiratory assessment forms completed. Samples should be collected for all of these respiratory events even those not meeting the protocoldefined endpoint of LRTI. Subjects who have a primary hospitalization for a respiratory infection (ie, upper or lower respiratory tract), a respiratory deterioration during a hospitalization, or who seek outpatient medical attention (including ER visits) for a lower respiratory illness, will be assessed clinically for the presence of LRTI and for RSV by central laboratory diagnostic testing of respiratory secretions. In addition to the clinical assessment of LRTI, there is a protocol definition using objective criteria for the determination of a protocol-defined medically attended LRTI. To meet the protocol-defined endpoint of medically attended LRTI, subjects with signs of LRTI must have documented at least one physical examination finding of rhonchi, rales, crackles, or wheeze AND at least one of the following clinical signs: Increased respiratory rate at rest (age < 2 months, \\u2265 60 breaths\\/minute; age 2 to 6 months, \\u2265 50 breaths\\/minute; age > 6 months, \\u2265 40 breaths\\/minute), OR Hypoxemia (in room air: oxygen saturation < 95% at altitudes \\u2264 1,800 meters or < 92% at altitudes > 1,800 meters), OR Clinical signs of severe respiratory disease (eg, acute hypoxic or ventilatory failure, new onset apnea, nasal flaring, intercostal, subcostal or supraclavicular retractions, grunting) or dehydration secondary to inadequate oral intake due to respiratory distress (need for intravenous fluid) A diagnosis of RSV LRTI requires having a respiratory sample positive for RSV. Testing for RSV will be performed centrally in China using an RT-PCR assay.\",\"roi_id\":{\"table_roi_id\":\"717bf5c9-580a-4a74-94c6-562a58af1122\",\"row_roi_id\":\"52f61f25-8bba-4f44-af6f-ab30760004ce\",\"column_roi_id\":\"23d0d626-3091-407f-b9ed-0d445f9737fb\",\"datacell_roi_id\":\"ed1f164e-be24-4395-817d-6a4c5f3664e3\"},\"table_index\":3.0,\"qc_change_type\":\"\"},\"4.0\":{\"entities\":[{\"start_idx\":113,\"end_idx\":122,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"}],\"content\":\"STUDY DESIGN Study D5290C00006  is a Phase 3, randomized, double-blind, placebo-controlled study to determine if nirsevimab will prevent medically attended RSV-confirmed LRTI in healthy preterm and term infants born \\u2265 29 weeks 0 days GA and entering their first RSV season. Approximately 800 subjects will be randomized. Randomization will be stratified by subject age at the time of randomization (\\u2264 3 months, > 3 to \\u2264 6 months, > 6 months), and by GA (< 35 weeks GA, \\u2265 35 weeks GA). Enrollment of infants > 6 months of age will be limited to approximately 100. All subjects will be followed through 1 year after dose administration. Subjects will be monitored throughout the study for LRTI. All subjects seeking medical attention for a respiratory illness (inpatient or outpatient setting) will be evaluated for the occurrence of LRTI. All subjects found to have an LRTI and all subjects who require hospitalization for a respiratory infection, even if there is not a diagnosis of LRTI, should have respiratory samples obtained and respiratory assessment forms completed. Samples should be collected for all of these respiratory events even those not meeting the protocoldefined endpoint of LRTI. Subjects who have a primary hospitalization for a respiratory infection (ie, upper or lower respiratory tract), a respiratory deterioration during a hospitalization, or who seek outpatient medical attention (including ER visits) for a lower respiratory illness, will be assessed clinically for the presence of LRTI and for RSV by central laboratory diagnostic testing of respiratory secretions. In addition to the clinical assessment of LRTI, there is a protocol definition using objective criteria for the determination of a protocol-defined medically attended LRTI. To meet the protocol-defined endpoint of medically attended LRTI, subjects with signs of LRTI must have documented at least one physical examination finding of rhonchi, rales, crackles, or wheeze AND at least one of the following clinical signs: Increased respiratory rate at rest (age < 2 months, \\u2265 60 breaths\\/minute; age 2 to 6 months, \\u2265 50 breaths\\/minute; age > 6 months, \\u2265 40 breaths\\/minute), OR Hypoxemia (in room air: oxygen saturation < 95% at altitudes \\u2264 1,800 meters or < 92% at altitudes > 1,800 meters), OR Clinical signs of severe respiratory disease (eg, acute hypoxic or ventilatory failure, new onset apnea, nasal flaring, intercostal, subcostal or supraclavicular retractions, grunting) or dehydration secondary to inadequate oral intake due to respiratory distress (need for intravenous fluid) A diagnosis of RSV LRTI requires having a respiratory sample positive for RSV. Testing for RSV will be performed centrally in China using an RT-PCR assay.\",\"roi_id\":{\"table_roi_id\":\"717bf5c9-580a-4a74-94c6-562a58af1122\",\"row_roi_id\":\"52f61f25-8bba-4f44-af6f-ab30760004ce\",\"column_roi_id\":\"23d0d626-3091-407f-b9ed-0d445f9737fb\",\"datacell_roi_id\":\"ed1f164e-be24-4395-817d-6a4c5f3664e3\"},\"table_index\":3.0,\"qc_change_type\":\"\"},\"5.0\":{\"entities\":[{\"start_idx\":113,\"end_idx\":122,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"}],\"content\":\"STUDY DESIGN Study D5290C00006  is a Phase 3, randomized, double-blind, placebo-controlled study to determine if nirsevimab will prevent medically attended RSV-confirmed LRTI in healthy preterm and term infants born \\u2265 29 weeks 0 days GA and entering their first RSV season. Approximately 800 subjects will be randomized. Randomization will be stratified by subject age at the time of randomization (\\u2264 3 months, > 3 to \\u2264 6 months, > 6 months), and by GA (< 35 weeks GA, \\u2265 35 weeks GA). Enrollment of infants > 6 months of age will be limited to approximately 100. All subjects will be followed through 1 year after dose administration. Subjects will be monitored throughout the study for LRTI. All subjects seeking medical attention for a respiratory illness (inpatient or outpatient setting) will be evaluated for the occurrence of LRTI. All subjects found to have an LRTI and all subjects who require hospitalization for a respiratory infection, even if there is not a diagnosis of LRTI, should have respiratory samples obtained and respiratory assessment forms completed. Samples should be collected for all of these respiratory events even those not meeting the protocoldefined endpoint of LRTI. Subjects who have a primary hospitalization for a respiratory infection (ie, upper or lower respiratory tract), a respiratory deterioration during a hospitalization, or who seek outpatient medical attention (including ER visits) for a lower respiratory illness, will be assessed clinically for the presence of LRTI and for RSV by central laboratory diagnostic testing of respiratory secretions. In addition to the clinical assessment of LRTI, there is a protocol definition using objective criteria for the determination of a protocol-defined medically attended LRTI. To meet the protocol-defined endpoint of medically attended LRTI, subjects with signs of LRTI must have documented at least one physical examination finding of rhonchi, rales, crackles, or wheeze AND at least one of the following clinical signs: Increased respiratory rate at rest (age < 2 months, \\u2265 60 breaths\\/minute; age 2 to 6 months, \\u2265 50 breaths\\/minute; age > 6 months, \\u2265 40 breaths\\/minute), OR Hypoxemia (in room air: oxygen saturation < 95% at altitudes \\u2264 1,800 meters or < 92% at altitudes > 1,800 meters), OR Clinical signs of severe respiratory disease (eg, acute hypoxic or ventilatory failure, new onset apnea, nasal flaring, intercostal, subcostal or supraclavicular retractions, grunting) or dehydration secondary to inadequate oral intake due to respiratory distress (need for intravenous fluid) A diagnosis of RSV LRTI requires having a respiratory sample positive for RSV. Testing for RSV will be performed centrally in China using an RT-PCR assay.\",\"roi_id\":{\"table_roi_id\":\"717bf5c9-580a-4a74-94c6-562a58af1122\",\"row_roi_id\":\"52f61f25-8bba-4f44-af6f-ab30760004ce\",\"column_roi_id\":\"23d0d626-3091-407f-b9ed-0d445f9737fb\",\"datacell_roi_id\":\"ed1f164e-be24-4395-817d-6a4c5f3664e3\"},\"table_index\":3.0,\"qc_change_type\":\"\"}}]",
      "SectionHeaderPrintPage": "1",
      "TableIndex": "4",
      "TableName": "Protocol Synopsis",
      "Header": [
        0,
        1
      ]
    },
    "font_info": {
      "IsBold": true,
      "font_size": 20,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "317c701e-1c1c-4c2c-a63b-66aa251328fa",
        "childbox": "fe2b1871-c3fd-4d53-a0ab-50fc85de879d",
        "subtext": "396b7824-c0d5-4b4d-a0f5-9df9d0504b86"
      },
      "Bold": true,
      "Caps": false,
      "ColorRGB": 0,
      "DStrike": false,
      "Emboss": false,
      "Highlight": "",
      "Imprint": false,
      "Italics": false,
      "Outline": false,
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": 20,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "derived_section_type": "table",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 1,
    "line_id": 33,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "af8a46cf-fc56-4e62-9100-0592fb98269e",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 1,
    "line_id": 34,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "b7b4ef41-942a-490a-8d22-ddbd56bd5b52",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 1,
    "line_id": 35,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "aa7deb56-2b85-43ca-9e92-c27678e2b53f",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 1,
    "line_id": 36,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "7d80553a-d5a2-4272-980d-0c1a3c070b28",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 1,
    "line_id": 37,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "2a70ee1c-bf39-4cb4-a80b-03add7011965",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 1,
    "line_id": 38,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "50a23e33-9fec-49fc-af37-db9e3c8a4962",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 1,
    "line_id": 39,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "c3d49ad6-6b9d-4f48-95fd-b97fb696e8e0",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 1,
    "line_id": 40,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "faec1e3f-2277-45ee-bed7-7b57744f9b8d",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 1,
    "line_id": 41,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "9c98cd5f-812c-40ca-a51f-3d4ca2363827",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 1,
    "line_id": 42,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "f57f61f5-c658-449e-850c-36144625d63c",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 1,
    "line_id": 43,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": {
      "Table": "<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th>ColIndex</th>\n      <th>1.0</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>TARGET SUBJECT POPULATION  Healthy preterm and term infants > 29 weeks 0 days GA entering their first RSV season.</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>TREATMENT GROUPS AND REGIMENS  Subjects will be randomly assigned in a 2:1 ratio to receive a single IM dose of nirsevimab (N = 530) or placebo (N = 270). The nirsevimab dose level will be stratified by body weight at time of dosing: 50 mg nirsevimab for infants < 5 kg or 100 mg nirsevimab for infants ≥ 5 kg.</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>STATISTICAL METHODS  General Considerations There are 2 planned analyses for this study: the primary analysis and the final analysis. The primary analysis will be conducted after all randomized subjects have completed the Day 151 visit, and the final analysis will be conducted when all subjects have completed the last visit of the study (Day 361). Tabular summaries will be presented by treatment group. Categorical data will be summarized by the number and percentage of subjects in each category. Continuous variables will be summarized by descriptive statistics. Additional details of statistical analyses will be described in the statistical analysis plan. The Intent-to-treat (ITT) Population is defined as all subjects who are randomized. Subjects will be included in the treatment group corresponding to their randomized treatment. All efficacy and HRU analyses will be performed on the ITT Population unless otherwise specified. The As-treated Population will include all subjects who are randomized and who receive any amount of investigational product. Subjects will be included in the treatment group corresponding to the treatment actually received. All safety and ADA analyses will be performed on the As-treated Population. The PK Population will include all subjects who have received any dose of investigational product, and who have at least one measurable post-dose serum PK observation and for whom PK blood samples are assumed not to be affected by factors such as important protocol deviations (to be determined prior to unblinding). PK analyses will be performed on the PK Population. Sample Size  This study will randomize approximately 800 subjects of whom approximately 530 subjects will receive nirsevimab and approximately 270 subjects will receive placebo. Considering 10% attrition, this sample size has at least 90% power to detect 70% relative risk reduction (RRR), assuming a placebo medically attended RSV LRTI incidence of 8%, with a 2-sided α = 0.05. The assumption of 8% incidence is supported both by the literature and the observed placebo incidence rate (9.5%) in the Phase 2b Study D5290C00003. The 70% RRR assumption is based on the Phase 2b Study D5290C00003 in which nirsevimab prophylaxis resulted in 70.1% RRR in the incidence of medically attended RSV LRTI (9.5% placebo, 2.6% nirsevimab; p < 0.0001) and 78.4% RRR in the incidence of RSV hospitalization (4.1% placebo, 0.8% nirsevimab; p = 0.0002). To evaluate risk, a sample size of 530 subjects exposed to nirsevimab will provide a > 95% probability of observing at least one adverse event (AE) if the true event rate is 0.6%; if no AEs are observed, this study provides 95% confidence that the true event rate is < 0.6%. Efficacy Analyses The primary and secondary efficacy hypotheses will be assessed in the primary analysis by a hierarchical order. That is, the secondary hypothesis will be tested at a significance level of 0.05 only if the treatment effect on the primary efficacy endpoint is demonstrated at the significance level of 2-sided 0.05. With that, the overall Type I error is controlled at 0.05. Therefore, no further multiplicity adjustment is necessary.  The incidence of medically attended RSV LRTI (inpatient and outpatient) through 150 days post dose (ie, during a typical 5-month RSV season) for all infants, based on RSV test results (performed centrally using RT-PCR) and objective protocol-defined LRTI criteria, is the primary endpoint and will be presented by treatment groups. For subjects with multiple events, only the first occurrence will be used in the analysis.</td>\n    </tr>\n  </tbody>\n</table>",
      "TableProperties": "[{\"1.0\":{\"entities\":[],\"content\":\"TARGET SUBJECT POPULATION  Healthy preterm and term infants > 29 weeks 0 days GA entering their first RSV season.\",\"roi_id\":{\"table_roi_id\":\"687ea22e-ae09-4aad-ab66-d752b0386c0a\",\"row_roi_id\":\"e6571259-0887-4984-a851-b292a1979818\",\"column_roi_id\":\"283ec4ce-2fd2-44a9-a018-50e0d05f3b81\",\"datacell_roi_id\":\"875b95a6-2d2b-4bee-a21d-412c601f973b\"},\"table_index\":4.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[{\"start_idx\":112,\"end_idx\":121,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":159,\"end_idx\":168,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":240,\"end_idx\":249,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":280,\"end_idx\":289,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":112,\"end_idx\":121,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":159,\"end_idx\":168,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":240,\"end_idx\":249,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":280,\"end_idx\":289,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"}],\"content\":\"TREATMENT GROUPS AND REGIMENS  Subjects will be randomly assigned in a 2:1 ratio to receive a single IM dose of nirsevimab (N = 530) or placebo (N = 270). The nirsevimab dose level will be stratified by body weight at time of dosing: 50 mg nirsevimab for infants < 5 kg or 100 mg nirsevimab for infants \\u2265 5 kg.\",\"roi_id\":{\"table_roi_id\":\"687ea22e-ae09-4aad-ab66-d752b0386c0a\",\"row_roi_id\":\"73667fa2-5b7a-4894-abbd-339d6cb4a1e5\",\"column_roi_id\":\"364bbb96-3ed9-4a6c-bda1-9a7c474e5864\",\"datacell_roi_id\":\"82915f91-d53a-46e8-a409-89b623d49d7b\"},\"table_index\":4.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[{\"start_idx\":222,\"end_idx\":224,\"standard_entity_name\":\"OTHER: Person Name\",\"subcategory\":\"OTHER: Person Name\",\"confidence\":100.0,\"text\":\"Day\"},{\"start_idx\":340,\"end_idx\":342,\"standard_entity_name\":\"OTHER: Person Name\",\"subcategory\":\"OTHER: Person Name\",\"confidence\":100.0,\"text\":\"Day\"},{\"start_idx\":3259,\"end_idx\":3261,\"standard_entity_name\":\"OTHER: Person Name\",\"subcategory\":\"OTHER: Person Name\",\"confidence\":100.0,\"text\":\"Day\"},{\"start_idx\":1723,\"end_idx\":1732,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":2212,\"end_idx\":2221,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":2325,\"end_idx\":2334,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":2423,\"end_idx\":2432,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":2507,\"end_idx\":2516,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":1723,\"end_idx\":1732,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":2212,\"end_idx\":2221,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":2325,\"end_idx\":2334,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":2423,\"end_idx\":2432,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":2507,\"end_idx\":2516,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":1723,\"end_idx\":1732,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":100.0,\"text\":\"nirsevimab\"},{\"start_idx\":2212,\"end_idx\":2221,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":100.0,\"text\":\"nirsevimab\"},{\"start_idx\":2325,\"end_idx\":2334,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":100.0,\"text\":\"nirsevimab\"},{\"start_idx\":2423,\"end_idx\":2432,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":100.0,\"text\":\"nirsevimab\"},{\"start_idx\":2507,\"end_idx\":2516,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":100.0,\"text\":\"nirsevimab\"}],\"content\":\"STATISTICAL METHODS  General Considerations There are 2 planned analyses for this study: the primary analysis and the final analysis. The primary analysis will be conducted after all randomized subjects have completed the Day 151 visit, and the final analysis will be conducted when all subjects have completed the last visit of the study (Day 361). Tabular summaries will be presented by treatment group. Categorical data will be summarized by the number and percentage of subjects in each category. Continuous variables will be summarized by descriptive statistics. Additional details of statistical analyses will be described in the statistical analysis plan. The Intent-to-treat (ITT) Population is defined as all subjects who are randomized. Subjects will be included in the treatment group corresponding to their randomized treatment. All efficacy and HRU analyses will be performed on the ITT Population unless otherwise specified. The As-treated Population will include all subjects who are randomized and who receive any amount of investigational product. Subjects will be included in the treatment group corresponding to the treatment actually received. All safety and ADA analyses will be performed on the As-treated Population. The PK Population will include all subjects who have received any dose of investigational product, and who have at least one measurable post-dose serum PK observation and for whom PK blood samples are assumed not to be affected by factors such as important protocol deviations (to be determined prior to unblinding). PK analyses will be performed on the PK Population. Sample Size  This study will randomize approximately 800 subjects of whom approximately 530 subjects will receive nirsevimab and approximately 270 subjects will receive placebo. Considering 10% attrition, this sample size has at least 90% power to detect 70% relative risk reduction (RRR), assuming a placebo medically attended RSV LRTI incidence of 8%, with a 2-sided \\u03b1 = 0.05. The assumption of 8% incidence is supported both by the literature and the observed placebo incidence rate (9.5%) in the Phase 2b Study D5290C00003. The 70% RRR assumption is based on the Phase 2b Study D5290C00003 in which nirsevimab prophylaxis resulted in 70.1% RRR in the incidence of medically attended RSV LRTI (9.5% placebo, 2.6% nirsevimab; p < 0.0001) and 78.4% RRR in the incidence of RSV hospitalization (4.1% placebo, 0.8% nirsevimab; p = 0.0002). To evaluate risk, a sample size of 530 subjects exposed to nirsevimab will provide a > 95% probability of observing at least one adverse event (AE) if the true event rate is 0.6%; if no AEs are observed, this study provides 95% confidence that the true event rate is < 0.6%. Efficacy Analyses The primary and secondary efficacy hypotheses will be assessed in the primary analysis by a hierarchical order. That is, the secondary hypothesis will be tested at a significance level of 0.05 only if the treatment effect on the primary efficacy endpoint is demonstrated at the significance level of 2-sided 0.05. With that, the overall Type I error is controlled at 0.05. Therefore, no further multiplicity adjustment is necessary.  The incidence of medically attended RSV LRTI (inpatient and outpatient) through 150 days post dose (ie, during a typical 5-month RSV season) for all infants, based on RSV test results (performed centrally using RT-PCR) and objective protocol-defined LRTI criteria, is the primary endpoint and will be presented by treatment groups. For subjects with multiple events, only the first occurrence will be used in the analysis.\",\"roi_id\":{\"table_roi_id\":\"687ea22e-ae09-4aad-ab66-d752b0386c0a\",\"row_roi_id\":\"cf442ad0-5755-4eec-bece-89fc1c07b616\",\"column_roi_id\":\"6f804c46-14c4-4cf9-bff2-2ad563f76ef6\",\"datacell_roi_id\":\"2d1a2669-f353-48a0-b196-c8a9c8f736a4\"},\"table_index\":4.0,\"qc_change_type\":\"\"}}]",
      "SectionHeaderPrintPage": "1",
      "TableIndex": "5",
      "TableName": "Protocol Synopsis",
      "Header": [
        2
      ]
    },
    "font_info": {
      "IsBold": true,
      "font_size": 20,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "01164741-697a-448b-bf4c-f08a89163c91",
        "childbox": "c6adab17-0a93-4ca2-a230-f15aaf971e6d",
        "subtext": "20f6288a-8771-45c2-b041-26d0f5ea25d0"
      },
      "Bold": true,
      "Caps": false,
      "ColorRGB": 0,
      "DStrike": false,
      "Emboss": false,
      "Highlight": "",
      "Imprint": false,
      "Italics": false,
      "Outline": false,
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": 20,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "derived_section_type": "table",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 1,
    "line_id": 44,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "56a8ea98-e39d-4000-91fc-7da8beb0d442",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 1,
    "line_id": 45,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": {
      "Table": "<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th>ColIndex</th>\n      <th>1.0</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>RSV LRTI that occurs through 150 days post dose will contribute to the primary efficacy analysis. For subjects who do not have a medically attended RSV LRTI and are not followed through 150 days post dose, their event status will be imputed assuming the observed placebo RSV LRTI rate conditional on stratification factors using multiple imputation techniques and will be described in the statistical analysis plan. A Poisson regression model with robust variance, including treatment group and 2 stratification factors (age at randomization and GA group) as covariates, will be used as the primary efficacy analysis model. The RRR, defined as 1-Relative Risk, and its corresponding 2-sided 95% confidence interval, will be estimated from the model. In addition, the 2-sided p value testing null hypothesis that the incidence of medically attended RSV LRTI between nirsevimab and placebo groups are the same, will be obtained from the model. Statistical significance will be achieved if the 2-sided p value is ≤ 0.05. A Cochran-Mantel-Haenszel approach stratified by the 2 stratification factors will be used to compare the incidence of RSV LRTI through 150 days post dose between treatment groups as a secondary analysis for the primary endpoint. Additional analyses for the primary efficacy endpoint will be performed to compare the treatment group differences in time-to-first RSV LRTI. Summaries for age at onset of the first RSV LRTI, inpatient/outpatient visit settings, and RSV subtypes associated with the primary endpoint will also be provided. The primary efficacy endpoint will also be examined by prespecified subgroups, including subpopulations (ie, healthy preterm population, healthy late preterm and term population) corresponding to those enrolled in the global Studies D5290C00003 and D5290C00004. The incidence of RSV hospitalization through 150 days post dose for all infants is the secondary efficacy endpoint and will be presented by treatment group. Similar methods as described above for the primary efficacy endpoint will be used to assess efficacy on RSV hospitalization. Safety Analyses AEs will be graded according to the current version of the National Cancer Institute Common Terminology Criteria for Adverse Events where applicable for pediatric assessments. AEs will be coded by Medical Dictionary for Regulatory Activities (MedDRA), and the type, incidence, severity, and relationship to investigational product will be summarized. Other safety assessments will include the occurrence of AESIs defined as AEs of anaphylaxis and other serious hypersensitivity reactions, including immune complex disease (eg, vasculitis, endocarditis, neuritis, glomerulonephritis), or thrombocytopenia following investigational product administration, and the occurrence of NOCDs following investigational product administration. Pharmacokinetic Analyses Serum concentrations of nirsevimab at selected time points will be evaluated to confirm that adequate exposures for protection from RSV LRTI are maintained for at least 5 months after dosing. Nirsevimab serum concentration data will be presented in descriptive statistics. PK parameters (eg, maximum observed concentration, area under the concentration-time curve, apparent clearance, and terminal-phase half-life) will be estimated using noncompartmental analysis, if data permit. Antidrug Antibody Analyses The incidence of ADA to nirsevimab will be assessed and summarized by number and percentage of subjects who are ADA positive by treatment group. The impact of ADA on PK, efficacy, and association with TEAEs and TESAEs, will be assessed.  Exploratory Analyses Healthcare Resource Utilization  The magnitude of HRU (eg, number of admissions to hospitals and intensive care units and duration of stay; number of subjects who require respiratory support and supplemental oxygen and the duration of use; number and types of outpatient visits, eg, ER, outpatient clinic; and number of prescription and OTC medications and duration of use) will be summarized overall by treatment group, and for the following subgroups: subjects</td>\n    </tr>\n  </tbody>\n</table>",
      "TableProperties": "[{\"1.0\":{\"entities\":[{\"start_idx\":865,\"end_idx\":874,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":2895,\"end_idx\":2904,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":3063,\"end_idx\":3072,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":3404,\"end_idx\":3413,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":2173,\"end_idx\":2197,\"standard_entity_name\":\"ANY: Organization\",\"subcategory\":\"ANY: Organization\",\"confidence\":87.0,\"text\":\"National Cancer Institute\"},{\"start_idx\":865,\"end_idx\":874,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":2895,\"end_idx\":2904,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":3063,\"end_idx\":3072,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":3404,\"end_idx\":3413,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"nirsevimab\"},{\"start_idx\":865,\"end_idx\":874,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"Nirsevimab\"},{\"start_idx\":2895,\"end_idx\":2904,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"Nirsevimab\"},{\"start_idx\":3063,\"end_idx\":3072,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"Nirsevimab\"},{\"start_idx\":3404,\"end_idx\":3413,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"Nirsevimab\"},{\"start_idx\":865,\"end_idx\":874,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":100.0,\"text\":\"nirsevimab\"},{\"start_idx\":2895,\"end_idx\":2904,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":100.0,\"text\":\"nirsevimab\"},{\"start_idx\":3063,\"end_idx\":3072,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":100.0,\"text\":\"nirsevimab\"},{\"start_idx\":3404,\"end_idx\":3413,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":100.0,\"text\":\"nirsevimab\"}],\"content\":\"RSV LRTI that occurs through 150 days post dose will contribute to the primary efficacy analysis. For subjects who do not have a medically attended RSV LRTI and are not followed through 150 days post dose, their event status will be imputed assuming the observed placebo RSV LRTI rate conditional on stratification factors using multiple imputation techniques and will be described in the statistical analysis plan. A Poisson regression model with robust variance, including treatment group and 2 stratification factors (age at randomization and GA group) as covariates, will be used as the primary efficacy analysis model. The RRR, defined as 1-Relative Risk, and its corresponding 2-sided 95% confidence interval, will be estimated from the model. In addition, the 2-sided p value testing null hypothesis that the incidence of medically attended RSV LRTI between nirsevimab and placebo groups are the same, will be obtained from the model. Statistical significance will be achieved if the 2-sided p value is \\u2264 0.05. A Cochran-Mantel-Haenszel approach stratified by the 2 stratification factors will be used to compare the incidence of RSV LRTI through 150 days post dose between treatment groups as a secondary analysis for the primary endpoint. Additional analyses for the primary efficacy endpoint will be performed to compare the treatment group differences in time-to-first RSV LRTI. Summaries for age at onset of the first RSV LRTI, inpatient\\/outpatient visit settings, and RSV subtypes associated with the primary endpoint will also be provided. The primary efficacy endpoint will also be examined by prespecified subgroups, including subpopulations (ie, healthy preterm population, healthy late preterm and term population) corresponding to those enrolled in the global Studies D5290C00003 and D5290C00004. The incidence of RSV hospitalization through 150 days post dose for all infants is the secondary efficacy endpoint and will be presented by treatment group. Similar methods as described above for the primary efficacy endpoint will be used to assess efficacy on RSV hospitalization. Safety Analyses AEs will be graded according to the current version of the National Cancer Institute Common Terminology Criteria for Adverse Events where applicable for pediatric assessments. AEs will be coded by Medical Dictionary for Regulatory Activities (MedDRA), and the type, incidence, severity, and relationship to investigational product will be summarized. Other safety assessments will include the occurrence of AESIs defined as AEs of anaphylaxis and other serious hypersensitivity reactions, including immune complex disease (eg, vasculitis, endocarditis, neuritis, glomerulonephritis), or thrombocytopenia following investigational product administration, and the occurrence of NOCDs following investigational product administration. Pharmacokinetic Analyses Serum concentrations of nirsevimab at selected time points will be evaluated to confirm that adequate exposures for protection from RSV LRTI are maintained for at least 5 months after dosing. Nirsevimab serum concentration data will be presented in descriptive statistics. PK parameters (eg, maximum observed concentration, area under the concentration-time curve, apparent clearance, and terminal-phase half-life) will be estimated using noncompartmental analysis, if data permit. Antidrug Antibody Analyses The incidence of ADA to nirsevimab will be assessed and summarized by number and percentage of subjects who are ADA positive by treatment group. The impact of ADA on PK, efficacy, and association with TEAEs and TESAEs, will be assessed.  Exploratory Analyses Healthcare Resource Utilization  The magnitude of HRU (eg, number of admissions to hospitals and intensive care units and duration of stay; number of subjects who require respiratory support and supplemental oxygen and the duration of use; number and types of outpatient visits, eg, ER, outpatient clinic; and number of prescription and OTC medications and duration of use) will be summarized overall by treatment group, and for the following subgroups: subjects\",\"roi_id\":{\"table_roi_id\":\"d2a6bbc1-7b7f-4d7b-a7ec-8f173fbb916b\",\"row_roi_id\":\"ac398916-45d3-462b-bf51-8829673492c5\",\"column_roi_id\":\"b7700428-bfca-4176-bb43-54f02da7b63f\",\"datacell_roi_id\":\"2af80ec8-0069-48b4-8b13-454fef2ea4a9\"},\"table_index\":5.0,\"qc_change_type\":\"\"}}]",
      "SectionHeaderPrintPage": "1",
      "TableIndex": "6",
      "TableName": "Protocol Synopsis",
      "Header": [
        0
      ]
    },
    "font_info": {
      "IsBold": false,
      "font_size": 20,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "e07b9f33-7752-43da-b3a0-b3e37f4dcd11",
        "childbox": "ad68b904-4b21-46b0-a8a3-9fc42614a117",
        "subtext": "d0192a84-951f-4a25-8025-64b92e8ed33d"
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "DStrike": false,
      "Emboss": false,
      "Highlight": "",
      "Imprint": false,
      "Italics": false,
      "Outline": false,
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": 20,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "derived_section_type": "table",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 1,
    "line_id": 46,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "0d0664e0-77db-4936-b48e-c4ba037775c7",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 1,
    "line_id": 47,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": {
      "Table": "<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th>ColIndex</th>\n      <th>1.0</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>with at least one medically attended LRTI caused by RT-PCR-confirmed RSV, subjects with medically attended LRTI not caused by RSV, and subjects with non-protocol-defined LRTIs, which may be further broken down by RSV status. Monitoring RSV Resistance to Nirsevimab  Genotypic analysis of the full-length mature F protein will be conducted on all RSV-positive isolates confirmed centrally using an RT-PCR assay. RSV genotypic analysis will report the sequence changes in the mature F protein from all RSV positive isolates compared to contemporary RSV A and RSV B reference strains. Susceptibility of novel recombinant RSV variants to nirsevimab will be tested and compared to laboratory-adapted RSV A2 or B9320 viruses.  RSV LRTI Occurring From Day 152 to Day 361  The incidence of medically attended RSV LRTI (inpatient and outpatient) from Day 152 to Day 361 will be based on RSV test results (performed centrally via RT-PCR) and objective clinical LRTI criteria and will be summarized by treatment group. Interim Analyses No interim analyses are planned.</td>\n    </tr>\n  </tbody>\n</table>",
      "TableProperties": "[{\"1.0\":{\"entities\":[{\"start_idx\":254,\"end_idx\":263,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"Nirsevimab\"},{\"start_idx\":634,\"end_idx\":643,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":75.0,\"text\":\"Nirsevimab\"},{\"start_idx\":254,\"end_idx\":263,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":100.0,\"text\":\"nirsevimab\"},{\"start_idx\":634,\"end_idx\":643,\"standard_entity_name\":\"Molecule\",\"subcategory\":\"Molecule\",\"confidence\":100.0,\"text\":\"nirsevimab\"},{\"start_idx\":745,\"end_idx\":747,\"standard_entity_name\":\"OTHER: Person Name\",\"subcategory\":\"OTHER: Person Name\",\"confidence\":100.0,\"text\":\"Day\"},{\"start_idx\":756,\"end_idx\":758,\"standard_entity_name\":\"OTHER: Person Name\",\"subcategory\":\"OTHER: Person Name\",\"confidence\":100.0,\"text\":\"Day\"},{\"start_idx\":842,\"end_idx\":844,\"standard_entity_name\":\"OTHER: Person Name\",\"subcategory\":\"OTHER: Person Name\",\"confidence\":100.0,\"text\":\"Day\"},{\"start_idx\":853,\"end_idx\":855,\"standard_entity_name\":\"OTHER: Person Name\",\"subcategory\":\"OTHER: Person Name\",\"confidence\":100.0,\"text\":\"Day\"},{\"start_idx\":745,\"end_idx\":747,\"standard_entity_name\":\"OTHER: Person Name\",\"subcategory\":\"OTHER: Person Name\",\"confidence\":100.0,\"text\":\"Day\"},{\"start_idx\":756,\"end_idx\":758,\"standard_entity_name\":\"OTHER: Person Name\",\"subcategory\":\"OTHER: Person Name\",\"confidence\":100.0,\"text\":\"Day\"},{\"start_idx\":842,\"end_idx\":844,\"standard_entity_name\":\"OTHER: Person Name\",\"subcategory\":\"OTHER: Person Name\",\"confidence\":100.0,\"text\":\"Day\"},{\"start_idx\":853,\"end_idx\":855,\"standard_entity_name\":\"OTHER: Person Name\",\"subcategory\":\"OTHER: Person Name\",\"confidence\":100.0,\"text\":\"Day\"}],\"content\":\"with at least one medically attended LRTI caused by RT-PCR-confirmed RSV, subjects with medically attended LRTI not caused by RSV, and subjects with non-protocol-defined LRTIs, which may be further broken down by RSV status. Monitoring RSV Resistance to Nirsevimab  Genotypic analysis of the full-length mature F protein will be conducted on all RSV-positive isolates confirmed centrally using an RT-PCR assay. RSV genotypic analysis will report the sequence changes in the mature F protein from all RSV positive isolates compared to contemporary RSV A and RSV B reference strains. Susceptibility of novel recombinant RSV variants to nirsevimab will be tested and compared to laboratory-adapted RSV A2 or B9320 viruses.  RSV LRTI Occurring From Day 152 to Day 361  The incidence of medically attended RSV LRTI (inpatient and outpatient) from Day 152 to Day 361 will be based on RSV test results (performed centrally via RT-PCR) and objective clinical LRTI criteria and will be summarized by treatment group. Interim Analyses No interim analyses are planned.\",\"roi_id\":{\"table_roi_id\":\"6ad1d778-b481-4ba8-9d40-0731925a0260\",\"row_roi_id\":\"3bf20474-0849-4106-9b50-7b9c4cf92fb8\",\"column_roi_id\":\"16980e02-6b64-4b23-b0eb-a97e7c0deaa5\",\"datacell_roi_id\":\"8a96b831-1a4c-4516-9b1c-ab41843714fe\"},\"table_index\":6.0,\"qc_change_type\":\"\"}}]",
      "SectionHeaderPrintPage": "1",
      "TableIndex": "7",
      "TableName": "Protocol Synopsis",
      "Header": [
        0
      ]
    },
    "font_info": {
      "IsBold": false,
      "font_size": 20,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "28d97d0c-9695-4f07-a368-9284fc9f1082",
        "childbox": "41e3c6b4-229c-41de-8f54-f7861cb3019c",
        "subtext": "2bd1ad04-a52f-4451-b5ac-209f983e7683"
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "DStrike": false,
      "Emboss": false,
      "Highlight": "",
      "Imprint": false,
      "Italics": false,
      "Outline": false,
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": 20,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "derived_section_type": "table",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 1,
    "line_id": 48,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "b8034d7a-97ac-45aa-9c2f-fff563041f67",
        "childbox": "4fd7bccb-2d8b-4d52-91c5-df699f4ed908",
        "subtext": "b033815f-0678-4a9f-abaa-25cf38c67083"
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "DStrike": false,
      "Emboss": false,
      "Highlight": "",
      "Imprint": false,
      "Italics": false,
      "Outline": false,
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 1,
    "line_id": 49,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "source_file_section": "TABLEOF CONTENTS",
    "source_heading_number": "Table",
    "parent_heading_num_seq": [
      "Table"
    ],
    "parent_sec_id_seq": [
      2
    ],
    "derived_heading_level": 1,
    "pt_from_ontology": [
      ""
    ],
    "medical_terms": [],
    "page": 0,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "2_section_metadata",
    "sec_id": 2,
    "child_secid_seq": [
      [
        2,
        "Table",
        "TABLEOF CONTENTS",
        1
      ]
    ]
  },
  {
    "content": "TABLE OF CONTENTS",
    "font_info": {
      "IsBold": true,
      "font_size": 28,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "7b142977-d513-4359-b848-1a92256ff96f",
        "childbox": "c6bd1f1e-5be7-4ff0-a3a2-1ad010ed1a03",
        "subtext": "0976574e-db92-4a54-bf84-856b068d7903"
      },
      "Bold": true,
      "Caps": false,
      "ColorRGB": 0,
      "DStrike": false,
      "Emboss": false,
      "Highlight": "",
      "Imprint": false,
      "Italics": false,
      "Outline": false,
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": 28,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 50,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "PROTOCOL SYNOPSIS 2",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "f044d8d2-11aa-466e-b380-f9c3f9fa7902",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 51,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "LIST OF ABBREVIATIONS 11",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "4400b8fc-0b8e-4e51-876a-6db4b3739457",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 52,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "1 INTRODUCTION 13",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "40ee9165-3d2e-4dbd-a06c-7a4ea7839b6c",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 53,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "1.1 Disease Background 13",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "340b7480-e9d5-4ca4-8e65-7f7cf02d1401",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 54,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "1.2 Nirsevimab Background 14",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [
        {
          "start_idx": 4,
          "end_idx": 13,
          "standard_entity_name": "Molecule",
          "subcategory": "Molecule",
          "confidence": 12,
          "text": "Nirsevimab"
        }
      ],
      "roi_id": {
        "para": "cf5da85d-87fb-4dcd-b6d4-5883927b06cb",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 55,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "1.3 Summary of Nonclinical Experience 15",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "ee3e8881-31d1-4355-9701-ee2d30af2a17",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 56,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "1.4 Summary of Clinical Experience 16",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "9af6ceb6-9c65-4d85-92cd-1e2e4bd87312",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 57,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "1.4.1 Phase 1a Study D5290C00001 16",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "adabd24a-8d72-43b3-8d8e-d22b52a0e537",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 58,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "1.4.2 Phase 1b/2a Study D5290C00002 17",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "029cb217-c8dc-4953-b68a-b4bbe92f9d12",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 59,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "1.4.3 Phase 2b Study D5290C00003 18",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "17aa9f2c-ed21-4933-a266-3cc5554529b5",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 60,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "1.5 Rationale for Conducting the Study 20",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "097a89ab-fd4e-4abc-865b-a964256de7b1",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 61,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "1.6 Benefit-Risk and Ethical Assessment 21",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "77b1f54c-ba4b-4412-9df7-793063a07aef",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 62,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "1.7 Research Hypotheses 21",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "a43cd55b-237f-4388-bac9-1a8b5e85a4b9",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 63,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "1.7.1 Primary Hypothesis 21",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "6627baa2-aa65-42b4-9eda-ea6a61a6c658",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 64,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "1.7.2 Secondary Hypotheses 21",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "2f83c4bd-0140-4de8-8bf0-684ca8469d92",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 65,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "2 OBJECTIVES AND ENDPOINTS 22",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "077cdf35-110f-4c1f-876b-a62f849c0c06",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 66,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "2.1 Primary Objective and Associated Endpoint 22",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "54aaf4e9-5092-4568-b502-cf6ed7d0bf63",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 67,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "2.2 Secondary Objectives and Associated Endpoints 22",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "e7df6dde-f932-429b-9240-81faa4116dd0",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 68,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "2.3 Exploratory Objectives and Associated Endpoints 23",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "44cac61e-bbd6-4fbd-8f67-cea38eb3024f",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 69,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "3 STUDY DESIGN 23",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "2063837e-c186-4c7c-8af9-9a6572b1325b",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 70,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "3.1 Description of the Study 23",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "ade8cffb-751b-461d-9d3e-2536e103477c",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 71,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "3.1.1 Overview 23",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "0f375415-e50c-4a95-988f-ba2c13963ff6",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 72,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "3.1.2 Treatment Regimen 25",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "d867580e-cbdc-49bf-aaee-cdffed985199",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 73,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "3.2 Rationale for D ose, Population, and Endpoints 25",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "5e03d4a7-f129-4a93-8701-f5a352bdcffb",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 74,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "3.2.1 Dose Rationale 25",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "7cf62178-da98-476d-8819-c752d3f567c5",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 75,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "3.2.2 Rationale for Study Population 26",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "4c983d26-d93a-4c18-ab18-0d7236bc2999",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 76,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "3.2.3 Rationale for Endpoints 26",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "b81fbf21-9614-4717-beef-9fd49332d737",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 77,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4 MATERIALS AND METHODS 27",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "37952be4-cd44-417a-a775-b5ef3174aded",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 78,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.1 Subjects 27",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "5058f8e3-6fc0-43c1-9d00-39c36d146ae8",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 79,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.1.1 Number of Subjects 27",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "2d5e77ab-4df0-41ba-9df8-21f84356f894",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 80,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.1.2 Inclusion Criteria 27",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "84366a11-67e7-4942-9d52-134fd1bb4082",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 81,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.1.3 Exclusion Criteria 28",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "d059620c-7f4e-4794-9eff-697c2c90d690",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 82,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.1.4 Subject Enrollment and Randomization 29",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "390c1d23-dd21-4a23-bb72-3e6db7ad0fdd",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 83,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.1.5 Withdrawal from the Study 29",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "43659c32-b771-4dfc-82bf-2afba3537843",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 84,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.1.6 Discontinuation of Investigational Product 29",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "52f061fc-0bc3-4a64-9325-b35e918de0bc",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 85,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.1.7 Lost to Follow-up 30",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "e1d2f7a2-b2c5-4002-91b6-6248df5e49f0",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 86,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.1.8 Replacement of Subjects 30",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "7a7e997b-1140-4293-8aa3-0d3d5b1229b3",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 87,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.1.9 Withdrawal of Informed Consent for Data and Biolo gical Samples 30",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "7d675df3-4eda-41b5-905a-3fdd66368fbc",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 88,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.2 Schedule of Study Procedures 31",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "b9cd7587-56db-4983-828c-041b85106721",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 89,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.2.1 Enrollment/Screening Period 31",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "65b296b6-bf69-4603-aed5-a026b68983a5",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 90,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.2.2 Treatment and Follow-up Periods 32",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "91af99de-253e-4f06-a7d1-1e724f6b5a0e",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 91,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.3 Description of Study Procedures 35",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "97ab897d-4746-44c1-8dbb-7cdaf5115402",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 92,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.3.1 Efficacy 35",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "025e4bd2-2431-4db0-8592-61ab46ac37c2",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 93,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.3.1.1 Lower Respiratory Tract Infection 35",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "7313e2b6-12fb-4129-bc30-cf735d7d8dfb",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 94,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.3.2 Medical History and Physical Examination, Weight, and Vital Signs 38",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "ecc7fc02-c6b3-4ad8-a7d8-35048c134146",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 95,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.3.3 Pharmacokinetics and Antidrug Antibody 38",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "f7c3e8ec-b46d-4181-9b72-c8f16c577d4f",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 96,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.3.3.1 Pharmacokinetic Evaluation 38",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "b206147c-7811-4f4c-95c9-b57da7c0cd7b",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 97,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.3.3.2 Antidrug Antibody Evaluation 38",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "98b27e37-6c7e-4a7d-a0b6-7cd1de7985da",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 98,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.3.4 Healthcare Resource Utilization 39",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "03e5d0f0-88c1-4247-a8ba-604e3a08c4dd",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 99,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.3.5 Skin Reactions 39",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "b174048e-9e26-424d-8b78-c9968dbcc1ac",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 100,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.4 Study Suspension or Termination 39",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "2e32b5e0-5073-4e6a-a495-5ba970125c3a",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 101,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.5 Investigational Products 40",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "89663d4e-0aa1-43e1-b98f-d34350ea8020",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 102,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.5.1 Identity of Investigational Products 40",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "20adf2b8-9e1a-4d2c-9a6b-aa5f94d42bc9",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 103,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.5.1.1 Investigational Product Inspection 41",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "ad85cb1a-e9a3-4ceb-889a-d7e41a383f97",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 104,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.5.1.2 Dose Administration Steps 41",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "9905e87a-a053-494d-a31d-db2939e7e038",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 105,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.5.1.3 Treatment Administration 41",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "091662c5-1d4b-40aa-a143-ad38100a0063",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 106,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.5.1.4 Monitoring of Dose Administration 42",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "ab0e0b1f-6e9d-47d9-bae4-bef88319dce6",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 107,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.5.1.5 Reporting Product Complaints 42",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "dbde2ecc-540a-4dbb-a93a-610b384f343d",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 108,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.5.2 Additional Study Medications 42",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "72525cb3-42ed-481a-82b1-aa6568ca88a8",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 109,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.5.3 Labeling 42",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "40412c3a-9b81-4fa0-b505-fd8dcda6e165",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 110,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.5.4 Storage 43",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "914c8cba-732d-4383-842d-fec46fb39809",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 111,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.5.5 Treatment Compliance 43",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "591d6a1b-ee7c-45e4-93aa-f2f8912963dd",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 112,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.5.6 Accountability 43",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "24c1aa3f-38ca-4b34-8d3f-07a83ab8c94d",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 113,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.6 Treatment Assignment and Blinding 43",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "cde8e3d4-3059-49da-a1df-814620e986f3",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 114,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.6.1 Methods for Assigning Treatment Groups 43",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "fa4467f5-d99d-4544-a593-238f5682b2f8",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 115,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.6.2 Methods to Ensure Blinding 44",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "529aafb4-3dcb-4b74-8e7f-3d3c9c9df5d4",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 116,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.6.3 Methods for Unblinding 44",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "543a10c7-0182-4b4d-95df-37311af063d9",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 117,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.6.3.1 Unblinding in the Event of a Medical Emergency 44",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "4298bd1a-d064-41d6-89b8-d343afe7901c",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 118,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.7 Restrictions During the Study and Concomitant Treatment(s) 44",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "02ca7cf7-fc69-4e30-b8e3-3b034fe8a1cf",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 119,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.7.1 Permitted Concomitant Medications 4 4",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "07284e48-31d5-48b8-8917-542649c7b48c",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 120,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.7.2 Prohibited Concomitant Medications 45",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "bd664017-6493-4ca6-bb0c-5db405ded313",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 121,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.8 Statistical Evaluation 45",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "73f87bf4-4c9c-4338-88d6-7129da5a9c93",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 122,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.8.1 General C onsiderations 45",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "c101b994-8b1e-471a-bc27-1ded882275fb",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 123,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.8.2 Sample Size 45",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "c2b218e3-8da3-4fbf-95ea-1e237c9269fd",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 124,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.8.3 Efficacy 46",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "4c2eb1d5-dc25-469e-a9ab-92e6da5b3aec",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 125,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.8.3.1 Primary Efficacy A nalysis 46",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "61243b40-7016-4f19-a118-ad464d167087",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 126,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.8.3.2 Secondary Analyses of the Primary Endpoint 47",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "ce7a74e7-2817-44cc-ac87-ae9ce407f2b3",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 127,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.8.3.3 Supplementary Analyses of the Primary Endpoint 47",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "46db45bd-6055-4d2e-b985-8cf3cabd6d65",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 128,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.8.3.4 Secondary Efficacy Analyses 48",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "bc2f5d25-a8d6-4145-bbde-cc7536478ddd",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 129,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.8.4 Safety 49",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "ae6f8467-7490-4cbb-8ee2-28a3d2471fd6",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 130,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.8.5 Analysis of Pharmacokinetics and Antidrug Antibody 49",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "5dd0aa64-ea58-4cb6-8283-725d28a03015",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 131,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.8.5.1 Pharmacokinetic Analysis 49",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "79dbbf44-d12e-40ef-8362-5c5861e58587",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 132,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.8.5.2 Antidrug Antibody Analysis 50",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "4a8af6b9-9b2e-4f35-9d50-d7fa9cdfb064",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 133,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.8.6 Exploratory Analysis 50",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "322601ae-c49d-407d-907e-b3a65e0fedc9",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 134,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.8.6.1 Healthcare Resource Utilization 50",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "877e8198-2f0c-4f26-bd08-41cb5d4d7ee2",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 135,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.8.6.2 Monitoring RSV Resistance to Nirsevimab 50",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [
        {
          "start_idx": 37,
          "end_idx": 46,
          "standard_entity_name": "Molecule",
          "subcategory": "Molecule",
          "confidence": 75,
          "text": "Nirsevimab"
        }
      ],
      "roi_id": {
        "para": "2384f8c0-2bcb-4345-9d11-d8cc9a9e1a7b",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 136,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.8.6.3 RSV LRTI Occurring from Day 152 to Day 361 50",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [
        {
          "start_idx": 32,
          "end_idx": 34,
          "standard_entity_name": "OTHER: Person Name",
          "subcategory": "OTHER: Person Name",
          "confidence": 100,
          "text": "Day"
        },
        {
          "start_idx": 43,
          "end_idx": 45,
          "standard_entity_name": "OTHER: Person Name",
          "subcategory": "OTHER: Person Name",
          "confidence": 100,
          "text": "Day"
        }
      ],
      "roi_id": {
        "para": "70be394c-16aa-4338-9c62-076cfddb214c",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 137,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.8.7 Data Monitoring Committee 50",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "16136d3f-427f-4660-9f89-dab34d9252cb",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 138,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "4.8.8 Interim Analysis 50",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "a4f8e59a-d784-4f03-af5f-feb0f26515dc",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 139,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "5 ASSESSMENT O F SAFETY 51",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "9ad6e588-5cb2-430d-9ae4-056ee637cb49",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 140,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "5.1 Definition of Adverse Events 51",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "c45201d9-7df0-42b9-a0e6-c1e4dca36915",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 141,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "5.2 Definition of Serious Adverse Events 51",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "db2dc7c6-fe62-4186-a801-c2ae6918be56",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 142,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "5.3 Definition of Adverse Events of Special Interest 52",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "210f9b2c-ef50-4f18-855a-146d5e8c1f88",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 143,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "5.3.1 Anaphylaxis and Other Serious Hypersensitivity Reactions Including Immune",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "b50de11c-d711-4c0f-a01f-2924da8616c8",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 144,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "Complex Disease 52",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "3f09eb79-e7f0-47fd-b563-3b87005bfdb9",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 145,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "5.3.2 Th rombocytopenia 52",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "a2dc4445-36e4-4632-9e21-5884e291951b",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 146,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "5.4 Definition of New Onset Chronic Disease 53",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "b9ea0a4d-62cd-4855-b8aa-6a75b4072c73",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 147,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "5.5 Recording of Adverse Events 53",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "1185907a-21b2-4f21-a152-10a0709b6358",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 148,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "5.5.1 Time Period for Collection of Adverse Events 53",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "31e45fa4-cc51-4cbb-bd54-2c6599fe2d0d",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 149,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "5.5.2 Follow-up of Unresolved Adverse Events 53",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "c626df6d-08ea-405c-bcd0-dc43e98755a8",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 150,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "5.5.3 Deaths 53",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "0b4b2970-c208-4cad-bf7f-0c0c8dd5db71",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 151,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "5.5.4 Potential Hy’s Law and Hy’s Law 54",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "50bd7a22-02b6-4895-a82a-6e8e2c27a7aa",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 152,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "5.6 Reporting of Serious Adverse Events 54",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "c405ab5f-015c-4eec-929b-ce38301a6778",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 153,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "5.7 Other Events Requiring Immediate Reporting 55",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "ffc81727-843e-4ae0-82e8-f3f70e0f2d8f",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 154,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "5.7.1 Overdose 55",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "310004e4-409a-40f0-bc59-8a6ce888c847",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 155,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "5.7.2 Medication Error 55",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "c3843eb1-b1d7-4c1a-98b1-837818c364d8",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 156,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "5.7.3 Adverse Events of Special Interest 56",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "8ab5af0f-1cb6-44a8-969c-feb8b49aad72",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 157,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "5 .7.3.1 Anaphylaxis and Other Serious Hypersensitivity Reactions Including Immune",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "30c5db7f-7c3d-4a9d-a63d-fe3c6c23ee8e",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 158,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "Complex Disease 56",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "7837ea87-a903-4a1e-b74d-1675cda77345",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 159,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "5.7.3.2 Thrombocytopenia 57",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "51d9a207-9588-484c-8fcc-6c595c3d59af",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 160,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "5.7.4 New Onset Chronic Diseas e 57",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "eafb0182-ebd1-496b-bc29-579e46bd9ee8",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 161,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "6 STUDY AND DATA MANAGEMENT 57",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "3ba7a4dd-8d4e-4273-ba97-4d32171acdc5",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 162,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "6.1 Training of Study Site Personnel 57",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "3d426434-0bdb-48c7-9eda-e24c5a4eb753",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 163,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "6.2 Monitoring of the Study 58",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "face98fa-9d98-4059-b8a0-a2ff7efb26fc",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 164,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "6.2.1 Source Data 58",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "eafed246-2a0d-4d29-8d2f-dde59ce1fc43",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 165,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "6.2.2 Study Agreements 58",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "1323d32a-1b0a-4afb-b1df-b6ef6434b3f5",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 166,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "6.2.3 Archiving of Study Documents 58",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "913a9d6c-8c97-4a13-aeb7-58557452abda",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 167,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "6.3 Study Timetable and End of Study 59",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "8cfd9bdb-4922-4231-b139-3e7a0c97fc38",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 168,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "6.4 Data Management 59",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "1bcdbc14-86b4-436f-9834-0f5bbc09709e",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 169,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "6.5 Study Physician Coverage 59",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "0dae8a27-c95d-4498-b121-38ff7eb6f168",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 170,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "7 ETHICAL AND REGULATORY REQUIREMENTS 59",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "7e205f49-2f7d-470d-b96b-c1ddae24dcec",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 171,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "7.1 Subject Data Protection 59",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "3a01ab19-dd60-4896-a689-328a45d14f62",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 172,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "7.2 Ethics and Regulatory Review 60",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "83d0d73d-7480-4b36-9000-1c08e8703ffa",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 173,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "7.3 Informed Consent 60",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "ef34ec00-98e1-44ef-851f-5e8039d1a3fa",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 174,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "7.4 Changes to the P rotocol and Informed Consent Form 61",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "8af6de0f-08b4-4d70-b47c-293a58b07114",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 175,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "7.5 Audits and Inspections 61",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "c528bdc2-8d86-48d2-a70a-f3203d33e666",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 176,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "8 REFERENCES 62",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "0ea97248-0414-420f-a896-4eb30dcc57ae",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 177,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "04bda440-721b-41b8-b956-a703c6ede992",
        "childbox": "a4fb6950-3d3b-481b-870c-01b951ebe269",
        "subtext": "c8fd8745-f6eb-43ba-8c49-8080665405d2"
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "DStrike": false,
      "Emboss": false,
      "Highlight": "",
      "Imprint": false,
      "Italics": false,
      "Outline": false,
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 178,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "81abb66a-fa88-413b-b966-cc6d7faadd02",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 179,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "LIST OF TABLES",
    "font_info": {
      "IsBold": true,
      "font_size": 28,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "b18682b0-7248-431e-93c2-b631e0b88562",
        "childbox": "d8d650da-8448-4c3a-9afd-bc811ea5dc3a",
        "subtext": "48e3f7e0-c27b-49ad-959f-5227b0a6cec3"
      },
      "Bold": true,
      "Caps": false,
      "ColorRGB": 0,
      "DStrike": false,
      "Emboss": false,
      "Highlight": "",
      "Imprint": false,
      "Italics": false,
      "Outline": false,
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": 28,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 180,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": {
      "Table": "<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th>ColIndex</th>\n      <th>1.0</th>\n      <th>2.0</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>Table 1</td>\n      <td>Primary Objective and Associated Endpoint ............................................ 22</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>Table 2</td>\n      <td>Secondary Objectives and Associated Endpoints...................................... 22</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>Table 3</td>\n      <td>Exploratory Objectives and Associated Endpoints ................................... 23</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>Table 4</td>\n      <td>Schedule of Screening Procedures ........................................................... 31</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>Table 5</td>\n      <td>Schedule of Treatment Period and Follow-up Period Study Procedures.... 33</td>\n    </tr>\n    <tr>\n      <th>5</th>\n      <td>Table 6</td>\n      <td>Criteria for Meeting the Protocol-defined Endpoint of Medically Attended RSV LRTI ................................................................................ 36</td>\n    </tr>\n    <tr>\n      <th>6</th>\n      <td>Table 7</td>\n      <td>Identification of Investigational Products ................................................. 40</td>\n    </tr>\n  </tbody>\n</table>",
      "TableProperties": "[{\"1.0\":{\"entities\":[],\"content\":\"Table 1 \",\"roi_id\":{\"table_roi_id\":\"7ec458ba-8636-4e37-897f-8053fc798bf2\",\"row_roi_id\":\"1f9fdad7-bd65-4b5e-b6fa-5620148ee588\",\"column_roi_id\":\"52236b18-4973-425f-83ad-793c3e78b94a\",\"datacell_roi_id\":\"582d67af-a862-47ee-8f6c-0ee50bdd4b5c\"},\"table_index\":7.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"Primary Objective and Associated Endpoint ............................................ 22 \",\"roi_id\":{\"table_roi_id\":\"7ec458ba-8636-4e37-897f-8053fc798bf2\",\"row_roi_id\":\"1f9fdad7-bd65-4b5e-b6fa-5620148ee588\",\"column_roi_id\":\"7b2250e5-1f98-4ef4-81c2-3e0d45f103e5\",\"datacell_roi_id\":\"7d4661ae-733e-4e28-bb73-177494e56ed0\"},\"table_index\":7.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"Table 2 \",\"roi_id\":{\"table_roi_id\":\"7ec458ba-8636-4e37-897f-8053fc798bf2\",\"row_roi_id\":\"49b30e39-4a20-4e49-8919-469df5660a5f\",\"column_roi_id\":\"29c8926d-6c85-4ea0-89bc-bfb57ed4a7d3\",\"datacell_roi_id\":\"231eb289-5d3d-4a2a-b10f-70dc01594e05\"},\"table_index\":7.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"Secondary Objectives and Associated Endpoints...................................... 22 \",\"roi_id\":{\"table_roi_id\":\"7ec458ba-8636-4e37-897f-8053fc798bf2\",\"row_roi_id\":\"49b30e39-4a20-4e49-8919-469df5660a5f\",\"column_roi_id\":\"b419d692-8cf8-460d-90f4-b99fca4c477b\",\"datacell_roi_id\":\"9ecd123c-a062-4480-9fdb-45eaf2d96668\"},\"table_index\":7.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"Table 3 \",\"roi_id\":{\"table_roi_id\":\"7ec458ba-8636-4e37-897f-8053fc798bf2\",\"row_roi_id\":\"7fdf8a83-71b0-4fff-927f-bb990a5699c8\",\"column_roi_id\":\"9f1686e2-f29e-4708-ab44-77ffea06a2a0\",\"datacell_roi_id\":\"9ad12f83-237a-4e3a-8020-96621426c507\"},\"table_index\":7.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"Exploratory Objectives and Associated Endpoints ................................... 23 \",\"roi_id\":{\"table_roi_id\":\"7ec458ba-8636-4e37-897f-8053fc798bf2\",\"row_roi_id\":\"7fdf8a83-71b0-4fff-927f-bb990a5699c8\",\"column_roi_id\":\"cc5205f6-c235-49fa-af76-79760a3915f7\",\"datacell_roi_id\":\"a94e2ccf-ab37-4a8e-b8d4-6c4e6c0df1cf\"},\"table_index\":7.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"Table 4 \",\"roi_id\":{\"table_roi_id\":\"7ec458ba-8636-4e37-897f-8053fc798bf2\",\"row_roi_id\":\"34600cb0-44a0-4516-9551-231a9a507300\",\"column_roi_id\":\"ab430863-82a4-4833-8ab6-88abcdb8be90\",\"datacell_roi_id\":\"51bd414f-a5e5-4ecc-a8e5-6f06cd6f97fc\"},\"table_index\":7.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"Schedule of Screening Procedures ........................................................... 31 \",\"roi_id\":{\"table_roi_id\":\"7ec458ba-8636-4e37-897f-8053fc798bf2\",\"row_roi_id\":\"34600cb0-44a0-4516-9551-231a9a507300\",\"column_roi_id\":\"8116ecdf-269c-42df-b55f-85be10bed15a\",\"datacell_roi_id\":\"e8aab013-cac1-4e94-9e75-2ce39ef0f902\"},\"table_index\":7.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"Table 5 \",\"roi_id\":{\"table_roi_id\":\"7ec458ba-8636-4e37-897f-8053fc798bf2\",\"row_roi_id\":\"95f7a985-8d86-48eb-ac51-2ebeb7a77f0e\",\"column_roi_id\":\"19b7bb3e-acb1-4f5b-af89-56e731954871\",\"datacell_roi_id\":\"bf96e61c-deaf-43b6-bf7d-03af97847af2\"},\"table_index\":7.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"Schedule of Treatment Period and Follow-up Period Study Procedures.... 33 \",\"roi_id\":{\"table_roi_id\":\"7ec458ba-8636-4e37-897f-8053fc798bf2\",\"row_roi_id\":\"95f7a985-8d86-48eb-ac51-2ebeb7a77f0e\",\"column_roi_id\":\"a51b08a2-6629-4939-b840-440839afed7d\",\"datacell_roi_id\":\"53506da9-6c1b-48b8-be25-15aff3acbc42\"},\"table_index\":7.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"Table 6 \",\"roi_id\":{\"table_roi_id\":\"7ec458ba-8636-4e37-897f-8053fc798bf2\",\"row_roi_id\":\"a6a49690-fe08-46dc-a492-8b0a05c0a4f6\",\"column_roi_id\":\"aa8e7608-7d26-4d60-bc18-58b1a389cf2e\",\"datacell_roi_id\":\"12e40130-5c3b-44c0-aa04-3b7be0eb5e10\"},\"table_index\":7.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"Criteria for Meeting the Protocol-defined Endpoint of Medically Attended RSV LRTI ................................................................................ 36 \",\"roi_id\":{\"table_roi_id\":\"7ec458ba-8636-4e37-897f-8053fc798bf2\",\"row_roi_id\":\"a6a49690-fe08-46dc-a492-8b0a05c0a4f6\",\"column_roi_id\":\"060d94c2-f617-4e43-8a11-bf965db94dc4\",\"datacell_roi_id\":\"15efe04c-79fa-4a84-b9c7-e16260a35fd4\"},\"table_index\":7.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"Table 7 \",\"roi_id\":{\"table_roi_id\":\"7ec458ba-8636-4e37-897f-8053fc798bf2\",\"row_roi_id\":\"4c50923b-d57d-485c-9af9-1d52d62773b5\",\"column_roi_id\":\"6382f8bb-8ded-4cbf-8148-4d876ac5f7ef\",\"datacell_roi_id\":\"0fd96ab0-4510-4599-9378-23e5be4a7cbc\"},\"table_index\":7.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"Identification of Investigational Products ................................................. 40 \",\"roi_id\":{\"table_roi_id\":\"7ec458ba-8636-4e37-897f-8053fc798bf2\",\"row_roi_id\":\"4c50923b-d57d-485c-9af9-1d52d62773b5\",\"column_roi_id\":\"6e309d7f-131c-4996-a8e1-29a34846fec4\",\"datacell_roi_id\":\"6e6af6de-458a-4658-ab12-0fb66ad1372c\"},\"table_index\":7.0,\"qc_change_type\":\"\"}}]",
      "SectionHeaderPrintPage": "6",
      "TableIndex": "8",
      "TableName": "TABLE OF CONTENTS",
      "Header": []
    },
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "582d67af-a862-47ee-8f6c-0ee50bdd4b5c",
        "childbox": "a7e1c4bb-2938-4db9-95ee-8f18283cfb12",
        "subtext": "d55b9c81-a192-4c86-9955-8955d4cd6fbf"
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "DStrike": false,
      "Emboss": false,
      "Highlight": "",
      "Imprint": false,
      "Italics": false,
      "Outline": false,
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "derived_section_type": "table",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 181,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "71375d11-dcc7-4a76-88f5-ffa347c81607",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 182,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "LIST OF FIGURES",
    "font_info": {
      "IsBold": true,
      "font_size": 28,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "6817030a-17cc-49fe-9e53-aa61c0e656c0",
        "childbox": "9fb57d00-ea88-4846-a931-98822b27c06c",
        "subtext": "019bcd04-97aa-48dc-b191-8763f2d1840a"
      },
      "Bold": true,
      "Caps": false,
      "ColorRGB": 0,
      "DStrike": false,
      "Emboss": false,
      "Highlight": "",
      "Imprint": false,
      "Italics": false,
      "Outline": false,
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": 28,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 183,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "Figure 1",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "ec7a35d3-2739-440c-b576-ec73e3565cdf",
        "childbox": "61dc0d72-485d-435a-8197-32579cb74594",
        "subtext": "325024f9-0eb8-46b8-b698-7878a77e206d"
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "DStrike": false,
      "Emboss": false,
      "Highlight": "",
      "Imprint": false,
      "Italics": false,
      "Outline": false,
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 184,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": 22,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "ec7a35d3-2739-440c-b576-ec73e3565cdf",
        "childbox": "61dc0d72-485d-435a-8197-32579cb74594",
        "subtext": "85ff876a-c693-4699-9678-b9af5e194aa1"
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "DStrike": false,
      "Emboss": false,
      "Highlight": "",
      "Imprint": false,
      "Italics": false,
      "Outline": false,
      "rFonts": "Calibri",
      "rStyle": "",
      "Shadow": false,
      "Size": 22,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 185,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": 22,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "ec7a35d3-2739-440c-b576-ec73e3565cdf",
        "childbox": "e004ae79-c25c-4461-9eec-76685ae126d3",
        "subtext": "b1cd872c-f266-4c54-92d2-bdd98d0fb869"
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "DStrike": false,
      "Emboss": false,
      "Highlight": "",
      "Imprint": false,
      "Italics": false,
      "Outline": false,
      "rFonts": "Calibri",
      "rStyle": "",
      "Shadow": false,
      "Size": 22,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 186,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "Study Flow Diagram ................................................................................",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "ec7a35d3-2739-440c-b576-ec73e3565cdf",
        "childbox": "8207e1b8-eba7-4e03-8356-f761e6728f6c",
        "subtext": "1ae8956d-7c9c-4eea-b3c2-4858211ae7c6"
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "DStrike": false,
      "Emboss": false,
      "Highlight": "",
      "Imprint": false,
      "Italics": false,
      "Outline": false,
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 187,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "25",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "ec7a35d3-2739-440c-b576-ec73e3565cdf",
        "childbox": "441c18ff-3bea-4cd1-939e-76f226afe07a",
        "subtext": "1ae8956d-7c9c-4eea-b3c2-4858211ae7c6"
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "DStrike": false,
      "Emboss": false,
      "Highlight": "",
      "Imprint": false,
      "Italics": false,
      "Outline": false,
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 188,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": 22,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "ec7a35d3-2739-440c-b576-ec73e3565cdf",
        "childbox": "441c18ff-3bea-4cd1-939e-76f226afe07a",
        "subtext": "84f50acd-47db-4280-ac0f-e7ac8bea3628"
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "DStrike": false,
      "Emboss": false,
      "Highlight": "",
      "Imprint": false,
      "Italics": false,
      "Outline": false,
      "rFonts": "Calibri",
      "rStyle": "",
      "Shadow": false,
      "Size": 22,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 189,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "fb947cbb-3e43-4436-ba7b-1ccad0b5309a",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 190,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "LIST OF APPENDICES",
    "font_info": {
      "IsBold": true,
      "font_size": 28,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "6fbf3e80-2e17-4d5b-9c85-9211539e50e5",
        "childbox": "6af39177-57d9-4cbe-bf38-cf57ac17d765",
        "subtext": "bf69bab4-229a-4cb0-8d93-611c64424174"
      },
      "Bold": true,
      "Caps": false,
      "ColorRGB": 0,
      "DStrike": false,
      "Emboss": false,
      "Highlight": "",
      "Imprint": false,
      "Italics": false,
      "Outline": false,
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": 28,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 191,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "Appendix A",
    "font_info": {
      "IsBold": true,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "ae188a1d-3b86-4012-b606-526025c690a0",
        "childbox": "48d8f7de-8a56-4f45-89f3-93e02a05d1ea",
        "subtext": "0fd53391-c7b1-455f-b8bb-650f07796754"
      },
      "Bold": true,
      "Caps": false,
      "ColorRGB": 0,
      "DStrike": false,
      "Emboss": false,
      "Highlight": "",
      "Imprint": false,
      "Italics": false,
      "Outline": false,
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 192,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "ae188a1d-3b86-4012-b606-526025c690a0",
        "childbox": "48d8f7de-8a56-4f45-89f3-93e02a05d1ea",
        "subtext": "35aeeb3f-27a8-476f-bd16-2c3616b9ce3a"
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "DStrike": false,
      "Emboss": false,
      "Highlight": "",
      "Imprint": false,
      "Italics": false,
      "Outline": false,
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 193,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "ae188a1d-3b86-4012-b606-526025c690a0",
        "childbox": "2a4404cb-9387-426b-9036-ac739c896e3c",
        "subtext": "b2db0893-dc1d-4644-aae8-18a7a85305e2"
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "DStrike": false,
      "Emboss": false,
      "Highlight": "",
      "Imprint": false,
      "Italics": false,
      "Outline": false,
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 194,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "Additional Safety Guidance .....................................................................",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "ae188a1d-3b86-4012-b606-526025c690a0",
        "childbox": "c9bf403a-d4a4-44e1-bd00-a3d19f084ee0",
        "subtext": "b2db0893-dc1d-4644-aae8-18a7a85305e2"
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "DStrike": false,
      "Emboss": false,
      "Highlight": "",
      "Imprint": false,
      "Italics": false,
      "Outline": false,
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 195,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "66",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "ae188a1d-3b86-4012-b606-526025c690a0",
        "childbox": "bbdb3810-7ae1-4267-9b2c-b50e70987905",
        "subtext": "b2db0893-dc1d-4644-aae8-18a7a85305e2"
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "DStrike": false,
      "Emboss": false,
      "Highlight": "",
      "Imprint": false,
      "Italics": false,
      "Outline": false,
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 196,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": 22,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "ae188a1d-3b86-4012-b606-526025c690a0",
        "childbox": "bbdb3810-7ae1-4267-9b2c-b50e70987905",
        "subtext": "5e281519-28f4-4cc2-a19c-1ea26a5bca61"
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "DStrike": false,
      "Emboss": false,
      "Highlight": "",
      "Imprint": false,
      "Italics": false,
      "Outline": false,
      "rFonts": "Calibri",
      "rStyle": "",
      "Shadow": false,
      "Size": 22,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 197,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "Appendix B",
    "font_info": {
      "IsBold": true,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "09fa0edc-78f0-438a-9498-817de1c7cb73",
        "childbox": "e732a7c9-b293-4d3a-ab72-ce3515c2bf5a",
        "subtext": "136ff86f-009c-4b98-841a-b7a90bfd3fba"
      },
      "Bold": true,
      "Caps": false,
      "ColorRGB": 0,
      "DStrike": false,
      "Emboss": false,
      "Highlight": "",
      "Imprint": false,
      "Italics": false,
      "Outline": false,
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 198,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "National Institute of Allergy and Infectious Diseases and Food Allergy and Anaphylaxis Network Guidance for Anaphylaxis Diagnosis ..............",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [
        {
          "start_idx": 34,
          "end_idx": 69,
          "standard_entity_name": "ANY: Organization",
          "subcategory": "ANY: Organization",
          "confidence": 87,
          "text": "Infectious Diseases and Food Allergy"
        },
        {
          "start_idx": 0,
          "end_idx": 69,
          "standard_entity_name": "ANY: Organization",
          "subcategory": "ANY: Organization",
          "confidence": 87,
          "text": "National Institute of Allergy and Infectious Diseases and Food Allergy"
        },
        {
          "start_idx": 70,
          "end_idx": 93,
          "standard_entity_name": "ANY: Organization",
          "subcategory": "ANY: Organization",
          "confidence": 87,
          "text": " and Anaphylaxis Network"
        }
      ],
      "roi_id": {
        "para": "09fa0edc-78f0-438a-9498-817de1c7cb73",
        "childbox": "e732a7c9-b293-4d3a-ab72-ce3515c2bf5a",
        "subtext": "cdf7284f-79b3-46eb-a0dd-bb471212e86f"
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "DStrike": false,
      "Emboss": false,
      "Highlight": "",
      "Imprint": false,
      "Italics": false,
      "Outline": false,
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 199,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "70",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "09fa0edc-78f0-438a-9498-817de1c7cb73",
        "childbox": "49ec2be4-80aa-408f-994b-740588b92122",
        "subtext": "cb3c87c9-fc0d-48a2-9fb9-0e1ed4d911c7"
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "DStrike": false,
      "Emboss": false,
      "Highlight": "",
      "Imprint": false,
      "Italics": false,
      "Outline": false,
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 200,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": 22,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "09fa0edc-78f0-438a-9498-817de1c7cb73",
        "childbox": "49ec2be4-80aa-408f-994b-740588b92122",
        "subtext": "f3a2d2e4-e2eb-4542-9aec-f45c18c8c4a9"
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "DStrike": false,
      "Emboss": false,
      "Highlight": "",
      "Imprint": false,
      "Italics": false,
      "Outline": false,
      "rFonts": "Calibri",
      "rStyle": "",
      "Shadow": false,
      "Size": 22,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 201,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "Appendix C",
    "font_info": {
      "IsBold": true,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "144ddfec-b217-47b8-8609-1a3a4c32139f",
        "childbox": "0f4dceb3-ac6f-4116-a7cc-bde270cf525d",
        "subtext": "b0af0984-bd81-44ef-a4e2-ed88db0666b1"
      },
      "Bold": true,
      "Caps": false,
      "ColorRGB": 0,
      "DStrike": false,
      "Emboss": false,
      "Highlight": "",
      "Imprint": false,
      "Italics": false,
      "Outline": false,
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 202,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "144ddfec-b217-47b8-8609-1a3a4c32139f",
        "childbox": "0f4dceb3-ac6f-4116-a7cc-bde270cf525d",
        "subtext": "3066cd55-5373-4930-aba4-f77fd464a1ae"
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "DStrike": false,
      "Emboss": false,
      "Highlight": "",
      "Imprint": false,
      "Italics": false,
      "Outline": false,
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 203,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "144ddfec-b217-47b8-8609-1a3a4c32139f",
        "childbox": "921907ec-8704-461a-b069-75f82270f472",
        "subtext": "fef12bdc-77a3-4a35-8fae-93145f052818"
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "DStrike": false,
      "Emboss": false,
      "Highlight": "",
      "Imprint": false,
      "Italics": false,
      "Outline": false,
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 204,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "Actions Required in Cases of Increases in Liver Biochemistry and",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "144ddfec-b217-47b8-8609-1a3a4c32139f",
        "childbox": "a9bee0ae-1f68-4b48-88f0-519ee18dcea3",
        "subtext": "fef12bdc-77a3-4a35-8fae-93145f052818"
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "DStrike": false,
      "Emboss": false,
      "Highlight": "",
      "Imprint": false,
      "Italics": false,
      "Outline": false,
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 205,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "Evaluation of Hy’s Law ...........................................................................",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "d4045b0c-aac9-46f7-ba8d-d8f16da4eba5",
        "childbox": "c2cf5c00-8c2f-40cb-a646-228c07f8ae07",
        "subtext": "d21a4c15-700d-4b00-9f59-5591dd5301e3"
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "DStrike": false,
      "Emboss": false,
      "Highlight": "",
      "Imprint": false,
      "Italics": false,
      "Outline": false,
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 206,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "71",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "d4045b0c-aac9-46f7-ba8d-d8f16da4eba5",
        "childbox": "30b95316-6da2-4689-9e51-1ca92f68137a",
        "subtext": "13c1a120-a47c-4589-9f20-50119cb45367"
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "DStrike": false,
      "Emboss": false,
      "Highlight": "",
      "Imprint": false,
      "Italics": false,
      "Outline": false,
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 207,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": 22,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "d4045b0c-aac9-46f7-ba8d-d8f16da4eba5",
        "childbox": "30b95316-6da2-4689-9e51-1ca92f68137a",
        "subtext": "2e192e55-66a8-4990-b8cd-d0f261181079"
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "DStrike": false,
      "Emboss": false,
      "Highlight": "",
      "Imprint": false,
      "Italics": false,
      "Outline": false,
      "rFonts": "Calibri",
      "rStyle": "",
      "Shadow": false,
      "Size": 22,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 208,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "6dad90e7-aaad-4cff-8d83-44d0c7b3bb67",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 209,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "8fccb662-0642-4b62-9b94-d6cf8d07bdcd",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 2,
    "line_id": 210,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "source_file_section": "LIST OF ABBREVIATIONS",
    "source_heading_number": "",
    "parent_heading_num_seq": [
      ""
    ],
    "parent_sec_id_seq": [
      3
    ],
    "derived_heading_level": 1,
    "pt_from_ontology": [
      ""
    ],
    "medical_terms": [],
    "page": 1,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "2_section_metadata",
    "sec_id": 3,
    "child_secid_seq": [
      [
        3,
        "",
        "LIST OF ABBREVIATIONS",
        1
      ]
    ]
  },
  {
    "content": "LIST OF ABBREVIATIONS",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "Heading1",
      "entity": [],
      "roi_id": {
        "para": "230a8091-d983-4ad4-a507-a1affbc632fc",
        "childbox": "",
        "subtext": ""
      },
      "Bold": false,
      "Caps": false,
      "ColorRGB": 0,
      "DStrike": false,
      "Emboss": false,
      "Highlight": "",
      "Imprint": false,
      "Italics": false,
      "Outline": false,
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": -1,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "derived_section_type": "header",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 3,
    "line_id": 211,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": {
      "Table": "<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th>ColIndex</th>\n      <th>1.0</th>\n      <th>2.0</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>Abbreviation or Specialized Term</td>\n      <td>Definition</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>aa</td>\n      <td>amino acid</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>ADA</td>\n      <td>antidrug antibody</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>AE</td>\n      <td>adverse event</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>AESI</td>\n      <td>adverse event of special interest</td>\n    </tr>\n    <tr>\n      <th>5</th>\n      <td>ALT</td>\n      <td>alanine aminotransferase</td>\n    </tr>\n    <tr>\n      <th>6</th>\n      <td>AST</td>\n      <td>aspartate aminotransferase</td>\n    </tr>\n    <tr>\n      <th>7</th>\n      <td>AUC</td>\n      <td>area under the concentration time-curve</td>\n    </tr>\n    <tr>\n      <th>8</th>\n      <td>AUC 0- ∞</td>\n      <td>area under the concentration-time curve from time 0 to infinity</td>\n    </tr>\n    <tr>\n      <th>9</th>\n      <td>CHD</td>\n      <td>congenital heart disease</td>\n    </tr>\n    <tr>\n      <th>10</th>\n      <td>CI</td>\n      <td>confidence interval</td>\n    </tr>\n    <tr>\n      <th>11</th>\n      <td>CLD</td>\n      <td>chronic lung disease</td>\n    </tr>\n    <tr>\n      <th>12</th>\n      <td>CMH</td>\n      <td>Cochran-Mantel-Haenszel</td>\n    </tr>\n    <tr>\n      <th>13</th>\n      <td>eCRF</td>\n      <td>electronic case report form</td>\n    </tr>\n    <tr>\n      <th>14</th>\n      <td>EDC</td>\n      <td>electronic data capture</td>\n    </tr>\n    <tr>\n      <th>15</th>\n      <td>ER</td>\n      <td>emergency room</td>\n    </tr>\n    <tr>\n      <th>16</th>\n      <td>Fc</td>\n      <td>fragment cystallizable</td>\n    </tr>\n    <tr>\n      <th>17</th>\n      <td>FcRn</td>\n      <td>neonatal Fc receptor</td>\n    </tr>\n    <tr>\n      <th>18</th>\n      <td>FDA</td>\n      <td>Food and Drug Administration</td>\n    </tr>\n    <tr>\n      <th>19</th>\n      <td>GA</td>\n      <td>gestational age</td>\n    </tr>\n    <tr>\n      <th>20</th>\n      <td>GCP</td>\n      <td>Good Clinical Practice</td>\n    </tr>\n    <tr>\n      <th>21</th>\n      <td>HIV</td>\n      <td>human immunodeficiency virus</td>\n    </tr>\n    <tr>\n      <th>22</th>\n      <td>hMPV</td>\n      <td>human metapneumovirus</td>\n    </tr>\n    <tr>\n      <th>23</th>\n      <td>HRU</td>\n      <td>healthcare resource utilization</td>\n    </tr>\n    <tr>\n      <th>24</th>\n      <td>ICH</td>\n      <td>International Council for Harmonisation</td>\n    </tr>\n    <tr>\n      <th>25</th>\n      <td>IEC</td>\n      <td>Independent Ethics Committee</td>\n    </tr>\n    <tr>\n      <th>26</th>\n      <td>IgG</td>\n      <td>immunoglobulin G</td>\n    </tr>\n    <tr>\n      <th>27</th>\n      <td>IM</td>\n      <td>intramuscular</td>\n    </tr>\n    <tr>\n      <th>28</th>\n      <td>IRB</td>\n      <td>Institutional Review Board</td>\n    </tr>\n    <tr>\n      <th>29</th>\n      <td>ITT</td>\n      <td>Intent-to-treat</td>\n    </tr>\n    <tr>\n      <th>30</th>\n      <td>IV</td>\n      <td>intravenous</td>\n    </tr>\n    <tr>\n      <th>31</th>\n      <td>IWRS</td>\n      <td>interactive web response system</td>\n    </tr>\n    <tr>\n      <th>32</th>\n      <td>LRTI</td>\n      <td>lower respiratory tract infection</td>\n    </tr>\n    <tr>\n      <th>33</th>\n      <td>mAb</td>\n      <td>monoclonal antibody</td>\n    </tr>\n    <tr>\n      <th>34</th>\n      <td>MedDRA</td>\n      <td>Medical Dictionary for Regulatory Activities</td>\n    </tr>\n    <tr>\n      <th>35</th>\n      <td>NAb</td>\n      <td>neutralizing antibody</td>\n    </tr>\n    <tr>\n      <th>36</th>\n      <td>NCI CTCAE</td>\n      <td>National Cancer Institute Common Terminology Criteria for Adverse Events</td>\n    </tr>\n    <tr>\n      <th>37</th>\n      <td>NOCD</td>\n      <td>new onset chronic disease</td>\n    </tr>\n    <tr>\n      <th>38</th>\n      <td>OTC</td>\n      <td>over-the-counter</td>\n    </tr>\n    <tr>\n      <th>39</th>\n      <td>PK</td>\n      <td>pharmacokinetic(s)</td>\n    </tr>\n    <tr>\n      <th>40</th>\n      <td>RRR</td>\n      <td>relative risk reduction</td>\n    </tr>\n    <tr>\n      <th>41</th>\n      <td>RSV</td>\n      <td>respiratory syncytial virus</td>\n    </tr>\n    <tr>\n      <th>42</th>\n      <td>RT-PCR</td>\n      <td>reverse transcriptase-polymerase chain reaction</td>\n    </tr>\n    <tr>\n      <th>43</th>\n      <td>SAE</td>\n      <td>serious adverse event</td>\n    </tr>\n    <tr>\n      <th>44</th>\n      <td>SID</td>\n      <td>subject identification</td>\n    </tr>\n    <tr>\n      <th>45</th>\n      <td>SUSAR</td>\n      <td>suspected unexpected serious adverse reaction</td>\n    </tr>\n    <tr>\n      <th>46</th>\n      <td>t 1/2</td>\n      <td>terminal half-life</td>\n    </tr>\n    <tr>\n      <th>47</th>\n      <td>TBL</td>\n      <td>total bilirubin</td>\n    </tr>\n    <tr>\n      <th>48</th>\n      <td>TEAE</td>\n      <td>treatment-emergent adverse event</td>\n    </tr>\n    <tr>\n      <th>49</th>\n      <td>TESAE</td>\n      <td>treatment-emergent serious adverse event</td>\n    </tr>\n    <tr>\n      <th>50</th>\n      <td>ULN</td>\n      <td>upper limit of normal</td>\n    </tr>\n    <tr>\n      <th>51</th>\n      <td>URTI</td>\n      <td>upper respiratory tract infection</td>\n    </tr>\n    <tr>\n      <th>52</th>\n      <td>US</td>\n      <td>United States</td>\n    </tr>\n    <tr>\n      <th>53</th>\n      <td>wGA</td>\n      <td>weeks gestational age</td>\n    </tr>\n    <tr>\n      <th>54</th>\n      <td>YTE</td>\n      <td>M257Y/S259T/T261E triple amino acid substitution</td>\n    </tr>\n  </tbody>\n</table>",
      "TableProperties": "[{\"1.0\":{\"entities\":[],\"content\":\"Abbreviation or Specialized Term\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"7ede3d84-4c34-4a34-b7da-e6f26d2f9ab4\",\"column_roi_id\":\"b0572cbb-9e79-428e-844a-7377fc0feac8\",\"datacell_roi_id\":\"dc36495c-987c-49ba-bf82-c8cbaed4fdf2\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"Definition\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"7ede3d84-4c34-4a34-b7da-e6f26d2f9ab4\",\"column_roi_id\":\"bc8d7a03-3a3a-4b82-8d8a-105ea711e11a\",\"datacell_roi_id\":\"cb567ebc-de85-4359-bd51-2d990bb4a2e5\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"aa\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"4d147010-d119-4cac-ad77-8a68688cd5db\",\"column_roi_id\":\"a7e1e946-192c-4646-b1db-4f089c3bcd4f\",\"datacell_roi_id\":\"bc11827a-2f5f-4415-adce-7c1f3246c34c\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"amino acid\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"4d147010-d119-4cac-ad77-8a68688cd5db\",\"column_roi_id\":\"6ee7a4cd-f78d-4503-a97b-9429adfd7bd1\",\"datacell_roi_id\":\"5e578826-9428-4b1e-9e48-f24496d8708e\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"ADA\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"e8ec4adc-283f-42f1-a90e-d372e5eb28b2\",\"column_roi_id\":\"088d842c-2a0e-4b3f-820b-b1965ad7f2a8\",\"datacell_roi_id\":\"1505814a-b762-40bf-af2c-58b5737fc119\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"antidrug antibody\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"e8ec4adc-283f-42f1-a90e-d372e5eb28b2\",\"column_roi_id\":\"d54650a9-247f-49ff-9e85-3ceb18a3c596\",\"datacell_roi_id\":\"87604342-af64-4063-8a66-e1935ab10a35\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"AE\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"792ef187-25ff-4550-aca3-982c645de40c\",\"column_roi_id\":\"aeec2b08-edcb-4048-9ac9-a8baeac0107b\",\"datacell_roi_id\":\"01ecc5b3-68fe-4479-9d54-6b06724e30be\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"adverse event\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"792ef187-25ff-4550-aca3-982c645de40c\",\"column_roi_id\":\"643c79e1-81f1-4132-81a2-a943cd9bb291\",\"datacell_roi_id\":\"2a7eff46-68ea-47c1-839a-13b23e48ffd8\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"AESI\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"758f6c3a-ebbe-4ac4-8ecf-1aa43c1bfa92\",\"column_roi_id\":\"6f343a1a-d781-4c72-b934-26bfd7a73a1b\",\"datacell_roi_id\":\"893cd5cf-ccf2-4c17-8d45-e166833bd96b\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"adverse event of special interest\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"758f6c3a-ebbe-4ac4-8ecf-1aa43c1bfa92\",\"column_roi_id\":\"e68b470d-7657-4e05-877d-fd1e03560a7f\",\"datacell_roi_id\":\"10d4512a-b9f7-4506-9624-0c1cc03f0afb\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"ALT\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"ddbd43e9-1715-4a79-a01e-13c5e6ef1de5\",\"column_roi_id\":\"1576ed52-a18e-497c-a21b-2fb9495fc62a\",\"datacell_roi_id\":\"4866e60f-d323-47de-aa86-7b2eedd5dc65\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"alanine aminotransferase\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"ddbd43e9-1715-4a79-a01e-13c5e6ef1de5\",\"column_roi_id\":\"e032a834-56b7-4466-a334-3173d057cdc1\",\"datacell_roi_id\":\"1cdd9118-976c-476b-b20c-ac16696f5a2f\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"AST\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"2106a22c-395a-4d60-9be6-58d6ea157ebc\",\"column_roi_id\":\"9c8936d2-fac0-46f0-b14c-c54c0b7a97a2\",\"datacell_roi_id\":\"58449c78-6789-4a9a-9673-4e0002728fb5\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"aspartate aminotransferase\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"2106a22c-395a-4d60-9be6-58d6ea157ebc\",\"column_roi_id\":\"7b2e4dd6-b588-4303-ad90-8b6e063eb2e7\",\"datacell_roi_id\":\"9298591d-eb80-4d13-bdda-30b67a0d1a3d\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"AUC\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"f889b1f1-d45c-4c3a-b96a-cb487d136762\",\"column_roi_id\":\"730be07b-90f1-4ed3-9eaa-0a03303e6b59\",\"datacell_roi_id\":\"69cddb12-fc5f-45f7-be07-e56570dfe986\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"area under the concentration time-curve\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"f889b1f1-d45c-4c3a-b96a-cb487d136762\",\"column_roi_id\":\"3760499a-b83b-4e88-bb95-64cfbb18bfda\",\"datacell_roi_id\":\"b103aa39-cf71-4b2b-894b-a54af63e9cd4\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"AUC 0- \\u221e \",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"dbc596e5-d0f2-4a37-bfcd-35133ddffa50\",\"column_roi_id\":\"c8fcc3bd-e8df-4694-89c6-2cd60eb9290f\",\"datacell_roi_id\":\"c80425f9-d72f-46e4-b609-cda742c49f24\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"area under the concentration-time curve from time 0 to infinity\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"dbc596e5-d0f2-4a37-bfcd-35133ddffa50\",\"column_roi_id\":\"8883e4a4-c146-4202-98d0-58a5f736f89a\",\"datacell_roi_id\":\"64322407-adf3-4576-9163-06bebbce8dac\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"CHD\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"523b8568-6f09-4b72-abd5-5e2a14b449d3\",\"column_roi_id\":\"ec7294b7-2cd8-40ff-a667-23cb05622d5e\",\"datacell_roi_id\":\"13538cea-d6a3-4ebd-b4de-1d134582222b\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"congenital heart disease\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"523b8568-6f09-4b72-abd5-5e2a14b449d3\",\"column_roi_id\":\"dc964e59-8e0a-4e7b-b920-a2e09d3ba56b\",\"datacell_roi_id\":\"db80884e-786d-4aa2-bab8-71edc88f668a\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"CI\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"a2804de9-6948-443d-b3a1-9d04dc55dc32\",\"column_roi_id\":\"8aa8a4a1-df2a-4db1-8b1d-f7ec89a8e413\",\"datacell_roi_id\":\"6a31e214-8a5d-41a2-a4ff-b0670fde3c0d\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"confidence interval\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"a2804de9-6948-443d-b3a1-9d04dc55dc32\",\"column_roi_id\":\"36f32e55-8e01-42fa-9756-9f742e6a5c58\",\"datacell_roi_id\":\"b5023c31-16fd-4b30-9270-7ff9fb7890df\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"CLD\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"1439eb08-34ae-4796-ba48-c4c2bb68dc25\",\"column_roi_id\":\"0819a4bb-d791-4aad-bd82-131682d9bfb8\",\"datacell_roi_id\":\"51b6138d-2492-431d-9515-a052b57256db\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"chronic lung disease\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"1439eb08-34ae-4796-ba48-c4c2bb68dc25\",\"column_roi_id\":\"96208dcd-6389-4f51-9f94-c766c2d20823\",\"datacell_roi_id\":\"66783c19-1585-48fd-b8c9-95f70ec31bd0\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"CMH\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"0a34e8a4-b3e8-4ad9-b974-20b0f5c75696\",\"column_roi_id\":\"73e7900d-7752-4249-8bde-9175da744071\",\"datacell_roi_id\":\"54d84ea5-936d-4fb1-9ef4-991f159931e2\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"Cochran-Mantel-Haenszel\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"0a34e8a4-b3e8-4ad9-b974-20b0f5c75696\",\"column_roi_id\":\"d8a226a9-fa2a-4583-b4ea-b8ae4bb03195\",\"datacell_roi_id\":\"a9dfb9c8-db16-497f-aa08-9fa35cbabc70\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"eCRF\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"e31c9b56-de39-4865-9b9c-cc1674a620ce\",\"column_roi_id\":\"00b79213-e3ff-44c8-8b88-c25abeb389b8\",\"datacell_roi_id\":\"f2382f55-2f77-4dca-b6f0-5c952f330cd3\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"electronic case report form\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"e31c9b56-de39-4865-9b9c-cc1674a620ce\",\"column_roi_id\":\"fbf3680a-ce4d-47b2-965a-49e2a796d704\",\"datacell_roi_id\":\"8c017af4-eb88-475f-87d5-88a2ec6f616c\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"EDC\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"4f67eaba-62fb-4b23-a9d8-31a7d3210e63\",\"column_roi_id\":\"a5ab4a61-8b48-44d9-b7fc-540fe9c014fe\",\"datacell_roi_id\":\"75a9b2f6-d90b-46aa-af5c-02d99f54b2bb\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"electronic data capture\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"4f67eaba-62fb-4b23-a9d8-31a7d3210e63\",\"column_roi_id\":\"7dd9ea42-48f2-4c52-b640-6a23e0656581\",\"datacell_roi_id\":\"e2d89766-6ad4-4a92-a01b-ab3454c706b9\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"ER\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"4bf14a6a-ea92-46a6-8a21-95cbeffc2007\",\"column_roi_id\":\"a38a411c-2d40-4a4e-b804-5052bb14c756\",\"datacell_roi_id\":\"2980df07-7bcc-4c49-826c-b0947205d953\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"emergency room\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"4bf14a6a-ea92-46a6-8a21-95cbeffc2007\",\"column_roi_id\":\"6c703dd5-4ccc-460b-8f63-12f034230fe2\",\"datacell_roi_id\":\"b56b8674-4d77-4c67-b811-31a491f40950\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"Fc\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"7644f98f-0579-4147-b0be-70494ff00338\",\"column_roi_id\":\"e1670102-770c-4f4f-850a-d459a9c6e0bc\",\"datacell_roi_id\":\"4c08458c-2d41-4dfc-8c12-e30813498b20\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"fragment cystallizable\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"7644f98f-0579-4147-b0be-70494ff00338\",\"column_roi_id\":\"e1d6c6fe-84ba-4bfc-89c6-a31565567f25\",\"datacell_roi_id\":\"07e86c16-e790-4c0f-8840-e627e00721ad\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"FcRn\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"35029c84-5d54-46b3-93d1-ca4c78e3b401\",\"column_roi_id\":\"c2ceb168-4873-4a83-a205-77c7299704a9\",\"datacell_roi_id\":\"c96433a5-4e0f-4ed8-bedc-3245f99880ed\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"neonatal Fc receptor\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"35029c84-5d54-46b3-93d1-ca4c78e3b401\",\"column_roi_id\":\"a1fb48ea-b692-4da8-9504-c029b344b1aa\",\"datacell_roi_id\":\"cc324da4-44ef-49e9-b27f-0710f1de98e6\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[{\"start_idx\":0,\"end_idx\":2,\"standard_entity_name\":\"ANY: Organization\",\"subcategory\":\"ANY: Organization\",\"confidence\":37.0,\"text\":\"FDA\"}],\"content\":\"FDA\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"2e7457b2-3eb9-420f-9c3c-d7766aefe59a\",\"column_roi_id\":\"c185ea45-010d-4c75-bacc-edc3ebf9d73e\",\"datacell_roi_id\":\"cf1c6ca8-68b6-4242-849e-f471083556ec\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"Food and Drug Administration\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"2e7457b2-3eb9-420f-9c3c-d7766aefe59a\",\"column_roi_id\":\"737233ed-410b-4ce9-ae27-c3c7567007ef\",\"datacell_roi_id\":\"3c747184-cef6-4270-9531-1c9609f9f5f7\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"GA\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"ebd72f57-dcb6-4480-be02-cb3ff291ee82\",\"column_roi_id\":\"e9297c4d-7526-4dd6-8010-64d537937d29\",\"datacell_roi_id\":\"8d4b6e55-0df0-48fd-8256-8d05dc0562f0\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"gestational age\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"ebd72f57-dcb6-4480-be02-cb3ff291ee82\",\"column_roi_id\":\"e1a6a823-7901-4deb-93d5-b78b4ef44594\",\"datacell_roi_id\":\"a2b9fa85-6945-40e2-8b5c-4803a7364d0b\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"GCP\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"b108a77e-eaa9-408b-bee9-ca71f7ac45dd\",\"column_roi_id\":\"b1411b92-d311-43ee-b1dc-ef17406058e9\",\"datacell_roi_id\":\"c611c86b-9cc2-4d85-aae1-d1460e0b0076\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"Good Clinical Practice\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"b108a77e-eaa9-408b-bee9-ca71f7ac45dd\",\"column_roi_id\":\"fa415151-9f04-49e2-a83b-06ee10d5af62\",\"datacell_roi_id\":\"1cfccac5-3f84-4fd9-8c54-506de4016b4e\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"HIV\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"43c10e8e-f264-4cf1-a663-7115cee4e507\",\"column_roi_id\":\"ba45e6c4-311c-44eb-9ed7-ef42b6c4c7a8\",\"datacell_roi_id\":\"1e2a1457-d759-4cc8-8608-062b1fd615ca\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"human immunodeficiency virus\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"43c10e8e-f264-4cf1-a663-7115cee4e507\",\"column_roi_id\":\"0ed711f8-b04c-43cb-853b-1574db091c74\",\"datacell_roi_id\":\"28f0af75-fc70-46c5-b62e-bd3fcd7c8a81\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"hMPV\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"ac223bf7-bcf3-4df1-a958-9299923c507d\",\"column_roi_id\":\"84e50728-178d-4e8e-8002-e253e6f089a4\",\"datacell_roi_id\":\"05d18f78-a6af-48fa-82d0-56ab7ff448a1\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"human metapneumovirus\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"ac223bf7-bcf3-4df1-a958-9299923c507d\",\"column_roi_id\":\"05ba4fef-dfd5-465e-ada9-6b16adadc2bd\",\"datacell_roi_id\":\"0d37482f-d6b8-438f-97c5-8136d5228f6b\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"HRU\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"ccab37fa-be04-49e2-a3e4-fe25c55343bd\",\"column_roi_id\":\"4b46ae82-5519-4860-8e04-7b4da15f7617\",\"datacell_roi_id\":\"081400f9-da63-49ae-a9c9-842dd96b6a4f\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"healthcare resource utilization\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"ccab37fa-be04-49e2-a3e4-fe25c55343bd\",\"column_roi_id\":\"615aca85-4e29-41fc-9559-b0df582e9ea3\",\"datacell_roi_id\":\"af168a83-d8cf-43ec-bf8a-bb01af34b64f\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"ICH\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"c6406eed-7c94-47e0-80b6-655602f8bc7f\",\"column_roi_id\":\"58778fec-b6ce-4a60-a87b-fcddd5141f5b\",\"datacell_roi_id\":\"d69d2bc3-2058-41af-996e-9952b5c5a615\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"International Council for Harmonisation\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"c6406eed-7c94-47e0-80b6-655602f8bc7f\",\"column_roi_id\":\"cdbb04a6-5fe2-4121-8445-ba527122485e\",\"datacell_roi_id\":\"991cd863-6c76-421f-b43b-712383c38246\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"IEC\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"e753be62-1881-4bcb-bb56-4f092b1d8e63\",\"column_roi_id\":\"e49206d1-9a75-495d-871f-6add728f21dc\",\"datacell_roi_id\":\"d4069ecc-3761-468e-95cd-a2824a9f90f6\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"Independent Ethics Committee\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"e753be62-1881-4bcb-bb56-4f092b1d8e63\",\"column_roi_id\":\"2781304f-756f-432a-95ed-2c89fb7ddf21\",\"datacell_roi_id\":\"6122043c-2557-42c4-b86d-6d0587816305\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"IgG\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"88d1d554-27f2-4e42-8446-f42b15a54039\",\"column_roi_id\":\"25ad8695-af23-4788-a264-0a8570222638\",\"datacell_roi_id\":\"dd76919b-ec0a-4812-913b-0b5ea5bb5b23\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"immunoglobulin G\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"88d1d554-27f2-4e42-8446-f42b15a54039\",\"column_roi_id\":\"41edaced-b9b2-47f2-b000-0bf4349bd12d\",\"datacell_roi_id\":\"39aba2f5-dd49-4e6a-9ea6-dd5643d5d463\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"IM\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"7f10e7ae-1cd9-47c9-acb2-89dd5f22a7e1\",\"column_roi_id\":\"a88a376f-c5c7-4368-8c82-81a8927d073b\",\"datacell_roi_id\":\"874c3f32-d639-402c-91a7-c90499ae6dcb\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"intramuscular\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"7f10e7ae-1cd9-47c9-acb2-89dd5f22a7e1\",\"column_roi_id\":\"e8cfad51-2253-488b-a0f2-56a3e785dbbd\",\"datacell_roi_id\":\"ec03d6f6-2098-4a20-ac21-9d3ab200c639\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"IRB\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"6a6acf95-8c0d-4703-878e-50b66801c360\",\"column_roi_id\":\"447af65e-3b32-4e20-b808-0ee1f69cd4b2\",\"datacell_roi_id\":\"8a147818-e9a4-48f3-8f26-1f33ab3cc55f\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"Institutional Review Board\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"6a6acf95-8c0d-4703-878e-50b66801c360\",\"column_roi_id\":\"671e8893-7729-44a8-9684-86bcb3417262\",\"datacell_roi_id\":\"772d06cd-bea0-4721-b02d-438d88aeeccc\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"ITT\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"b5435d2b-7dfa-4ffe-acef-fc29c16ea348\",\"column_roi_id\":\"9c763ad6-da9e-4980-b373-ee944eac15de\",\"datacell_roi_id\":\"708c646f-1875-4579-a0b8-123f3726f682\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"Intent-to-treat\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"b5435d2b-7dfa-4ffe-acef-fc29c16ea348\",\"column_roi_id\":\"8b640e92-9fd2-4a0b-a002-12d086d31e0a\",\"datacell_roi_id\":\"effc62b1-a83e-48cc-92c9-530a8fdce193\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"IV\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"167cf2fa-f923-4c45-9814-6f3024f889cb\",\"column_roi_id\":\"5ac55841-3ee8-4e28-9d0e-2c71ef124ff8\",\"datacell_roi_id\":\"f5c2bc51-33b4-49ef-a94e-5b71bb916919\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"intravenous\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"167cf2fa-f923-4c45-9814-6f3024f889cb\",\"column_roi_id\":\"2fa9726e-819c-4d4a-807d-0acc313459c8\",\"datacell_roi_id\":\"469a896a-4255-4a2d-b442-b4579c67b713\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"IWRS\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"414ab5b0-5eb8-49dd-8ac3-214285e92f07\",\"column_roi_id\":\"f96a4334-b0c8-4a1c-b05c-c50231901697\",\"datacell_roi_id\":\"ea9be2d2-8925-4907-9b1d-d5b854f7c9bf\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"interactive web response system\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"414ab5b0-5eb8-49dd-8ac3-214285e92f07\",\"column_roi_id\":\"41754902-fdfd-4ce1-ac3b-91bdacb5c8e8\",\"datacell_roi_id\":\"cebb3e52-0c37-4b45-9d2b-7496301c152e\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"LRTI\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"bc12ba25-0b99-47ce-9f1f-159d8c7a9a3f\",\"column_roi_id\":\"8180ad50-6dd7-4cf2-ae13-c59b30b7e3df\",\"datacell_roi_id\":\"6b6a4820-d700-4a6c-8fd9-7e66c6b0622e\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"lower respiratory tract infection\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"bc12ba25-0b99-47ce-9f1f-159d8c7a9a3f\",\"column_roi_id\":\"8f2bc8b8-04a2-4ace-b5fa-c37ee0858348\",\"datacell_roi_id\":\"77d5b8dc-91cc-41b7-b417-d270b6eac021\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"mAb\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"b3795412-9d1b-46a4-8f15-982119171178\",\"column_roi_id\":\"3b32d34d-7c44-425c-8ec7-6a32f9ca3a76\",\"datacell_roi_id\":\"410a0616-212a-4432-b2c4-82c019b92074\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"monoclonal antibody\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"b3795412-9d1b-46a4-8f15-982119171178\",\"column_roi_id\":\"83e9b8d2-86ec-4f27-9694-9b0f24d60658\",\"datacell_roi_id\":\"b600e4d3-3fe6-4312-a85a-37a2ed8a79cc\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"MedDRA\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"3d381b61-9438-413b-86d6-e9a63e58dc3b\",\"column_roi_id\":\"34c8b7f7-6e9a-46f7-8bd4-90d509df22f1\",\"datacell_roi_id\":\"144b2321-1a85-4391-8e4b-65398eae7193\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"Medical Dictionary for Regulatory Activities\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"3d381b61-9438-413b-86d6-e9a63e58dc3b\",\"column_roi_id\":\"67d79c64-7676-40bd-86d6-97f276dcb634\",\"datacell_roi_id\":\"01a8ef0d-50e0-44da-858d-baeeef932806\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"NAb\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"9ea6ca0e-b8a4-468c-8330-9ed3eef1e748\",\"column_roi_id\":\"cdfe1cd0-8586-48f0-b0d4-92a6b32f4d5e\",\"datacell_roi_id\":\"1a1fa52d-481d-4b00-88cb-99fdd6d62e9c\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"neutralizing antibody\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"9ea6ca0e-b8a4-468c-8330-9ed3eef1e748\",\"column_roi_id\":\"1be6168f-4c0c-4e8a-842a-2dd9639f25b0\",\"datacell_roi_id\":\"204555a5-44ea-41ad-a219-c879c43fa692\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[{\"start_idx\":0,\"end_idx\":2,\"standard_entity_name\":\"ANY: Organization\",\"subcategory\":\"ANY: Organization\",\"confidence\":37.0,\"text\":\"NCI\"}],\"content\":\"NCI CTCAE\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"d33a75b3-ba77-4cd0-a0fc-3ffb4374868c\",\"column_roi_id\":\"a97b5571-3b40-433d-bedb-a9cd914129ce\",\"datacell_roi_id\":\"85911d67-8092-4603-9242-6be595810472\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[{\"start_idx\":0,\"end_idx\":24,\"standard_entity_name\":\"ANY: Organization\",\"subcategory\":\"ANY: Organization\",\"confidence\":87.0,\"text\":\"National Cancer Institute\"}],\"content\":\"National Cancer Institute Common Terminology Criteria for Adverse Events\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"d33a75b3-ba77-4cd0-a0fc-3ffb4374868c\",\"column_roi_id\":\"73b3f4ea-3d7b-4107-a224-de1966a7b096\",\"datacell_roi_id\":\"3e58957d-7742-471c-b5ae-f8ab29dc3192\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"NOCD\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"f0cb5f81-152a-4b5b-bfd1-38485857fdb4\",\"column_roi_id\":\"4c8a1cce-45eb-4e4e-8447-fd21fc7f8181\",\"datacell_roi_id\":\"c4163cc2-fe45-4611-b770-5414590f2c0c\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"new onset chronic disease\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"f0cb5f81-152a-4b5b-bfd1-38485857fdb4\",\"column_roi_id\":\"38d498c9-6f66-4abc-ad4a-00cad15b4444\",\"datacell_roi_id\":\"01866136-c497-4f97-81b8-b4ab28478472\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"OTC\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"c4a91cb5-eda3-44f1-bee9-5888e64a9e72\",\"column_roi_id\":\"4d755e04-d2a5-459a-8f9a-9b0896a3f58c\",\"datacell_roi_id\":\"d9f922c8-9247-4522-a066-0e0aa6d39a4d\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"over-the-counter\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"c4a91cb5-eda3-44f1-bee9-5888e64a9e72\",\"column_roi_id\":\"139c08d1-965f-4894-af22-34f1b1062a83\",\"datacell_roi_id\":\"3121d2a4-09e2-4269-8c67-5c459fa2fb35\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"PK\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"3e72af4b-a16a-4e12-b85a-60fe957f031f\",\"column_roi_id\":\"89442cd6-1144-46c4-8561-3949a5a3109e\",\"datacell_roi_id\":\"3d01c901-64ea-463c-ba03-6163ab54d0fb\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"pharmacokinetic(s)\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"3e72af4b-a16a-4e12-b85a-60fe957f031f\",\"column_roi_id\":\"8a7323bc-982c-4436-9309-0c78323375ec\",\"datacell_roi_id\":\"7cdcc87c-072d-4244-80d4-d75c43bdce75\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"RRR\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"29e1d85a-634c-4132-a068-dcd5fa58e723\",\"column_roi_id\":\"b1935743-c535-41fb-96b4-778afd8e1ca9\",\"datacell_roi_id\":\"33d59a94-8dbc-4034-a001-4f602f4ec3c3\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"relative risk reduction\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"29e1d85a-634c-4132-a068-dcd5fa58e723\",\"column_roi_id\":\"6f514ace-1599-48d2-8969-b5f7d4d19b4e\",\"datacell_roi_id\":\"32dcb718-43f5-4696-b6d1-25c3375ddf97\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"RSV\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"f05fd4eb-9d75-4491-9d16-42ad95638bad\",\"column_roi_id\":\"e02c4db8-8dd1-4a80-8b3c-9878e660a36d\",\"datacell_roi_id\":\"7689d422-797e-4eb1-89a6-b1772c9e64ea\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"respiratory syncytial virus\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"f05fd4eb-9d75-4491-9d16-42ad95638bad\",\"column_roi_id\":\"29761ac5-566f-4013-bb32-8292d9e950a9\",\"datacell_roi_id\":\"f9fcc092-a6b0-4872-be25-dc8691ad9f56\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"RT-PCR\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"2236aca9-dba2-45a4-9f21-a558d4f8d988\",\"column_roi_id\":\"41cdbd11-1a09-446e-a9e1-5a0d5e895425\",\"datacell_roi_id\":\"36dc59b4-8db9-4ae0-8ce9-b60310cc7bd5\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"reverse transcriptase-polymerase chain reaction\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"2236aca9-dba2-45a4-9f21-a558d4f8d988\",\"column_roi_id\":\"3b99202c-000c-413f-a250-2c1001b0e35f\",\"datacell_roi_id\":\"82c52c77-9a0a-43ef-8405-3217da189a06\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"SAE\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"f52dde40-23e9-4a30-87ef-0a6255d34f8f\",\"column_roi_id\":\"7289f8d7-dbab-440d-9c58-617d5cac832f\",\"datacell_roi_id\":\"7d54ee29-8325-4e14-986a-f9a12f52d1fd\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"serious adverse event\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"f52dde40-23e9-4a30-87ef-0a6255d34f8f\",\"column_roi_id\":\"b77a5f1a-da9a-439c-ad41-5c5024ac94d8\",\"datacell_roi_id\":\"4828d08d-ed32-4edc-b7bf-754084ff8ea6\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"SID\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"2f6ed6b8-7705-4591-8427-46ab687a6fb7\",\"column_roi_id\":\"cd191906-82fd-407d-9d26-318ecb2c19f6\",\"datacell_roi_id\":\"b4440d1f-7a07-47b5-b6bc-7546839d54ec\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"subject identification\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"2f6ed6b8-7705-4591-8427-46ab687a6fb7\",\"column_roi_id\":\"ffcb4900-bbd3-4c6d-a35f-5148524f7fe4\",\"datacell_roi_id\":\"15925be5-fe78-4065-8dc8-28919ce81b69\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"SUSAR\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"15a8ad54-9b87-49c8-94a8-331109405daf\",\"column_roi_id\":\"bbf500b9-131f-4873-bc84-11f55566b644\",\"datacell_roi_id\":\"ef2a7d00-cccb-481b-8035-503c0168f92d\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"suspected unexpected serious adverse reaction\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"15a8ad54-9b87-49c8-94a8-331109405daf\",\"column_roi_id\":\"c5c94de5-bfef-4342-a94a-a3c469fa0fe4\",\"datacell_roi_id\":\"1b58858b-8f05-40a0-91c3-de1c14adb3ee\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"t 1\\/2 \",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"2e045f33-6c5f-459f-8a21-f4ccb40728ed\",\"column_roi_id\":\"e14d3068-2f96-4ea3-bff7-ac0a1704161f\",\"datacell_roi_id\":\"8a0af924-edff-423b-a59e-b7e7f9f68a34\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"terminal half-life\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"2e045f33-6c5f-459f-8a21-f4ccb40728ed\",\"column_roi_id\":\"c8539705-fc00-4e02-b963-e1dfd414ab7c\",\"datacell_roi_id\":\"09a2a6ff-2835-469f-af62-b226fd64cd69\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"TBL\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"4fc64f0e-379e-46d9-a571-a4b0bb26b7a9\",\"column_roi_id\":\"ab5b27e9-ceb4-4c85-a875-2e89fd3d8480\",\"datacell_roi_id\":\"e1ed39c5-691a-46fd-b0cc-59dea0c86b6c\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"total bilirubin\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"4fc64f0e-379e-46d9-a571-a4b0bb26b7a9\",\"column_roi_id\":\"b47ce0d8-13c5-4424-a381-ab9553d26c81\",\"datacell_roi_id\":\"74bee12f-9a63-49cc-9e9d-abde8a631b40\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"TEAE\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"9c1be83f-fd82-4c2b-9938-6d40032da4e2\",\"column_roi_id\":\"01252a09-26bb-443e-b7d3-270bccb527ed\",\"datacell_roi_id\":\"2f6a9b78-87e7-4edb-9bd8-5b9a90f29b15\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"treatment-emergent adverse event\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"9c1be83f-fd82-4c2b-9938-6d40032da4e2\",\"column_roi_id\":\"24d7b8a6-f047-408d-8292-02e4ed386c30\",\"datacell_roi_id\":\"9a319ed1-10eb-4ca7-835e-c6a1b797853b\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"TESAE\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"f0b6ab84-f0aa-4d23-9490-686ddd5c6f95\",\"column_roi_id\":\"8d94cad3-8ee0-4986-b8e1-58d96778cea7\",\"datacell_roi_id\":\"3bd7f50f-3ed1-412b-8b87-c5485b024bf9\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"treatment-emergent serious adverse event\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"f0b6ab84-f0aa-4d23-9490-686ddd5c6f95\",\"column_roi_id\":\"f8421f0a-cf3b-4669-8f61-1c810af3950b\",\"datacell_roi_id\":\"e031320b-fc46-4a11-9a7b-e46cb9adc686\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"ULN\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"7aa49928-bb43-4af3-ac2f-cce866468f39\",\"column_roi_id\":\"2d23cd91-92f0-4131-86b7-7b30e8e1dba6\",\"datacell_roi_id\":\"762e1c63-9928-4a86-bdf6-edf02d9c7120\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"upper limit of normal\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"7aa49928-bb43-4af3-ac2f-cce866468f39\",\"column_roi_id\":\"7b060de2-798d-4b20-94c1-961cf0f4593a\",\"datacell_roi_id\":\"f1496a45-dd90-4eaa-85ef-a5f0fef08393\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"URTI\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"b1b830fa-57cf-485c-99af-0682a35759aa\",\"column_roi_id\":\"5e433612-059d-4cc1-b965-8aeda71a935a\",\"datacell_roi_id\":\"a72ab584-3ee4-441f-8352-0cb92397bb73\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"upper respiratory tract infection\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"b1b830fa-57cf-485c-99af-0682a35759aa\",\"column_roi_id\":\"3e50388a-f360-400b-a61f-09b93ef8bcfd\",\"datacell_roi_id\":\"c28eb51f-fe92-4d9b-8d18-44dca3730efc\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"US\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"fd04ca80-4d09-44a5-9ce3-5d847252b2e0\",\"column_roi_id\":\"c3eeaacc-0c89-4d01-9ff5-e856c4b382a3\",\"datacell_roi_id\":\"c0a5e3c6-c0ed-4b1f-862b-a55bc352d783\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"United States\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"fd04ca80-4d09-44a5-9ce3-5d847252b2e0\",\"column_roi_id\":\"9ba692f9-2a00-4732-805f-2787aabbbad9\",\"datacell_roi_id\":\"a618032a-2c00-4f69-99ba-0a19c4f890d0\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"wGA\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"b7415ffe-36a8-45d7-93f1-674568f37e43\",\"column_roi_id\":\"ae682b63-7082-4b7e-8378-b8899bc2600a\",\"datacell_roi_id\":\"f2a25959-0eec-4ea8-9211-f60747b232c7\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"weeks gestational age\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"b7415ffe-36a8-45d7-93f1-674568f37e43\",\"column_roi_id\":\"5df28be0-7fdc-425f-9161-6fe341226043\",\"datacell_roi_id\":\"fa5fb644-ce7a-42d4-8cfa-af8ff54a472d\"},\"table_index\":8.0,\"qc_change_type\":\"\"}},{\"1.0\":{\"entities\":[],\"content\":\"YTE\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"bb962b02-3dce-45b0-bc24-fcf7ae7a6fd5\",\"column_roi_id\":\"9c2a2c69-6493-47a9-a36d-5a2789e9e6b3\",\"datacell_roi_id\":\"2e7f7201-318a-4036-8c87-4d355acba7c6\"},\"table_index\":8.0,\"qc_change_type\":\"\"},\"2.0\":{\"entities\":[],\"content\":\"M257Y\\/S259T\\/T261E triple amino acid substitution\",\"roi_id\":{\"table_roi_id\":\"ddca908f-959b-44a0-8620-35f40969cc1e\",\"row_roi_id\":\"bb962b02-3dce-45b0-bc24-fcf7ae7a6fd5\",\"column_roi_id\":\"7b8c26a4-38f4-48df-8563-a9912e5a4dec\",\"datacell_roi_id\":\"f1f062af-f8bd-4bb1-b544-5658fa1ed9ba\"},\"table_index\":8.0,\"qc_change_type\":\"\"}}]",
      "SectionHeaderPrintPage": "10",
      "TableIndex": "9",
      "TableName": "List of Abbreviations",
      "Header": [
        0
      ]
    },
    "font_info": {
      "IsBold": true,
      "font_size": 20,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "d67191cd-9eb9-4f97-95e7-0de6b0c9aa3e",
        "childbox": "2129a26e-8a47-4ae9-a34b-4ccd0c24a0cf",
        "subtext": "ec5dee36-4da4-4a1f-822c-48e291fbe9df"
      },
      "Bold": true,
      "Caps": false,
      "ColorRGB": 0,
      "DStrike": false,
      "Emboss": false,
      "Highlight": "",
      "Imprint": false,
      "Italics": false,
      "Outline": false,
      "rFonts": "",
      "rStyle": "",
      "Shadow": false,
      "Size": 20,
      "SmallCaps": false,
      "Strike": false,
      "Underline": "",
      "Vanish": false,
      "VertAlign": ""
    },
    "derived_section_type": "table",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 3,
    "line_id": 212,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  },
  {
    "content": "",
    "font_info": {
      "IsBold": false,
      "font_size": -1,
      "font_style": "",
      "entity": [],
      "roi_id": {
        "para": "2dcf5ac7-0c71-4c76-a171-6c1176d1008a",
        "childbox": "",
        "subtext": ""
      }
    },
    "derived_section_type": "text",
    "synonyms_extracted_terms": "",
    "semantic_extraction": "",
    "qc_change_type": "",
    "sec_id": 3,
    "line_id": 213,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "3_line_item"
  }
]